Occupational exposure to malathion by National Institute for Occupational Safety and Health.
criteria for a recommended standard . . . . 
occupational exposure to
MALATHION
l i  **
]■ V-!i‘
U.S. DEPARTMENT OF HEALTH, EDUCATION, AND v iÉ L F ftR E '
Public Health Service / Center for Disease Control




U.S. DEPARTMENT OF HEALTH, EDUCATION, AND WELFARE
Public Health Service 
Center for Disease Control 
National Institute for Occupational Safety and Health
JUNE 1976
HEW Publication No. (NIOSH) » -2 0 5
CONTENTS
PREFACE lv
NIOSH REVIEW COMMITTEE viii
NIOSH REVIEW CONSULTANTS ix
I. RECOMMENDATIONS FOR A MALATHION STANDARD 1
Section 1 - Environmental (Workplace Air) 2
Section 2 - Medical 3
Section 3 - Labeling and Posting 5
Section 4 - Personal Protective Equipment and Clothing 7
Section 5 - Informing Employees of Hazards from
Malathion 9
Section 6 - Work Practices 11
Section 7 - Sanitation Practices 12
Section 8 - Monitoring and Recordkeeping Requirements 13
II. INTRODUCTION 15
III. BIOLOGIC EFFECTS OF EXPOSURE 17
Extent of Exposure 18
Historical Reports 19
Effects on Humans 20
Epidemiologic Studies 50
Animal Toxicity 52
Correlation of Exposure and Effect 78
IV. ENVIRONMENTAL DATA AND BIOLOGIC EVALUATION
Sampling and Analytical Methods 85






V. DEVELOPMENT OF STANDARD
Basis for Previous Standards 102
Basis for the Recommended Standard 104
VI. WORK PRACTICES 108
VII. RESEARCH NEEDS 112
VIII. REFERENCES 114
IX. APPENDIX I - Method for Sampling Malathion in Air 129
X. APPENDIX II - Analytical Method for Malathion 134
XI. APPENDIX III - Notes on the Diagnosis and Medical
Management of Organophosphorus
Intoxication 141
XII. APPENDIX IV - Method of Sampling and Analysis for
Biochemical Determination of
Cholinesterase Activity 146
XIII. APPENDIX V - Material Safety Data Sheet 153
XIV. APPENDIX VI - Clinical Classes of Malathion Poisoning 163
XV. TABLES AND FIGURES 164
iv
PREFACE
The Occupational Safety and Health Act of 1970 emphasizes the need 
for standards to protect the health and safety of workers exposed to an 
ever-increasing number of potential hazards at their workplace. The 
National Institute for Occupational Safety and Health has projected a 
formal system of research, with priorities determined on the basis of 
specified indices, to provide relevant data from which valid criteria for 
effective standards can be derived. Recommended standards for occupational 
exposure, which are the result of this work, are based on the health 
effects of exposure. The Secretary of Labor will weigh these 
recommendations along with other considerations, such as feasibility and 
means of implementation, in developing regulatory standards.
It Is intended to present successive reports as research and 
epidemiologic studies are completed and as sampling and analytical methods 
are developed. Criteria and standards will be reviewed periodically to 
ensure continuing protection of the worker.
I am pleased to acknowledge the contributions to this report on 
malathlon by members of my staff and the valuable constructive comments by 
the Review Consultants on Malathion, by the ad hoc committees of the 
American Industrial Hygiene Association and the Society of Toxicology, and 
by Robert B. O'Connor, M.D., NIOSH consultant In occupational medicine.
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The NIOSH recommendations for standards are not necessarily a consensus of 
all the consultants and professional societies that reviewed this criteria 
document on malathion. Lists of the NIOSH Review Committee members and of 
the Review Consultants appear on the following pages.
John F. Finklea, M.D.
Director, National Institute for 
Occupational Safety and Health
vl
The Division of Criteria Documentation and Standards 
Development, National Institute for Occupational 
Safety and Health, had primary responsibility for 
development of the criteria and recommended standard 
for malathion. The Division review staff for this 
document consisted of J. Henry Wills, Ph.D., 
Chairman, Herbert E. Christensen, D.Sc., and Richard 
A. Rhoden, Ph.D.
Stanford Research Institute developed the basic 
information for Consideration by NIOSH staff and 
consultants under contract CDC-99-74-31. Jerry LR 
Chandler, Ph.D., had NIOSH program responsibility 
and served as criteria manager.
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I. RECOMMENDATIONS FOR A MALATHION STANDARD
The National Institute for Occupational Safety and Health (NIOSH) 
recommends that employee exposure to malathion in the workplace be 
controlled by adherence to the following sections. The standard is 
designed to protect the health of employees for up to a 10-hour work shift 
and a 40-hour workweek during a working lifetime. Compliance with all 
sections of the standard should prevent adverse effects by malathion on the 
health of employees. The standard is measurable by techniques that are 
valid, reproducible, and available to Industry and government agencies. 
Sufficient technology exists to permit compliance with the recommended 
standard. Although the workplace environmental limit Is considered to be a 
safe exposure level based on current information, it should be regarded âs 
the upper boundary of exposure and every effort should be made to maintain 
the exposure as low as is technically feasible. The criteria and standard 
will be subject to review and revision as necessary.
"Malathion" is defined as 0,0-dimethyl S-(l,2-dicarboethoxyethyl) 
dithiopho8phate, regardless of production process, alone or in combination 
with other compounds. "Action level" is defined as one-half the 
recommended time-weighted average (TWA) environmental exposure limit for 
malathion. "Occupational exposure to malathion" is defined as exposure to 
airborne malathion at concentrations greater than the action level.
The criteria and recommended standard apply to any area in which 
malathion or materials containing malathion, alone or in combination with 
other substances, is produced, packaged, processed, mixed, blended,
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handled, stored In large quantities, or applied.
"Overexposure" is defined as either known or suspected exposure above 
the TWA concentration or any exposure which leads to the development of 
signs or symptoms of absorption of organophosphorus compounds and 
cholinesterase (ChE) Inhibition. Exposure to malathion at concentrations 
less than or equal to the action level will not require adherence to the 
recommended standard except for sections 2, 3(a), 4(a), 5, 6, 7(a-c), and
8(b). If employees are potentially exposed to chemicals such as pesticide 
vehicles, diluents, emulsifiers, or other pesticides, provisions of any 
applicable standards for such chemicals shall also be followed.
*
Section 1 - Environmental (Workplace Air)
(a) Concentration
When skin exposure is prevented, exposure to malathion in the 
workplace shall be controlled so that employees are not exposed to 
malathion at a TWA concentration greater than 15 mg/cu m of air for up to a 
10-hour work shift, 40-hour workweek.
(b) Sampling and Analysis
Procedures for the collection and analysis of environmental air 
samples shall be as provided in Appendices I and II, or by any methods 
shown to be at least equivalent in accuracy, precision, and sensitivity to 
the methods specified.
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Section 2 - Medical
Medical surveillance (medical management and biologic monitoring) 
shall be made available to workers as outlined below.
Physicians responsible for workers who may be occupationally exposed 
to organophosphate compounds should be familiar with the information 
contained in Appendix III which describes the diagnosis and treatment of
intoxication by these compounds.
(a) Medical Examinations
(1) Preplacement and periodic medical examinations shall
include:
(A) Comprehensive initial or Interim medical and
work histories.
(B) A physical examination which shall be directed
toward, but not limited to, evidence of frequent headache, dizziness,
nausea, tightness of the chest, dimness of vision, and difficulty in 
focusing the eyes.
(C) Determination, at the time of the preplacement
examination, of a baseline or working baseline erythrocyte ChE activity
(See (b), Biologic Monitoring).
(D) A judgment of the worker's physical ability to
use negative or positive pressure regulators as defined in 29 CFR 1910.134.
(2) Periodic examinations shall be made available on an 
annual basis or at some other interval determined by the responsible 
physician.
(3) Medical records shall be maintained for all workers 
engaged in the manufacture or formulation of malathion and such records
3
shall be kept for at least 1 year after termination of employment.
(4) Pertinent medical information shall be available to
authorized medical representatives of the Secretary of Labor, of the 
Secretary of Health, Education, and Welfare, of the employer, and of the 
employee or former employee.
(b) Biologic Monitoring
(1) Definitions
(A) "Preexposure baseline" for erythrocyte ChE is 
defined as the mean of two ChE activity determinations, each of which is 
derived from a separate sample of blood taken at least 1 day apart after a 
period of at least 60 days without known exposure to any ChE-inhibiting 
compounds. - If the determinations produce values differing by more than 
15%, additional determinations on new samples must be performed until 
successive tests do not differ by more than 15%.
( (B) "Working baseline" for erythrocyte ChE 4-s
defined as the mean of two ChE activity determinations, each of which is 
derived from a separate sample of blood taken at least 1 day apart and 
differing by no more than 1.5%, or the arithmetic mean of normal values for 
an appropriate control population of adults for that laboratory, whichever 
is higher. A "working baseline" need be determined only for an individual 
whose work history does not permit a preexposure baseline to be determined 
as specified in paragraph (b)(1)(A) of this section.
(C) "Mean of normal values" is defined as the 
arithmetic mean of erythrocyte ChE activities for healthy adults as 
determined by the laboratory's experience with repeated analyses, but which
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is not inconsistent with the mean baseline activities presented in Appendix
IV.
(2) Routine Monitoring
(A) All employees who are to be engaged in the
manufacture or formulation of malathion shall have preexposure erythrocyte 
ChE baselines determined whenever their work histories allow an accurate 
preexposure determination, as specified in paragraph (b)(1)(A) of this 
section. Those new employees with work histories precluding preexposure 
baseline ChE determinations shall have working baseline determinations 
performed.
(B) Within 60 days after the effective date of a
standard, all present employees potentially exposed to malathion shall have 
working baseline erythrocyte ChE activities determined.
(C) An employee who has been removed from malathion 
exposure shall not be allowed to return to work involving occupational 
malathion exposure until said employee's erythrocyte ChE activity has 
returned to at least 75% of the working or preexposure baseline value, or 
unless the responsible physician has approved said employee's return.
(D) All employees shall be provided a copy of their
initial, periodic, and any special ChE test results as soon as possible
after the test, plus an interpretation.
Section 3 - Labeling and Posting
(a) Labeling
Containers of malathion shall be labeled as follows:
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MALATHION
CAUTION! HARMFUL IF INHALED OR SWALLOWED 
HARMFUL IF LEFT ON SKIN
Do not breathe spray, vapor, or mist.
Do not take internally.
Avoid contact with eyes, skin, and clothing.
Wash hands before eating.
Take shower or bath after work.
Wear long-sleeved work clothing.
Change to clean clothing daily.
NOTE TO PHYSICIAN: Malathion is a cholinesterase inhibitor.
Atropine sulfate is antidotal.
(b) Posting
The following sign shall be posted in a readily visible location at 
or near entrances to manufacturing and formulating areas containing 
malathion, and at other areas in which there is a risk of exposure:
TOXIC CHEMICAL 
MALATHION IN USE
DO NOT BREATHE DUST OR MIST
Warning signs shall be printed in English and in the predominant 
language of non-English-speaking employees, if any, unless employers use 
equally effective means to ensure that non-English-speaking employees know 
the hazards associated with malathion and the areas in which there is 
exposure to malathion. Employers shall ensure that all illiterate 
employees also know these hazards and the location of these areas.
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(a) Protective Clothing
Any employee whose work involves likely exposure of the skin to 
malathion or malathion formulations, eg, mixing or formulating, shall wear 
full-body coveralls or the equivalent, impervious gloves, and impervious 
footwear and, when there is danger of malathion coming in contact with the 
eyes, safety goggles shall be provided and worn. Any employee who applies 
malathion shall be provided with and required to wear the following 
protective clothing and equipment: goggles, whole-body coveralls, and
impervious footwear.
(b) Respiratory Protection
Engineering controls shall be used wherever feasible to maintain 
airborne malathion concëntrations below the recommended workplace 
environmental limit. Compliance with the workplace environmental limit by 
the use of respirators is allowed only when airborne malathion 
concentrations are In excess of the workplace environmental limit because 
required engineering controls are being Installed or tested, when 
nonroutine maintenance or repair is being accomplished, or during 
emergencies. When a respirator Is thus permitted, it shall be selected and 
used In accordance with the following requirements:
(1) For the purpose of determining the type of respirator 
to be used, the employer shall measure, when possible, the atmospheric 
concentration of malathion in the workplace initially and thereafter 
whenever process, worksite, climate, or control changes occur which are 
likely to increase the airborne malathion concentrations; this requirement 
does not apply when only atmosphere-supplying positive pressure respirators
Section 4 - Personal Protective Equipment and Clothing
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are used. The employer shall ensure that no employee Is exposed to 
malathion at or above the workplace environmental limit because of Improper 
respirator selection, fit, use, or maintenance.
(2) A respiratory protective program meeting the require­
ments of 29 CFR 1910.134 and 30 CFR 11 shall be established and carried out 
by the employer.
(3) The employer shall provide respirators in accordance 
with Table 1-1 and shall ensure that the appropriate respirator is worn.
(4) Respiratory protective devices described in Table 1-1 
shall be of the type approved under the provisions of 29 CFR 1910.134 and 
30 CFR 11.
(5) Respirators specified for use in higher concentrations 
of malathion may be used in atmospheres of lower concentrations.
(6) The employer shall ensure that respirators are 
adequately cleaned, and that employees are instructed on the use of 
respirators assigned to them and on how to test for leakage.
(7) Canisters shall be discarded and replaced with fresh 
canisters in accord with the manufacturer's recommendation or if the odor 
of malathion breaks through. Unused canisters shall be discarded and 
replaced when seals are broken or on expiration of the manufacturer's 














(1) Chemical cartridge respirator 
with replaceable pesticide cartridge 
and half-mask facepiece
(2) Type C supplied-air respirator, 
demand type (negative pressure), 
with half-mask facepiece
300 mg/cu m 
or less
Full-face gas mask, chin-style with 
pesticide canister
750 mg/cu m 
or less
(1) Full-face gas mask, chest- or 
back-mounted type
(2) Type C supplied-air respirator, 
demand type (negative pressure), 




(1) Self-contained breathing appa­
ratus (positive pressure) with full 
facepiece
(2) Combination supplied-air respi­
rator, pressure-demand type, with 
auxiliary self-contained air supply
Section 5 - Informing Employees of Hazards from Malathion
(a) Before work involving potential exposure to malathion begins, 
all new or reassigned employees shall be informed of the hazards of 
malathion, relevant symptoms of overexposure to malathion, appropriate 
emergency procedures, and of the conditions and precautions required for
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safe handling of malathion.
(b) The information shall be posted in the work area, shall be 
kept on file, and shall be readily accessible to the worker at all places 
of employment where occupational exposure to malathion may occur.
(c) A program of employee education shall be instituted within 30 
days after the promulgation of the standard. The program shall be designed 
to ensure that all employees occupationally exposed to malathion understand 
and remain aware of job hazards as well as emergency, maintenance, and 
cleanup procedures, and that they know how to correctly use and maintain 
respiratory protective equipment and protective clothing. The training 
shall be repeated at least annually after the employee's initial training 
required under this paragraph.
(d) In addition to the requirements of paragraph (c) above, 
employees occupationally exposed to malathion shall be kept currently 
informed through posting as specified in Section 3(b), and shall be 
instructed as to the availability of biologic monitoring information. The 
information specified in Section 2(b)(2) shall be kept on file and shall be 
readily accessible to each employee at or near each workplace where 
exposure to malathion may occur. In addition, all employees shall be 
informed of their biologic monitoring results as specified in Section 
2(b)(2)(D).
Information as required shall be recorded on the "Material Safety 
Data Sheet" shown in Appendix V or on a similar form approved by the 
Occupational Safety and Health Administration, US Department of Labor.
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(a) Each employer shall contact and advise a physician or other 
nearby medical service that an emergency arising from exposure to malathion 
may occur.
(b) All malathion spills shall be cleaned up as soon as possible. 
Continuous surveillance of spills shall be provided until decontamination 
is completed. Contaminated areas shall be roped off or access to them 
otherwise prevented. They shall also be posted.
(c) Spills of malathion on floors shall be absorbed with absorbing 
clay. Sweeping compound shall be utilized to facilitate the removal of all 
visible traces of malathion-contaminated clay.
(d) Equipment and fixtures contaminated with malathion shall be 
decontaminated with an alkaline solution (5% NaOH) or with an equivalent or 
superior decontaminating solution.
(e) If empty metal containers contaminated with malathion are to 
be disposed of in a sanitary landfill, they shall be decontaminated with 
strong alkaline solution (10% NaOH), or with an equivalent or superior 
decontaminating solution, and punctured before disposal.
(f) If empty malathion-contaminated metal drums or containers are 
to be reclaimed, they shall be decontaminated or sealed tightly, and the 
reclaimer informed of the prior malathion contamination.
(g) The employer shall provide for cleaning and laundering of work 
clothing and personal protective equipment, and for their decontamination 
as needed.
(h) Whenever malathion significantly contaminates clothing or the 
insides of personal protective equipment, the contaminated articles shall
Section 6 - Work Practices
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be removed immediately, and the employee shall be required to wash with
soap and water.
(1) Extra clothes shall be available for use when employees'
personal clothing becomes contaminated with malathlon.
(j) Employees potentially exposed to malathlon while spraying
shall remain upwind from the spray whenever possible.
(k) Employers shall ensure that persons who launder clothes
contaminated with malathlon understand the hazards associated with 
malathlon's use.
Section 7 - Sanitation Practices
(a) Malathion-manufacturing and malathlon-formulatlng facilities
shall have eyewash fountains and showers as specified In 29 CFR
1910.151(c).
(b) The employer shall provide access to a free-flowing water 
source at fixed facilities, with soap and towels for all employees to use 
in emergencies.
(c) Employees shall be required to shower at the end of each work
shift.
(d) Employees shall be prohibited from eating, drinking, or 
smoking in malathion-contaminated areas.
(e) Employees occupationally exposed to malathlon shall be
required to wash hands and face before eating, drinking, smoking, or 
applying cosmetics or dermal preparations.
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Workers are not considered to have occupational exposure to malathion 
if environmental concentrations, as determined by an industrial hygiene 
survey conducted within 6 months of the promulgation of this recommended 
standard, do not exceed half the recommended TWA environmental limit, ie, 
action level. Surveys shall be repeated at least once every year and 
within 30 days after any process change likely to result In Increased 
airborne concentrations of malathion. Records of these surveys, including 
the basis for concluding that airborne concentrations of malathion are at 
or below the action level, shall be maintained. If the survey indicates 
that airborne concentrations of malathion exceed the action level, then the 
following requirements apply:
(a) Personal Monitoring
(1) A program of personal monitoring shall be instituted to 
identify and measure, or permit calculation of, the exposure of all 
employees who are occupationally exposed to malathion. Interim monitoring 
of employee exposure to airborne concentrations of malathion shall be 
conducted at least every 6 months. If monitoring of an employee's exposure 
to malathion reveals that the employee is exposed at concentrations in 
excess of the recommended TWA environmental limit, the exposure of that 
employee shall be measured at least once every 30 days, control measures 
shall be initiated, and the employee shall be notified of the exposure and 
of the control measures being implemented to correct the situation. Such 
monitoring shall continue until two consecutive samplings, at least a week 
apart, indicate that employee exposure no longer exceeds the TWA 
environmental limit specified in Section 1(a). Semiannual monitoring may
Section 8 - Monitoring and Recordkeeping Requirements
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then be resumed.
(2) In all personal monitoring, samples of airborne
malathion shall be collected which, when analyzed, will provide an accurate 
representation of the concentration of malathion in the air which the
worker breathes.
(3) For each TWA determination, a sufficient number of
samples shall be taken to characterize each employee's exposure during each 
work shift. Variations in work and production schedules shall be 
considered in deciding when samples are to be collected. The number of 
representative TWA determinations for an operation or process shall be 
based on the variations in location and job functions of employees in 
relation to that operation or process.
(b) Recordkeeping Procedures
Records shall be maintained for at least 5 years and shall include 
sampling and analytical methods, types of respiratory protective devices 
used, and TWA concentrations found. Each employee shall have access to 
data on the employee's own environmental exposures and records. These 
records shall be made available to the designated representatives of the 
Secretary of Health, Education, and Welfare. Pertinent records of required 
medical examinations shall be maintained for 1 year after the worker's 
employment has ended and shall be available to the designated medical 
representatives of the Secretary of Labor, of the Secretary of Health, 




This report presents the criteria and the recommended standard based 
thereon which were prepared to meet the need for preventing occupational 
diseases arising from exposure to malathlon. The criteria document 
fulfills the responsibility of the Secretary of Health, Education, and 
Welfare, under Section 20(a)(3) of the Occupational Safety and Health Act 
of 1970 to "...develop criteria dealing with toxic materials and harmful 
physical agents and substances which will describe...exposure levels at 
which no employee will suffer Impaired health or functional capacities or 
diminished life expectancy as a result of his work experience."
The National Institute for Occupational Safety and Health (NIOSH), 
after a review of data and consultation with others, formalized a system 
for the development of criteria upon which standards can be established to 
protect the health of employees from exposure to hazardous chemical and 
physical agents. Criteria for a recommended standard should enable 
management and labor to develop better engineering controls resulting in 
more healthful work practices and should not be used as a final goal.
These criteria for a standard for malathion are part of a continuing 
series of criteria developed by NIOSH. The proposed standard applies only 
to the manufacture, formulation, application, or other vocational exposure 
to malathion as applicable under the Occupational Safety and Health Act of 
1970. The standard was not designed for the population-at-large, and any 
extrapolation beyond vocational exposures is not warranted. It is intended 
to (1) protect against development of acute and chronic systemic and local 
effects on the skin and eyes, (2) be measurable by techniques that are
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valid, reproducible, and available to industry and government agencies, and
(3) be attainable with existing technology.
No attempt has been made in this document to cope with all the 
literature on malathion, such as that concerning insect data. Currently
available scientific evidence indicates that, compared with other 
organophosphates, malathion is of low toxicity in humans.
NIOSH believes that future research on malathion should be directed
toward the effects on enzymes, particularly allesterase, of chronic 
exposure to malathion and the physiologic significance of these effects* 
Additional data should be obtained on its potential mutagenic or 
carcinogenic effects. There should be research directed toward the 
development of an accurate field test for ChE monitoring, and toward 
simpler and more efficacious methods of collecting malathion aerosols and 
vapors. Also, NIOSH recommends that the rates and mechanisms of skin
absorption of various malathion formulations be determined and that certain 
biochemical constants and rates be determined. These recommendations are 
discussed further in Chapter VII.
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III. BIOLOGIC EFFECTS OF EXPOSURE
The normal function of the central nervous system (CNS) can be 
significantly altered by malathlon Intoxication. Acetylcholine (ACh), a 
choline ester, normally mediates neurotransmission in preganglionic 
autonomic fibers, postganglionic parasympathetic fibers, and in some 
postganglionic sympathetic fibers. [1] These fibers innervate the heart, 
iris, salivary glands, stomach, small intestine, urinary bladder, bronchial 
glands, eccrine sweat glands, and other structures. There is also evidence 
that ACh functions as a transmitter at neuromuscular junctions (motor 
endplates) and at certain synapses within the CNS. [1]
Two types of enzymes normally hydrolyze choline esters in humans: 
acetylcholinesterase (AChE) or true ChE (Enzyme Commission (EC) 3.1.1.7), 
and butyrylcholinesterase (BuChE) (EC 3.1.1.8), otherwise known as plasma 
ChE, serum ChE, or pseudocholinesterase. [1] AChE is found in neurons, at 
the neuromuscular junction, in erythrocytes, and in certain other tissues.
Inhibition of AChE leads to the accumulation of endogenous ACh [1] 
and, consequently, to the poisoning of the exposed individual.
BuChE is present in various types of glial or satellite cells of the 
central and peripheral nervous systems as well as in plasma, in the liver, 
and in other organs. [1] Its physiologic function is unknown; inhibition 
of the plasma enzyme at most sites produces no apparent functional 
derangement. [1] A diagram of the metabolism of malathlon is presented in 
Figure XV-1.
Malathlon itself has only a slight direct inhibitory action on 
erythrocyte ChE and nonspecific esterases but one of its metabolites,
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malaoxon, is an active Inhibitor. Malaoxon reacts with AChE to form the 
dimethylphosphoryl derivative, which is incapable of hydrolyzing ACh. 
[2-5] The resulting enzyme-inhibitor complex either may be slowly 
reactivated by dephosphorylation or permanently inactivated by aging via 
déméthylation to the monomethylphosphoryl enzyme. The aging reaction is 
believed to play a critical role in the toxic actions of many 
organophosphates containing secondary or tertiary alkyl groups. [6]
Reactivation of the erythrocyte enzyme-inhibitor complex is 
accelerated by nucleophilic reactivators such as choline, pyridine, 
hydroxylamine, hydroxamic acids, and oximes. [7] Childs et al [8] found
that the oximes were generally superior to the hydroxamic acids in
»
reactivating organophosphate-inhibited ChE's. Subsequent studies have 
shown that pyridine-2-aldoxime methachloride (pralidoxime chloride) is 
highly effective in the reactivation of inhibited erythrocyte and 
neuroeffector ChE's if aging has not occurred. Wilson and Ginsburg [9] 
reported that pyridine-2-aldoxime is capable of reducing the toxicity of 
parathion in rats.
Extent of Exposure
Malathion (0,0-dimethyl S-(l,2-dicarboethoxyethyl) dithiophosphate), 
formerly known as malathon, [10] belongs to the family of organophosphorus 
pesticides. Pertinent physical properties of malathion are presented in 
Table XV-1, [11] and common trade names and synonyms for malathion are in 
Table XV-2. [12] Malathion is a colorless to light-amber liquid, with a
solubility of 145 ppm in water at 25 C. While of limited solubility in
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petroleum oils, It Is miscible with most organic solvents. [13]
Malathion Is produced by the reaction of 0,0-dimethyl 
dithiophosphorlc acid and diethyl maleate dissolved in an alcohol or a 
ketone in the presence of a tertiary amine. An antipolymerization agent, 
such as hydroquinone, is usually used to inhibit polymerization of diethyl 
maleate. [13] Commercial malathion was Introduced in 1950 as an 
experimental insecticide bv the American Cyanamid Company [11] and patented 
by the same company In 1951 (US Patent 2,578,652). By 1971, the annual 
production of malathion in the US totaled about 35 million pounds. [14,15] 
Malathion is marketed as 99.6% technical grade liquid. Available 
formulations include wettable powders (25% and 50%), emulsifiable 
concentrates, dusts, and aerosols. [13,16]
Malathion is used in the control of certain Insect pests on fruits, 
vegetables, and ornamental plants. It has been used in the control of 
houseflies, mosquitoes, and* lice, [16] and on various farm and livestock 
animals. [17]
NIOSH estimates that approximately 75,000 workers in the US are 
occupationally exposed to malathion.
Historical Reports
The first indications that some organophosphorus compounds might be 
highly toxic appeared during the early 1930's when symptoms of ACh 
poisoning were experienced by the synthesizers of dimethyl and diethyl 
phosphorofluorldate. [18] In 1936, during an investigation of synthetic 
insecticides, Schrader studied the phosphorus compounds, and in 1937 he
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formula for organophosphate contact insecticides. [18]
Effects on Humans
Malathion absorption through the gastrointestinal tract, [19-26] the 
skin, [27-32] and the respiratory tract has been examined. [33,34] In 
vocational exposures, the skin is an impo rtant route of entry to the body, 
[35-37] and a case of intoxication following extensive skin exposure has 
been reported. [38] All but two reports of fatalities from malathion 
poisoning reviewed to date have involved ingestion [22,23,40]; two people 
may have died from contamination of the skin with malathion, but the 
attribution of the deaths to malathion remains somewhat uncertain.
Clyne and Shaffer [17] reported the experiences of three men who 
sprayed a liquid malathion formulation in grain-filled ship holds. 
Ceilings and inner walls of 34 ships' holds were sprayed intermittently 
during 4.5 months with either 5 or 10 quarts/ship of 57% emulsifiable 
liquid. The sprayers worked while lying on their backs on top of the grain 
and did not wear protective equipment. They did, however, wear coveralls 
which were changed daily; they showered after completing spraying for the 
day and washed their hands and faces after spraying each hold. The total 
duration of exposure was estimated to have been 35-40 hours. Erythrocyte 
and plasma ChE activities were monitored before, during, anH after the 
project and were reported to have remained normal throughout. No symptoms 
of illness were detected in the men, despite what must have been very heavy 
dermal and respiratory exposure and probable oral exposure by swallowing 
airborne material.
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The Expert Committee on Insecticides of the World Health Organization 
[41] briefly described Its summary conclusions from reports on a large- 
scale field trial of malathlon In Uganda In 1963-1965» and on routine 
spraying of malathlon in 29,000 Central American houses from 1963 to 1967. 
The one safety precaution observed was to keep the compound away from 
foodstuffs, yet the only report of Illness was in three sprayers whose 
uniforms were described as continually wet with malathlon in kerosene for 3 
days. Two of the sprayers were moderately ill for 3 days, and the third 
for 1 day, with symptoms of anticholinesterase poisoning. No further data 
were supplied in this report. Another case of symptomatic malathlon 
poisoning directly attributable to workplace exposure involved a 16-year- 
old man who for 10 days was heavily exposed in Florida to malathlon dust 
being applied to control the Mediterranean fruitfly (KM Clyne, written 
communication, February 1975). The young man used no protective measures 
to prevent exposure and, although his skin was visibly contaminated with 
dust, he reportedly did not bathe during the entire 10 days. He presumably 
Inhaled a great deal of the dust and, in addition, frequently drank water 
directly from his cupped hands. After 10 days of exposure, he became ill 
with obvious manifestations of organophosphorus pesticide Intoxication. He 
was admitted to a hospital, treated for 24 hours, and released as 
clinically well within 48 hours.
The State of California Department of Public Health publishes annual 
reports entitled Occupational Disease in California Attributed to 
Pesticides and Other Agricultural Chemicals— Some Current Problems. [42] 
The values contained in these reports are derived from data submitted by
California physicians in accordance with the state's "Doctor’s First Report
*
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of Work Injury" reporting law. [43] The report required by this law is a 
brief summary of initial diagnostic impression and is accepted for 
statistical purposes by the state with little or no further communication. 
The data in Table III-l were taken from the respective California 
Department of Health reports. In 1970, 33,085 occupational disease reports 
were included in the annual summary. Of these, 1,493, or 4.5%, were 
attributed to agricultural chemicals, but only 9, or 0.6%, of these reports 
Involved malathion.
TABLE III-l
REPORTS OF OCCUPATIONAL DISEASE ATTRIBUTED 
TO MALATHION BY INDUSTRY AND YEAR, CALIFORNIA
Year Industry Group
Agriculture Manufacturing All Other
1969 4 (162) 1 (40) 3 (29)
1970 5 (244) 0 (47) 4 (41)
1971 1 (197) 5 (31) 4 (41)
Numbers in parentheses refer to the total number of organophosphate poison­
ings.
Adapted from Occupational Disease in California Attributed to Pesticides 
and Other Agricultural Chemicals 1969— Some Current Problems [42]
A number of published case reports have been found which describe the 
toxic effects of acute exposure to malathion. Goldin et al, [39] in 1964, 
described the case of a 42-year-old woman who ingested a minimum of 120 ml 
of 50% malathion garden spray. She was admitted to a hospital 30 minutes
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later, at which time she was comatose, markedly cyanotic, flaccid, devoid 
of tendon reflexes, and markedly miotic. Immediate treatment was begun 
with 1 mg of atropine im and 500 mg of 2-PAM iv. The history obtained from 
her family revealed that she had suddenly become unconscious with a major 
convulsion lasting for several minutes, and that excessive salivation and 
bronchial hypersecretion had developed rapidly thereafter. Approximately 1 
hour after ingestion of the malathion, she received an additional 2,000 mg 
2-PAM iv (total dose 40 mg/kg). At this stage, profuse diarrhea and 
massive bronchial hypersecretion which necessitated frequent tracheal- 
bronchial suction developed. Subcutaneous atropine therapy, 1-3 mg/hour, 
was begun. After 24 hours, the patient was able to move her arms and legs 
sluggishly on command. While pronounced tongue tremor and brisk jaw jerk 
were present, areflexia and pinpoint pupils persisted, as did the bronchial 
hypersecretion and cyanosis. Strength of muscles, other than those of 
respiration, returned to normal on about the 10th day after ingestion. 
After approximately 15 days, diaphragmatic and intercostal strength had 
recovered sufficiently to maintain spontaneous breathing. Neurologic 
recovery was gradual, with the tongue tremor and brisk jaw jerk 
disappearing, and the tendon reflexes returning, within about 1 week. The 
patient was discharged 5 weeks after admission. Laboratory investigations 
during the patient's hospital course included determinations of plasma and 
erythrocyte ChE activities. Serum ChE activity was less than 22% of 
laboratory normal for the first 9 days. Thereafter, the level gradually 
rose to 100% by the 31st day. The erythrocyte ChE activity was first 
measured on the 12th day, when it was found to be 10% of normal. It 
remained between 10 and 25% of normal until the 45th day after hospital
23
admission and then gradually rose to 100% by 130 days after admission. By 
this time the patient had been discharged. Hematocrit measurement showed a 
small drop after admission, from 43 to 37%, and the reticulocyte count 
never rose above 2%. Sternal bone marrow examination on the 25th day was 
essentially normal. Blood urea levels rose to 77 mg/100 ml of blood during 
the first 5 days, thereafter returning to normal as the nonrenal uremia due 
to diarrhea and hypersecretion was controlled. Electrocardiograms (ECG'S) 
taken immediately after admission and daily thereafter showed a 
prolongation of the P-R interval that persisted for 5 days, as well as 
changes in the S-T segment which the authors [39] reported as consistent 
with panmyocardial ischemia. These latter changes disappeared gradually as 
the patient's respiratory function improved.
Crowley and Johns [19] in 1966 described the case of a 45-year-old 
maintenance worker who ingested between 50 and 90 cc of commercial 
insecticide containing 50% malathion in a petroleum hydrocarbon base. 
Within an hour, he developed nausea, vomiting, and profuse diarrhea; 
shortly after, he also developed generalized sweating, increased 
salivation, lacrimation, and visual blurring. He began to have wheezing, 
giddiness, a feeling of generalized numbness, loss of coordination, urinary 
and fecal incontinence, and violent shaking and tremors, but he did not 
lose consciousness. Two hours after ingestion, he was brought to the 
hospital emergency room where he was found to be hyperactive, irritable but 
alert, and in mild respiratory distress. His skin was slightly dusky, his 
pupils were pinpoint, and excessive amounts of secretions were present in 
his mouth, pharynx, and respiratory passages. Scattered moist rales and 
expiratory wheezes were heard throughout his lung fields, but chest
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expansion during respiration appeared adequate. Bowel sounds were active. 
Neurologic examination revealed normal sensory function with respect to 
superficial pain, touch, vibration, and proprioception. He had generalized 
skeletal muscle fasciculations and mild generalized weakness. Coordination 
was normal. Deep tendon reflexes were absent and his plantar responses 
were flexor. The patient was admitted to the hospital and immediately 
given 2 mg atropine iv, and this was continued as necessary until 18 days 
after admission. During the first 24 hours after malathion ingestion, his 
respiration became increasingly labored, apparently because of the 
increasing volume and tenacity of respiratory tract secretions together 
with pulmonary congestion and weakness of respiratory muscle contractions. 
The level of consciousness exhibited by the patient fluctuated widely from 
alertness to complete stupor. Skeletal muscle weakness increased, so that 
by 38 hours after ingestion of the insecticide the patient exhibited severe 
weakness of the trunk muscles and all extremities, with somewhat more power 
in the pelvic girdle and leg muscles and in muscles of the arms. He was 
able to initiate only a very weak muscular contraction, which fatigued 
after 5-10 seconds, followed by tremors involving the entire limb. This in 
turn was succeeded by flaccid paralysis of the limb. He had moderate 
ptosis of the eyelids with normal power of the extraocular muscles. There 
was weakness of the upper and lower facial muscles. He was able to open 
his mouth for 3-5 seconds but unable to protrude his tongue. On attempts 
to phonate, his palate elevated symmetrically. Therapy with 2-PAM was 
begun 48 hours after Ingestion of malathion with 500 mg administered iv at 
48 and 54 hours and 1 g iv each hour for 3 hours beginning 72 hours after 
ingestion. It was discontinued thereafter. The patient's level of
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consciousness continued to fluctuate for 5 days. He then began to regain 
muscle strength and endurance. Erythrocyte ChE activity, which measured 
less than 10% of laboratory normal in the first 48 hours, began to rise 
after the first 7 days. He was discharged from the hospital on the 28th 
day after ingestion and was not seen again until the 56th day. At that 
time, his erythrocyte ChE activity had risen to 66% of normal. No 
description of the clinical course between the 7th and 56th days was given, 
and no further followup visits were reported.
Amos and Hall [20] described the case of a 14-year-old boy weighing 
165 pounds who was admitted to the hospital 20 minutes after ingestion of 
approximately 4 ounces (120 ml) of a malathion preparation of unstated 
composition. At the time of admission, he had abdominal cramps, nausea, 
vomiting, excessive salivation, difficulty in breathing, and severe muscle 
weakness. Within several minutes of admission to the emergency room, he 
became cyanotic, developed pulmonary edema, and lapsed into coma. There 
were muscular fasciculations of the face, eyelids, and neck accompanied by 
mild muscular twitchings of the entire body. Pupils were pinpoint, round, 
regular, equal, and nonresponsive to light. Neurologic Investigation 
revealed the absence of deep tendon reflexes and the presence of marked 
motor weakness. The patient was atropinized with 1 intravenous (iv) dose 
of 0.4 mg and with intramuscular (lm) doses of 0.4 mg, 0.6 mg, and 0.6 mg 
in the 1st hour; and doses of 2 mg iv every 30 minutes from the 3d hour 
after admission onward; the authors reported total atropine dosage of 54 mg 
in the first 48 hours. After 3 hours, the state of deep coma, areflexia, 
and nonresponse to painful stimuli began to abate. The deep tendon 
reflexes returned and a slight increase in the size of the pupil with
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pupillary reaction to light was noted. The patient regained consciousness 
for several minutes and then became combative, confused, and disoriented. 
Several hours later, he appeared alert, with no evidence of motor paralysis. 
The day after admission, the patient began to deteriorate again, becoming 
progressively weaker with shallow respiration, rapid thready pulse, and a 
cloudy sensorium. There was the return of excessive salivation, difficult 
respiration, pinpoint pupils, muscular fasciculations of the face and neck, 
and twitching of the entire body as if convulsions were imminent. The 
patient was critically ill for the next 12 hours and required tracheostomy. 
Atropinization was continued and, after another 24 hours, his vital signs 
improved and respiration was again satisfactory. On the 3d hospital day, 
miotic pupils were again noted; his respiration was shallow and abdominal 
in type with no intercostal muscle function. No muscle twitching was 
present, but there was profound muscular weakness with inability to move 
the lower extremities more than a few inches from the bed. Ptosis of the 
eyelids suggested a severe myasthenia gravis-type weakness. At this time, 
the patient was rational with clear sensorium. Because of progressive 
respiratory failure complicated by pneumonia, it was decided to treat the 
patient with 2-PAM, 500 mg iv during 5 minutes, whereupon muscle function 
improved. During the next 24 hours, respiratory paralysis recurred, so 
that repetition of treatment with 2-PAM seemed necessary and was performed. 
After 72 hours, the hemogram, urinalysis, and ECG were normal. Atropine 
dosage was reduced to 0.5 mg/hour, and on the 7th day to 1 mg in every 4 
hours. The patient was discharged from the hospital on the 15th day in 
satisfactory condition.
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Harris et al [40] described the case of a 45-year-old woman who had 
ingested an indeterminate amount of malathion. She was admitted to 
hospital no more than 6 hours after ingestion and, by then, was unconscious 
and areflexic. She was in total cardiac and respiratory arrest. No 
involuntary motor activity was evident, although seizures did develop about 
8 hours later. Some mucus about the mouth had been seen by the patient's 
husband at home, but no salivation or frothy sputum was observed 
thereafter. Pupils were of intermediate size and unreactive to light. 
There was no excessive sweating, diarrhea, or retching. She had not been 
incontinent. Moderate bradycardia, without gross arrhythmia, was noted. 
Laboratory tests at the time of admission showed hyperglycemia and 4+ 
glycosuria, but subsequent estimations of concentrations of glucose in the 
plasma were within the normal range. Ventilation via an endotracheal tube 
was required and levarterenol was administered lv. The authors [40] noted 
that voluntary respiratory effort was Inadequate throughout most of the 
patient's hospital course. For the next 36 hours, maintenance of adequate 
blood pressure was dependent upon administration of levarterenol. The 
patient was initially given 4 mg of atropine iv. Throughout 
hospitalization, therapy was continued with 2-PAM, 1 g iv every 12-24 
hours, and atropine, 1-2 mg iv or im every 1-4 hours. Two days after her 
admission, the patient showed slight voluntary movement and responded 
momentarily to external stimuli. Her pupils were dilated and there seemed 
to be stronger respiratory effort. However, ventricular fibrillation 
occurred 4 hours thereafter and, following this, the patient remained 
comatose. ChE activity was absent from both erythrocytes and plasma. The 
patient expired 5.5 days after malathion ingestion. Autopsy revealed
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generalized edema, including severe pulmonary edema, and bronchopneumonia. 
These were probably indirect effects of shock and respiratory failure. A 
small subdural hematoma was also found, but no associated abnormalities to 
indicate head trauma were observed.
Windsor [44] reported the case of a 37-year-old woman admitted to the 
hospital after swallowing 60-85 ml of a malathion preparation (55% 
malathion, 35% crude naphthal extract), a dose the author calculated as 
equivalent to 35-50 g of malathion. She was an epileptic who was taking 
barbiturates, chloral hydrate, chlorpromazine, phenelzine, and phenytoin, 
and was under psychiatric care and had attempted suicide with 
chlorpromazine 2 years prior to this incident. On admission, the patient 
was described as "severely collapsed" and deeply cyanosed, with profoundly 
depressed respiration and bubbling rales throughout the chest. Pupils were 
pinpoint, but reflexes were detectable and symmetrical. Endotracheal 
intubation and bronchial aspiration were performed, and she was placed on a 
respirator. Gastric lavage resulted in the recovery of large, but 
unspecified, amounts of the malathion mixture. Atropine was administered 
in 2-mg doses every 15 minutes; pralidoxime chloride was administered iv in 
doses of 1 g at 2 and 6 hours after admission. The patient's pupils 
dilated and respiration improved, although during this time she had 
"several bouts" of diarrhea and generalized muscular fasciculations. The 
respirator was removed, but had to be replaced 24 hours after admission. 
Atropinization was continued until the morning after admission. It was 
resumed 14 hours later at a rate of 2 mg every 15 minutes, together with 
1 g of pralidoxime every 4 hours. Serum ChE activity was determined to be 
about 20% of the normal minimum 3 days after malathion ingestion and
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increased to about 45% of normal 1 week after the incident. Pralidoxime 
chloride was discontinued on the 5th hospital day, but atropinization was 
maintained until the 11th day, by which time a total of 1,065 mg of 
atropine had been administered. The respirator was withdrawn, and her 
recovery proceeded uneventfully.
Namba et al [25] reported the case of a 63-year-old man who was 
poisoned and admitted to a hospital after he drank between 120 and 180 ml 
of a malathion preparation (50% malathion, 42.4% xylene, and 7.6% inert 
ingredients) diluted in milk. Although roughly equivalent to 60-90 g of 
malathion, the quantity actually absorbed was probably less, according to 
the authors, as the subject had vomited and gastric lavage had been 
performed on him. The patient, an epileptic for 20 years, had been treated 
for that disorder with diphenylhydantoin and primidone. Upon admission to 
the emergency room, he was reportedly comatose and dyspneic. His blood 
pressure and radial pulse could not be recorded, mucous membranes were 
cyanotic, eye movements were absent, his conjunctivae were injected, and he 
had pinpoint pupils which were unresponsive to light. A foul-smelling, 
thick, whitish secretion filled his mouth and pharynx. The heart was not 
enlarged as determined by percussion, but heart sounds were distant and 
muffled by bilateral coarse rales and ronchi. The patient's limbs were 
flaccid and unresponsive to painful stimuli; neither tendon nor pathologic 
reflexes were observed. Also absent were the oculocephallc and caloric 
stimulation reflexes, as well as muscle fasciculatlons. He was incontinent 
and vomited copious amounts of garlic-smelling fluid. Treatment was begun 
with cardiac massage, assisted respiration, frequent tracheobronchial 
suctioning, and administration of 2 mg of atropine sulfate.
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Electrocardiographic abnormalities (incomplete right bundle branch block, 
S-T depression) were found, as were further neurologic abnormalities. 
During his first hospital day, the patient received 22 mg of atropine 
sulfate and 3 g of pralidoxime chloride iv. Plasma ChE activity was 
reduced to 13% of normal on the first day and 4% on the second, while the 
erythrocyte ChE level was reduced to 7% of normal on the second and 3% on 
the third day. An injection of 1 g of pralidoxime chloride on the second 
day was purportedly responsible for a "temporary" 24% elevation of both 
erythrocyte and plasma ChE activities. At the time of the victim's death, 
6 days after exposure, no lasting recovery of plasma (erythrocyte not 
mentioned) ChE activity had been achieved, nor had the ECG abnormalities 
resolved. During the course of treatment, he had received 24.4 mg of 
atropine sulfate iv and 12.0 mg im, and 6 mg of pralidoxime chloride iv. 
Autopsy disclosed basal adhesive meningitis (believed to have been 
associated with his history of epilepsy), arteriosclerotic changes in the 
coronary arteries without evidence of myocardial infarction, ulceration of 
the pharynx and trachea because of endotracheal intubation, right lung 
bronchogenic carcinoma (with left lung, hilar, and paratracheal node 
metastases), telangiectases in the buccal mucosa and jejunum, granulomas of 
the spleen and liver because of old histoplasma infection, and status post 
posterior colic gastrojejunostomy. ChE activities were reduced to 32% of 
normal in the cerebrum, 3% in the cerebellum, 1% in muscle, 19% in the 
liver, and 13% in the kidney on post mortem determination.
Richards [45] described the case of a 46-year-old woman who was 
admitted to the hospital after drinking 50 ml of 50% malathion solution. 
She was cyanotic and had marked respiratory depression. Artificial
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ventilation was instituted, and a total of 790 mg of atropine administered 
in the first 6.5 days of treatment was followed by 60 mg more in the 2 days 
following. Five hours after the malathion ingestion, 1 g of 2-PAH was 
administered as well. The patient recovered, despite her moribund status 
on admission.
Two incidents of malathion poisoning in Sarawak, Malaysia, subsequent 
to deliberate ingestion were reported by Mathewson and Hardy. [46] The 
first was that of a 31-year-old woman who drank 56 ml of 57% malathion 
solution, an amount equivalent to 35 g of malathion. On admission to the 
hospital a half hour later, she was conscious and not cyanosed. Gastric 
lavage was performed, and atropine administration im was begun at a rate of 
1.8 mg every 10 minutes. One and one-half hours after admission, by which 
time she had received 18 mg of atropine, the patient showed cyanosis, 
sweating, profuse salivation, pinpoint pupils, and muscular fasciculation. 
The subject was placed on artifical respiration, and atropine 
administration was continued at the same dose but iv. The next morning, 
despite apparent improvement in her condition, with better muscle power, 
less constricted pupils, and adequate self-ventilation (permitting 
withdrawal of the respirator), she deteriorated within a half hour after 
the respirator was removed and had to be reintubated. Paraldehyde was 
administered (6 ml iv) to stop generalized convulsions, and atropinizatlon 
was still continued every 10 minutes. Tracheostomy was performed on the 3d 
hospital day, and on the 4th day the patient was able to breathe 
spontaneously for only 4-5 minutes every 2 hours. Peripheral muscle power 
was described as poor, although she could lift her hands off the bed. 
Atropine was continued, with the dosage adjusted according to her pupil
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size. Spontaneous breathing returned for gradually longer periods, but 
artificial respiration could not be completely withdrawn until the 19th 
day. A total of 589 mg of atropine was administered to the woman in 37 
days, mostly by iv or im routes during the first two weeks, and by stomach 
tube thereafter. She was discharged to a mental hospital 46 days after 
admission.
The second case [46] was that of a 16-year-old boy who drank 6 or 7 
tablespoonsful of 57% malathion solution, a dose of about 30 g of 
malathion. On admission to the hospital 1.5 hours later, he was cyanosed 
and incontinent, with shallow bubbling respiration and pinpoint pupils. He 
was placed on a respirator and given 1 g of pyridine aldoxime
ethanosulphate (P2S) iv. Atropine was given 2.5 mg in every 15 minutes.
Gastric lavage was performed. An additional gram of P2S was administered 
iv after 2.5 hours; artificial ventilation was discontinued after 4.5 
hours. Atropinization was continued, and the patient still had pinpoint 
pupils. Eight hours later, artificial respiration had to be resumed and 
1.2 g of P2S was administered in divided doses. A fall in blood pressure 3 
hours later required a 24-hour infusion of metaraminol during which time an 
additional 1 g dose of P2S was given. Not until the 19th hospital day 
could the use of the respirator be discontinued; thereafter, small doses of 
atropine were administered, to a total of 613 mg by day 24 after admission.
Goldman and Teitel [47] reported in 1958 that a 34-month-old child,
weighing 21 kg (unusually heavy for this age), consumed 8 cc of 50% 
malathion in xylene. He was immediately given a glass of milk, a hard- 
boiled egg, and milk of magnesia. Fifteen minutes after ingestion, the 
child became limp ar>̂  was taken to a physician, who noted muscle
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flaccidity, miosis, and drooling. Stomach lavage was performed and the 
odor of malathion was noted in the material removed. One hour and forty 
minutes after ingestion of the pesticide, the patient was admitted to the 
hospital emergency room, stuporous, retching, and with rapid, noisy 
respiration. Miosis, hypersalivation, and excessive mucus secretion were 
observed, as were moist rales and expiratory wheezes. The child's deep 
tendon reflexes were absent, but abdominal and cremasteric reflexes were 
present and equal, and both the gag reflex and the response to painful 
stimuli were present. Incontinence and vomiting occurred. Gastric lavage 
was again administered. The progressive increase In respiratory distress 
and slight cyanosis prompted administration of atropine (0.15 mg lv and 
0.15 mg subcutaneously) 1 hour after admission, although It was noted that 
spontaneous resolution of these signs had begun immediately prior to drug 
treatment. Two and one-half hours after admission, the child was 
conscious, alert, oriented, and in no respiratory distress. His lungs were 
clear, pupils in mid-miosis, and salivation was normal. Three hours after 
admission, respiratory distress again appeared, but without rales. It was 
felt that this episode was in part a reaction to the local irritating 
effect of the mixture of malathion and xylene. High humidity, created by 
use of a nebulizer, was used to alleviate this, and by the 5th hour after 
admission (6 hours, 40 minutes after Ingestion), the child was asymptomatic 
and without clinical signs of intoxication.
These case reports [19,20,25,39,40,44-47] are consistent with the 
signs and symptoms attributable to the inhibition of AChE. The authors of 
these papers concluded, therefore, that malathion produces its acute toxic 
effects by this means; NIOSH concurs in this opinion.
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The major signs and symptoms of malathion poisoning are attributable 
to the potentiation of responses to the ACh released from preganglionic and 
postganglionic cholinergic and somatic motor nerve endings whenever nerve 
volleys reach the periphery. In milder cases, the postganglionic
stimulation may predominate. As listed in the case reports described 
above, these signs and symptoms include nausea, [19,20,27] vomiting, 
[19,20,25] diarrhea, [19,25,39] excessive sweating, [19,20,23,27] 
salivation, [19,20,23-25,27] miosis, [20,23-25,27,39] increased bronchial 
secretion, [19,20,24,25,27,39] bronchial constriction, [20,24,27] and the 
appearance of generalized muscular fasciculations followed by weakness.
[19.20.23.24.27.39] Central nervous system effects include anxiety, [20] 
restlessness, [19,24] headache [27] and, in more serious cases, tremors,
[19.20.39] confusion, [19] drowsiness, [19,20] slurred speech, [19] coma, 
[20,23,25,27,39,40] loss of reflexes, [19,20,24,25,27,39,40] and 
convulsions. [24,40]
The full range of manifestations of ChE inhibition is given in Table
III-2.
Nalin's [50] classification of the clinical status of a series of 264
people who Ingested malathion with suicidal intent is exceptionally
complete. He found that severity of illness could be classified as mild 
(56%), moderate (14%), or severe (30%) based on the clinical criteria 
tabulated in Appendix VI. Patients with mild cases frequently had about 
them the characteristic pungent odor of malathion. Nausea, vomiting, and 
dizziness were common.
Moderately ill patients [50] had a strong odor of malathion, 
which was present in the milky gastric aspirate. They had sialorrhea with
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TABLE III-2













(2) Nicotinic manifestations 
(a) Striated muscle
Signs or Symptoms
Anorexia, nausea, vomiting, 
abdominal cramps, diarrhea, 
tenesmus, involuntary defe­
cation, eructation, "heartburn," 




Bradycardia, fall in blood 
pressure
Sensation of tightness in chest, 
wheezing suggestive of broncho- 
constriction, dyspnea, cough, 
increased bronchial secretion, 
pulmonary edema
Pinpoint (miosis) and non­
reactive to light
Blurring of vision
Increased frequency of and 
involuntary urination
Muscular twitching, fasci­
culation, cramping, weakness 




SIGNS AND SYMPTOMS ASSOCIATED WITH ACUTE AND SUBACUTE EXPOSURES
TO MALATHION
Effector Organ Signs or Symptoms
(b) Sympathetic ganglia Pallor, tachycardia, elevation 
of blood pressure
(c) Adrenals Elevation of blood pressure, 
elevation of blood glucose
(3) CNS manifestations
Uneasiness, restlessness, 
anxiety, tremulousness, tension, 
apathy, giddiness, withdrawal 
and depression, headache, 
sensation of "floating,"
Insomnia with excessive dreaming 
(nightmares), ataxia, slurred and 
slow speech with repetition,
drowsiness, difficulty in con­
centrating, confusion, emotional 
lability, coma with absence of 
reflexes, Cheyne-Stokes respi­
rations, convulsions, hyper­
pyrexia, depression of respiratory 
and circulatory centers (with 
hypopnea or apnea and fall in blood 
pressure)
Derived from Grob et al [48] and Namba et al [49]
"foaming at the mouth," bronchospasm and bronchorrhea with rales or
rhonchi, sweating, tearing, tachycardia, and sometimes mild stupor. Pupils
were pinpoint except in a few milder cases. In 30% of the patients,
transient glycosuria, as determined by reaction with glucose oxidase 
strips, was found. Three of sixteen of these patients had elevated
concentrations of glucose In their blood. Blood urea concentrations
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remained normal, but lactic dehydrogenase activities were elevated in the 
seven moderately ill patients tested. Serum calcium was determined in only 
seven cases and was not found to be elevated. Hematocrits were normal, but 
the white blood counts were reported to be acutely high. Specific values 
were not reported for these determinations.
Severely ill patients [50] had all of the above symptoms and signs, 
as well as hypotension, coma, cyanosis, areflexia, and sometimes
convulsions, fasdculations, involuntary defecation, and Cheyne-Stokes 
respiration. Death occurred in 80% of the severely intoxicated patients 
despite intensive therapy. Nine of the severely ill patients had elevated 
blood pressures (mean, 170/110). Seven of these nine cases (four of them 
fatal) were females. Twitching of the eyelids, ankle clonus, muscle 
spasms, and acroparesthesias were occasionally noted.
Respiratory insufficiency was the cause of death in most reported 
cases of fatal malathion poisoning. [25] This terminal event was a 
consequence of one or more of the following: bronchial hypersecretion,
weakness or paralysis of the intercostal muscles and diaphragm, and
depression of the respiratory centers of the brain. [51]
The time of onset of signs and symptoms of poisoning after malathion
exposure has varied from a few minutes [20,39,52] to several hours, [19] 
and to as long as 14 hours in the case of a child poisoned by the 
application of a 50% malathion-xylene halrwash solution. [27]
Hyperglycemia and glycosuria have been reported by three authors in 
connection with six patients with malathion poisoning, [25,27,40] although 
the pathophysiologic significance of this occurrence is unknown. Reports 
on three of these six patients noted the absence of acetone in the urine.
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No comment on this finding was made in the other two cases. One case of 
glycosuria without hyperglycemia has been reported. [40] In one near-fatal 
accidental ingestion of malathion, the blood sugar was normal, and only a 
small amount of sugar was found in the urine. [19] Nalin [50] found 
transient glycosuria in 30% of the moderately ill cases. Five other 
reports of malathion intoxication [20,23,24,45,53] did not mention blood or 
urine glucose determinations. The degree of elevation of blood sugar that 
occurs in some cases of acute malathion poisoning has been shown to be much 
less than the levels associated with diabetic coma. [25]
Trinh Van Bao et al [54] conducted a study of 14 patients admitted to 
the hospital for malathion intoxication from either vocational exposure or 
attempted suicide. Blood samples were taken from all 14 patients within 3- 
6 days and thereafter at approximately 30 and 180 days from 12 of the 
group, one having died and another having declined to participate further 
in the study. Lymphocyte cultures were examined for chromosomal 
abnormalities and compared with those from 13 male and 2 female healthy 
unexposed controls. Stable chromosomal aberrations (ie, those containing 
deletions, translocations, and inversions) increased significantly 
immediately after intoxication, remained at a high level after 1 month, but
i.
returned to levels comparable with those seen in the controls after 6 
months. The incidence of stable aberrations was not correlated with the 
dose of malathion. Of the patients examined, all were treated with 
atropine, and 9 (8 of the 12 completing the study) of the 14 also received 
Toxogonin (bls(4-hydroxyimino methylpyridinium(l)methyl)ether dichloride). 
The authors commented that they had not observed chromosomal damage in 
patients not poisoned by malathion but "treated with atropine shock." They
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had no information to enable them to allow for the possible effects by 
Toxogonin, solvents, or vehicles involved in the poisoning and treatment on 
chromosomal structure.
Czeizel (unpublished manuscript) reported further data on the same 14 
patients studied by Trinh Van Bao et al. [54] The malathion implicated in 
these studies was manufactured in Czechoslovakia. "Peripheral blood"
samples, as cited by Trinh Van Bao et al, [54] revealed an "outstandingly
high number of structural chromosome aberrations." The results of
undefined animal experiments with malathion dissolved in cooking oil showed 
a higher frequency of break-isobreaks and deletions in bone marrow cells 
after 24 and 48 hours of treatment, and a higher occurrence of XY 
univalents and translocations in testicular tissue. This unpublished 
manuscript stated no doses, no correlation of the frequency of 
abnormalities with dose, and no numbers or types of experimental animals 
involved. In the absence of significant experimental details, such as dose 
and number of animals, and of Independent confirmation in other
laboratories, the significance of these unpublished observations for the 
human population is unknown. To this time, no human reproductive effects 
attributable to malathion seem to have been reported.
Mattson and Sedlak [55] measured the ether-extractable phosphates in 
the urine of an adult man who had been administered malathion in a single 
oral dose of 58 mg (0.84 mg/kg). A total of 23% of the Ingested dose was 
recovered in the ether-extractable, urinary phosphate fraction of the urine 
during the first 16.3 hours. Ninety-seven percent of this recovered dose 
was excreted in the first 7.5 hours. A smaller dose of 11 mg (0.16 mg/kg) 
gave a similar excretion pattern. Based on experiments in rats injected ip
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or fed 32P-labeled malathlon, the authors [55] found an average of 69 and 
36%, respectively, of the malathion excreted in the urine to be recoverable 
In the ether-extractable fraction.
Moeller and Rider [21] fed 10 healthy men daily doses of malathion 
dissolved in corn oil to determine the amount of malathion which can be 
Ingested over an extended period of time without causing ChE activity 
depression. Five subjects each received 16 mg/day of malathion for 47 
days, and five were given 24 mg/day for 56 days. Control ChE activities 
for these same subjects were determined twice weekly for 2 weeks preceding 
the experiment. The observed decrease in ChE activity reached a maximum 3 
weeks after discontinuation of administration of malathion. Both 
erythrocyte and plasma ChE activities rebounded to normal quite rapidly 
thereafter, erythrocyte ChE reaching the baseline value and plasma ChE 
leveling off at about 93% of baseline within 10 days. The erythrocyte ChE 
overshot the baseline value during the month following a 20-day postdose 
observation period, whereas the plasma ChE remained at 90-95% of baseline 
during this period. It is possible that some reservoir of malathion or 
some persistent effect of malathion on AChE and BuChE was exhausted about 
21 days after the cessation of dally doses.
Studies of humans exposed to malathion aerosols were reported by 
Golz. [56] For 42 consecutive days, three groups of four men each received 
a total of 84 1-hour exposures to malathion aerosols sprayed once into 
exposure-room air at calculated initial concentrations of 5.3, 21.2, or
84.8 mg/cu m. Since the aerosol concentrations represented a static 
exposure which must have declined rapidly, the actual dose received by each 
subject cannot be calculated. No significant decrease of ChE activity in
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either plasma or erythrocytes was noted, nor were any cholinergic signs or 
symptoms found at any time during the study.
In 1960, Mattson and Sedlak [55] described a chemical method to 
measure exposure to malathion, which entailed the study of the urinary 
excretion of malathion-derived materials in humans. The method was 
developed using laboratory animals. In the first experiment conducted, one 
male and one female rat were given 100 mg/kg of 32P-labeled malathion 
intraperitoneally (ip) dally for 5 consecutive days, and one male and one 
female rat were given peanut oil only by the same route. A device which 
separated urine and feces was used, and both were collected for each 
24-hour period. This separation, however, did not rule out the possibility 
of cross-contamination. The urine was first assayed for the total amount 
of radioactive materials present. The percentage of dose recovered ranged 
from 20 to 73 (average 46Z) for the 5-day period. The authors [55] noted 
that, as no extraordinary attempt was made to obtain quantitative recovery 
of all the urine, some of the variation in percentage recovery might have 
been due to collection losses. They reported that assay for total 
malathion metabolites established the presence of large amounts of these in 
the rat urine. Samples at 48, 72, and 96 hours after cessation of
ttreatment showed a rapid decline in the amount of metabolites recovered, 
although it was still measurable after 96 hours.
The acidified urine was extracted with carbon tetrachloride followed 
by ether. [55] The extracted urine was analyzed colorimetrically by both 
the procedure of Fiske and Subbarrow [57] and the Chen et al modification 
[58] of the Ammon and Hinsberg method, [59] with the latter method 
determined to be four times as sensitive as the former. The urinary
metabolites were calculated In terms of malathlon.
Ether extracted 13-43% of the dally dosage from acidified urine for 
the treatment period. This represented 47-78% (average 66%) of the total 
malathion-derived material excreted in the urine. Using this extremely 
sensitive method, ether-soluble, malathion-derived materials were also 
found to be excreted up to at least 96 hours after cessation of treatment.
The dose was next reduced to 25 mg/kg, with the other experimental 
parameters maintained the same. Urinary excretion of the total daily 
intake ranged from 37 to 47% (average 42%), and daily urine samples taken 
at 24-hour intervals after treatment showed amounts of malathion-derived 
material detectable by radioassay. Ether-eXtractable materials ranged from 
38 to 75% of the total dally intake, averaging 69%, which the authors [55] 
concluded was within the same range (average 66%) as for the higher level 
of intake. The authors deemed the amounts of ether-extractable urinary 
phosphates to be almost directly proportional to the dose of malathlon at 
both doses used.
Malathlon labeled with 32P administered orally to male and female
rats at a dose of 100 mg/kg was excreted to the extent of 24 and 48%,
respectively, in the urine, of which 31 and 36%, respectively, was ether- 
soluble. [55]
According to the authors, [55] colorimetric determination of 
phosphates in the ether-soluble materials gave good correlation with the 
radioassay. Ether extracts from the urine of control animals were reported 
to show no detectable amounts of organic phosphate.
The same method [55] was applied to human urine obtained from a man
who ingested 58 mg of technical malathlon (0.84 mg/kg). This dose was
43
below that capable of causing any detectable ChE inhibition. Preexposure 
urine samples showed no detectable amounts of ether-extractable phosphates. 
The amount of ether-extractable phosphates was seen by the authors [55] to 
rise quickly after dosage and then decrease to the predosage level. A 
total of 23% of the dose was recovered after 16.5 hours and 97% of this was 
excreted in the first 7.5 hours. The rate In mg/hour was greatest in the 
sample taken 1.3-3 hours after ingestion. A smaller dose of 11 mg of 
malathlon (0.15 mg/kg) gave a similar result so far as the percentage 
recovered was concerned. However, metabolites could be detected for a 
shorter time after Ingestion of the smaller dose of malathlon, even though 
the more sensitive method for detection was used.
Application [55] of malathlon In a talc dust to the skin of a man 
resulted in the appearance of ether-extractable phosphatic materials in the 
urine. One hundred milligrams of malathlon as a 1% dust was applied for 14 
hours; 1% of the dose was recovered during this period. It was reported 
that with higher amounts of malathlon the percentage recovery of 
metabolites from the urine was of the same order. No ChE inhibition was 
detected.
Using the method described by Mattson and Sedlak, [55] Hayes et al
[32] studied the urinary excretion of malathion-derlved material after
dermal application of various doses on human volunteers, as well as the 
effect of these applications on blood ChE activity. The malathlon (minimum 
95% purity) was formulated in talc at concentrations of 0, 1, 5, and 10%. 
Each volunteer was issued 90 g of powder 5 days/week for up to 16 weeks. 
After showering and contributing a blood sample if necessary, each
volunteer dusted his entire body except head, neck, and genitalia with
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powder. This required only 25-30 g, and the rest was sifted Into the 
clothing. Hands and forearms were washed Immediately after dusting. Prior 
to and after the experiment, physical examinations were conducted. Blood 
ChE activity was measured by the Nelson procedure [60] several days each 
week for the first few weeks, and weekly thereafter. Urine samples were 
collected In a hospital during an approximate 6-hour period every 6th 
night, both volume and sampling duration being recorded.
The Initial review of symptoms [32] indicated no complaints resulting 
from significant illness and no increased prevalence of symptoms in one 
group. Only two complaints, burning of the skin and visible dermatitis, 
were noted during the course of the experiment. Results of the 
bromsulphalein test remained normal (less than 10% retention) throughout 
the course of the experiment.
A Student's t-test showed that erythrocyte ChE activity values 
determined [32] on paired samples by the methods of Nelson [60] and Michel 
[61] could not be distinguished. The experimental design did not allow 
prediction of either the minimum dose necessary to produce a statistically 
significant inhibition of AChE activity or the dosage necessary to produce 
clinical symptoms of intoxication.
The highest rate of malathlon excretion [32] was 9.57 mg/hour, and 
the highest concentration of ether-extractable phosphate was 107 ppm 
calculated as malathion. The coefficient of correlation between body 
surface and the excretion of malathion-derived material ranged from 0.43 to 
0.64 for the groups receiving 5 and 10% malathlon; no correlation was found 
in the 1% group.
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The mean malathlon excretion rate [32] was 0.30 ± 0.19 mg/hour for 1% 
dusting powder, 1.74 ± 1.65 mg/hour for 5%, and 1.99 ± 1.25 mg/hour for 10% 
powder. Given 28 g as the amount of dusting powder actually applied, the 
formulations made available 0.28-2.8 g of malathlon. Mean minimum amounts 
of 7.8, 41.76, and 48 mg/day, respectively, of the malathlon In the 1, 5,
and 10% formulations, were excreted as measured ether-extractable material. 
As shown by Mattson and Sedlak, [55] these figures are in the order of one- 
third lower than the actual excretion rate because of the extraction of 
only a part of the malathlon and Its metabolites. Only with the 10% 
malathlon dust was there any evidence of possible depression of ChE, 
suggesting that the human body can be safely exposed to up to 2.8 g of 
malathlon in talc powder/day applied to the skin. This is equal to an 
absorbed dose of 40 mg/kg for a standard 70-kg man.
Mammalian tissues effectively detoxify malathlon. [62,63] An enzyme 
which hydrolytically cleaves one ethyl alcohol moiety from malathlon has 
been partially purified from human liver specimens by Main and Braid. [62] 
In addition to malathlon, the enzyme preparation (termed aliesterase) was 
found to hydrolyze several aliphatic and aromatic esters. The half-maximal 
velocity (Km) of the enzyme was estimated to be 48 i M . The ma^lminn 
capacity of human liver homogenates to degrade malathlon was estimated to 
be 7.9 ¡ M / g  of liver/minute. Since only 1 mole of a titratable acid was 
released for each mole of malathlon, the authors concluded that the 
reaction product was malathlon monoacid. Since neither malathlon monoacid 
nor malaoxon monoacid is a ChE inhibitor, the catalytic detoxification of 
malathlon by aliesterase is an important aspect of mammalian resistance to 
malathion-induced intoxication. Because most other commercial
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organophosphates do not contain a carboxy ester as a functional group, they 
are not substrates for allesterase and are not detoxified by this 
mechanism. This fact probably contributes to the relatively low order of 
toxicity of malathlon for mammals In comparison with that of other 
organophosphates. [64]
Matsumura and Ward [63] investigated the in vitro degradation of 
malathlon by fresh human liver samples. Tissue samples from livers frozen 
no later than 16 hours post mortem were homogenized in Kronecker's saline 
solution at a concentration of 20 mg of tissue/ml. Aliquots of 1 ml of 
homogenate were incubated with 0.00001 M malathlon for 1 hour. Unreacted 
malathlon and soluble metabolites were extracted twice from the aqueous 
fraction with an equal volume of chloroform. The combined solvent phase 
was reextracted with sodium phosphate buffer. The aqueous phase was washed 
with chloroform. All solvent phases were combined, dried over sodium 
sulfate, and analyzed by thin layer chromatography. The results were given 
by the authors In terms of percentage of substrate added. The authors [63] 
stated that the accuracy of recovery of their procedure was 96.7 ± 8.5%.
Six samples of human liver homogenate tested [63] hydrolyzed 99.57, 
95.28, 98.45, 98.44, 97.94, and 98.53% of the added malathlon. Of the 
hydrolysis products, 3.97-5.71% appeared as desmethyl malathlon, 0.07-1.23% 
as diethyl mercaptosuccinate, 0.08-0.48% as diethyl malate, 85.51-90.76% as 
carboxyesterase products, and 0.09-7.38% as "others." Although the data 
suggested that malathlon is efficiently detoxified by humans through the 
action of the carboxyesterase. Walker et al [65] found that in the human 
liver, this same carboxyesterase is beta-aliesterase. [64,66] Although the 
results of the Matsumura and Ward in vitro study [63] reinforce the
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knowledge that carboxyesterase activity is of prime Importance in the
detoxification of malathlon In humans, they cannot be taken as an absolute 
indication of the proportions of metabolites to be expected in vivo.
Milby and Epstein [67] studied the contact-sensitizing effect of 
malathion on skin under both experimental and field conditions. The 
experimental study utilized 87 healthy male volunteers divided into four 
groups. The first group was exposed for 2 days to 10Z malathion in ethanol 
on a skin site previously irritated by a 3-second freeze with 
dichlorodlfluoromethane (Freon 12). There were no controls for the first 
group. Group 2 was exposed to the 10% malathion solution applied to a 
nonirritated site. Groups 3 and 4 received the Freon 12 irritation and
were then exposed to 1.0 and 0.1% solutions of malathion in ethanol, 
respectively. All applications were made under occlusive dressings. After 
30 days, all subjects were retested at a new site with a nonirritating dose 
of malathion (1% in ethanol). The areas were graded after 2, 4, and 6 days 
for intensity of cutaneous response (1+, erythema and edema, to 4+, 
bullae). Ten percent malathion was found to induce contact sensitization 
readily and the reactions were marked. To further examine the degree of 
sensitization, five highly malathion-sensitlve subjects were tested with 
weak solutions of malathion in acetone and in water. A 1:10*6 (* means to 
the power of) concentration in acetone evoked 4+ reactions, and a 
commercial product consisting of 0.9% malathion in water with an
unidentified suspending agent evoked positive responses as well. The field
study comprised two occupationally exposed groups, the first composed of 
157 sprayers, mechanics, and supervisors from mosquito abatement districts 
(93% of the total work population of those districts), and the second of 43
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poultry-rancher volunteers (10% of the area's ranchers) who had used 
malathion for at least one season during the past 3 years. Each subject 
was Interviewed for history of past or present asthma, hay fever, allergy, 
skin disease, and systemic poisoning by pesticides. Records were made of 
each individual's exposure to malathion and other organophosphate 
pesticides. Exposure was quantified according to the total years of 
malathion use and an estimate of the number of times it was used. The 
subjects then were tested with an emulsion of 1% malathion in distilled
water applied on a cloth pledget under adhesive tape to the skin of the
\
upper arm for 2 days. Three days later, the reaction was observed and 
graded. Four of the 157 workers in the first group (3%) showed positive 
reactions. They were all considered heavily affected by the grader. Three 
of the four had previous histories of undiagnosed skin eruptions. The 
greatest number of sensitized individuals was found in a district which 
exclusively employed No. 2 diesel oil as the spray vehicle. The authors 
speculated that the properties of the oil may have contributed to the 
apparent skin sensitization. Two of the 43 poultry ranchers had positive 
reactions (5%). While these reactors had not been as heavily exposed as 
the mosquito abatement reactors, they also had histories of unexplained 
dermatitis. The results of these studies indicate that malathion may act 
as a contact skin sensitizer in humans, and that clinically significant 
dermatitis may occur under conditions of heavy field use. A chi-square 
test associating patch-test reactivity and history of dermatitis in 
mosquito abatement district workers was significant at the 5% level.
Several investigators have studied the exposure of workers to mala­
thion in agricultural pest and vector control operations. [35-37,68,69]
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These measurements of respiratory and skin exposure were undertaken to 
determine the margin of safety between exposure dose and estimated toxic 
dose. ChE activities, where determined, verified the absence of 
significant depression as a consequence of exposure to occupational field- 
encountered concentrations of malathion. These reports are described in 
Chapter IV.
Epidemiologic Studies
Only two epidemiologic reports on the effects of occupational 
exposure to malathion were found. Grech [69] examined alterations of the 
activities of serum BuChE, SGOT, SGPT, and serum aldolase, and the 
concentration of serum albumin in 12 agricultural workers exposed to 
malathion over a period of 6 months. Two groups of controls were used, 
consisting of 30 blood samples each, the first from randomly selected 
healthy blood donors and the second from healthy blood donors engaged in 
manual labor. The mean BuChE activity of the agricultural workers at the 
end of the exposure period was not significantly different from that of 
either group of controls. However, the author [69] stated that the enzyme 
activity of any single subject changed significantly after exposure. A 
reduction in BuChE activity was noted in 11 of 12 agricultural workers, and 
6 showed a sustained fall until the end of the study. Two showed slight 
increases over their preexposure activities at the end. Both SGOT and SGPT 
were found to be without significant difference between the two groups of 
controls, or between the mean values of the agricultural workers and those 
of the controls. The largest percent changes in the mean values of the 
agricultural workers during exposure to malathion were decreases in the
50
activities of serum aldolase, SGOT, and SGPT, with that of BuChE changing 
the least of the four serum enzymes studied. No significant differences 
were observed in serum albumin concentrations. This study indicates that 
BuChE depression secondary to malathion exposure under field conditions 
does occur.
In 1968, the New Jersey State Department of Health [70]
studied the medical records of 35 malathion- and/or Thiophos- (parathion- ) 
manufacturing employees, 11 of whom had been employed in this capacity for 
15 years or more. Medical examinations by the company had been done on a 
preemployment basis, and at 1-1.5 yearly Intervals thereafter. The
Department of Health reviewed the medical records of 16 employees who had 
averaged 15.5 years of work in the organophosphate-production facilities. 
Eleven of these men had been exposed primarily to malathion, with sporadic 
exposure to the organophosphates Abate, Zinophos, and parathion. After 
carefully reviewing and analyzing the company medical records, the 
Department of Health concluded that the 16 men were suffering no adverse 
chronic health effects from exposure to the materials used in the
• jmanufacture of the organophosphates. Beginning in March 1953, monthly ChE 
testing was done on workers in the manufacturing unit, which had begun
operation In 1951. All employees were required to wear protective 
coveralls, helmets, and boots upon entering the work area, as well as 
rubber gloves and respirators when in the work area or engaged in 
manufacturing operations. Accidental splash exposures occurred in two of 
the long-term workers: one because of a leak (following which the employee
showered and changed, but developed headache, nausea, and redness and
itching of the arms and chest); the other by malathion being sprayed on the
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face (no symptoms developed). ChE activities measured 33 and 34 days 
later, respectively, were within normal limits (erythrocyte 0.93 delta pH, 
plasma 1.1 delta pH in the first worker; bromthymol blue test, 90-100% 
activity in the second).
Animal Toxicity
Malathion is absorbed through the intestinal tract, [10,33] the skin, 
[10,33,71] and the respiratory tract. [33] Following absorption, it is 
transported via the circulatory system to the liver, where it is 
metabolized in part to products which are not inhibitors of ChE [72] and in 
part to its oxygen analog, malaoxon, a potent ChE inhibitor. [73] In the 
liver, both malathion and malaoxon are rapidly hydrolyzed, and thus 
detoxified, by an esterase enzyme system, [73,74] which itself is inhibited 
to some extent by malaoxon. [73,74] Hydrolysis of malathion is not 
restricted to the liver but occurs also in human brain, where two highly 
active esterases, two moderately active ones, and six others of lesser 
activity have been separated electrophoretically by Sakai and Matsumura. 
[75] This rapid enzymatic hydrolysis accounts for the low toxicity of 
malathion [76] to mammals as compared with insects, which have relatively 
less Capacity to hydrolyze malathion. [77] The metabolites of malathion 
are listed in Table XV-4. Compounds such as EPN which inhibit this system 
of enzymatic hydrolysis tend to enhance the toxicity of malathion. [78-80] 
Compounds which induce the enzymes tend to decrease malathion's toxicity. 
[6 6]
After formation in the lungs, kidneys, liver, and other organs, 
malaoxon is transported via the circulatory system to the nervous system
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and to muscle, where It sets In motion the following sequence of events: 
inhibition of ChE activity at synapses and motor endplates; accumulation of 
ACh at these sites; and the appearance of signs and symptoms of ChE 
inhibition or ACh poisoning. [64] The biochemical mechanism by which 
malaoxon Inhibits the enzyme ChE involves phosphorylation of the active 
site of the enzyme. The phosphorylated enzyme is incapable of hydrolyzing 
ACh. [64] In time, spontaneous reactivation of the enzyme occurs or the 
inhibited enzyme "ages," becoming nonsusceptlble to reactivation by 2-PAM 
and other oximes. [81]
The signs of acute intoxication which appear in animals poisoned with 
these agents are similar to those which occur in humans. These are listed 
in Table III-2. [82] Other manifestations of malathion toxicity which are 
unrelated to ChE inhibition are discussed later in this chapter.
The LD50's for rats, mice, and guinea pigs by various routes of 
exposure are given in Table XV-5.
The sex difference in susceptibility to the effects of malathion is 
generally confined to rodents. Sex differences in toxicity have been found 
for most organophosphorus pesticides. In a study [78] of the inhibition of 
the ChE's of the blood by malathion, the authors observed that larger doses 
were required to produce given Inhibition of the enzymes in the male than 
in the female because of the male's higher rate of metabolism of malathion 
by oxidative microsomal enzymes. [79] Species differences have been 
investigated and attributed to differences in rates of detoxification by 
hydrolytic enzymes.
Golz [33] reported Hazleton's results on the acute iv toxicity of 
malathion in dogs. A dose of 100 mg/kg had no apparent effect, while 200
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mg/kg produced severe signs and marked ChE inhibition and 250 mg/kg was 
lethal. No details of the purity of the malathlon or of the ages, sexes, 
or numbers of dogs used were provided, nor was there any clarification of 
the observed signs.
The subchronic toxicity of malathlon In rodents also has been 
investigated. Ten male and ten female rats [33] were given 90% technical 
malathlon at a concentration of 5,000 ppm in the diet for 4-6 weeks. The
average daily intake was 62 mg/kg for the male rats and 68 mg/kg for the
females. All animals survived until killed after the 4th, 5th, or 6th week 
of feeding. No signs of adverse effects and no physical or behavioral 
changes were noted. ChE activity determinations were made on brain, 
plasma, and erythrocytes. Essentially all tests showed ChE inhibition of 
at least 50%, presumably compared with control animals although this was 
not stated. Also unspecified were the sex distribution and distribution 
relative to week of killing for the five animals showing 100% erythrocyte 
ChE inhibition. In another study, [33] an unspecified number of rats of 
unstated age and sex were fed 90% technical malathlon at 5,000 ppm in the 
diet (77.9 mg/kg/day) for 63 weeks. At termination, the exposed animals 
weighed 12% less than the controls. ChE activity was not determined. The
author reported that no other effects were detected. Another group of six
rats of unspecified age and sex was given 99% malathlon at 20,000 ppm in 
the diet (275 mg/kg/day) for 68-70 weeks. Four of the animals died before 
the conclusion of the experiment; the two survivors weighed 36% less than 
the control rats.
Clyne and Shaffer [17] reported the results of 2-year feeding studies 
of technical grades of malathlon (90% technical and 99+% technical, both as
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25% wettable powder formulations) in male and female albino rats. 
Survival, effects on food intake and growth, and degrees of plasma, 
erythrocyte, and brain ChE inhibition determined when the animals were 
killed were measured for comparison with control group values. The 90% 
technical grade malathion was administered at concentrations of 100 ppm (6 
mg/kg of malathion) to 20 males, of 1,000 ppm to 20 males and 10 females 
(60 mg/kg and 80 mg/kg, respectively), and of 5,000 ppm (350 mg/kg) to 20 
males. The control group comprised 20 males and 10 females. Of the 
controls, 10/20 males and 5/10 females were alive after 2 years. Survival 
rates in the 100-, 1,000-, and 5,000-ppm groups were: 15/20 males, 11/20
males and 8/10 females, and 14/20 males, respectively. No effects on food 
Intake or growth were reported below the 5,000-ppm concentration; at that 
level, a retardation of growth was observed. Plasma, erythrocyte, and 
brain ChE activities were depressed 10-30% in the 100-ppm group. The 
1,000-ppm males showed 10-30% plasma, 60-95% erythrocyte, and 10-30% brain 
ChE inhibition, while the females in this group showed no plasma
inhibitions, but otherwise were the same as the males. Inhibition of 60-
95% in both plasma and brain ChE's and total inhibition of erythrocyte ChE
were found in the 5,000-ppm males.
The 99+% technical grade malathion [17] was administered at
concentrations of 500 ppm to four male and four female rats (30 and 40 
mg/kg, respectively), of 1,000 ppm to four males and four females (60 and 
80 mg/kg, respectively), of 5,000 ppm to three males and four females (380 
mg/kg for both sexes), and of 20,000 ppm to three males and three females 
(720 and 1,800 mg/kg, respectively). Survivals after 2 years for these 
groups were 2/4 males and 3/4 females at 500 ppm, 2/4 males and 1/4 females
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at 1,000 ppm, 3/3 males and 3/4 females at 5,000 ppm, and 0/3 males and 2/3 
females at 20,000 ppm (all males having died within 20 days at this level). 
No effects on food Intake or growth were noted In males at 500 ppm, or in 
either males or females at 1,000 ppm. No results for the 500-ppm females 
were given. At doses of 5,000 ppm, both males and females exhibited 
reduced food intakes, and growth in males was retarded. Because of the 
early death of the 20,000-ppm males, only data for reduction of food intake 
and retardation of growth for the females were given. No inhibition of 
plasma or brain ChE was noted, but erythrocyte ChE was inhibited by 60-95% 
in both sexes at the 500-ppm concentration. At 1,000 ppm, no inhibition of 
plasma ChE, 60-95% inhibition of erythrocyte ChE in males and complete 
inhibition in females, and 30-60% inhibition of brain ChE in males and 10- 
30% in females were reported. ChE inhibitions at 5,000 ppm were 10-30% in 
plasma and 100% in erythrocytes of both sexes; brain ChE was inhibited 30- 
60% in males and 10-30% in females. In the surviving female fed 20,000 
ppm, both plasma and brain ChE activities were inhibited by 60-95% and 
erythrocyte ChE by 100%. Gross and microscopic tissue examinations 
reportedly revealed no anatomic lesions attributable to the action of 
malathion. [17]
The experimental results of Fogelman on the effects of chronic 
feeding of malathion to rats were submitted to NIOSH (CB Shaffer, written 
communication, March 1976). Groups of three or four weanling albino rats 
(Carworth Farm strain) of each sex were fed diets containing 500, 1,000, or
5,000 ppm of 99% malathion for up to 104 weeks. In a parallel experiment 
with 90% malathion, 20 male rats and up to 10 female rats by group were fed 
0, 100, 1,000, or 5,000 ppm of malathion for up to 104 weeks. At autopsy,
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tissues from the liver, kidney, adrenal, spleen, large Intestine, small 
Intestine, brain, lung, bladder, and for females from the uterus, were 
examined microscopically from six animals of each group. Although no
evidence of neoplasia was reported, the number of animals used was
insufficient to allow a firm conclusion with respect to the induction of
cancer by malathlon in either this or any other species.
Using 32P-malathlon, Mattson and Sedlak [55] measured the urinary 
excretion of all 32P-containlng metabolites from one male and one female 
rat that had been Injected ip with 100 mg/kg of the material. The total 
number of rats in each group and sex distribution were not specified.
During the 24 hours after each of the five dally injections, the rats
excreted a mean of 46% of the dally dose. After the end of daily dosing,
the excretion rate fell rapidly but was still measurable after 96 hours. 
Male and female rats given 100-mg/kg oral doses of 32P-malathion excreted 
totals of 24 and 48%, respectively, in their urine. One male and one 
female rat Injected ip with 25 mg/kg of 32P-malathion on each of 5
consecutive days excreted a mean of 42% of the injected dose during each
24-hour period following a dose. [55] The male excreted an average of 45% 
and the female 38%. After the daily injections were stopped, the label was 
detected in the urine for up to 5 days; between 24 and 120 hours after the 
last dose, the male excreted 1.5% of the dally dose and the female 5.1%. 
In the urine obtained after ip injections of 32P-labeled malathlon, an 
average of 68% of the radioactivity was extracted from the urine by diethyl 
ether, whereas only 34% was similarly extractable after oral
administration. Although a device was used to separate the urine and feces 
during collection, the authors [55] admitted that some cross-contamination
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may have occurred. Fecal excretion of 32P-labeled material was not 
measured.
Hazleton and Holland [10] reported the results of inhalation studies 
on rats, guinea pigs, mice, rabbits, and dogs. Unspecified numbers of rats 
and guinea pigs were exposed to air bubbled through 90% technical malathlon 
at 30 C, 8 hours/day, 5 days/week, for 2 weeks. No fatalities, no signs 
suggestive of ChE toxicity, and no significant lowering of ChE activity 
were observed. The estimations of ChE activity were made by an unspecified 
electrometric method, and the chamber concentration of malathlon was not 
measured. Mice, rats, guinea pigs, and rabbits (numbers unspecified) were 
exposed to an aerosol of 90% malathlon at a concentration of approximately 
60 ppm for 6 hours/day for 2 days. The only responses noted were sneezing 
and rhinorrhea. Erythrocyte, plasma, and brain ChE activities were 
observed to be within normal limits for rats and guinea pigs, but they were 
not reported for mice and rabbits. Rats, guinea pigs, and a dog were 
exposed for 7 hours/day, 5 days/week, for 4 weeks to aerosolized malathlon 
at a concentration of 5 ppm. The dog and guinea pigs lacrimated, but no 
tremors, salivation, or other signs of intoxication by organophosphate 
compounds were seen. No significant reduction in the ChE activities of 
plasma, brain, or erythrocytes were found, and no gross pathologic changes 
were detected at necropsy. Microscopic examination disclosed thickening 
and leukocytic infiltration of the lntraalveolar septa.
Rats, guinea pigs, and dogs [10] exposed for 7 hours/day, 5 
day8/week, for 6 weeks to an aerosol containing dust equivalent to 5 ppm of 
malathlon showed no gross evidence of toxicity. Moderate inhibition of 
plasma, erythrocyte, and brain ChE's were noted In the rats. The guinea
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pigs had no significant Inhibition of these ChE activities; one of two dogs 
had slightly Inhibited plasma and erythrocyte ChE activities. Again, 
analytical methods were not detailed. "
Weeks et al [83] exposed groups of 6 male New Zealand white rabbits 
and 20 Coturnlx quail to aerosols of technical (95%) malathion and of 6% 
malathion in No. 2 fuel oil for periods of 6 hours. At concentrations of 6 
and of 34 mg/cu m of aerosolized technical malathion, there were no toxic 
signs or significant decreases in blood ChE activities of the rabbits. At 
34 mg/cu m, reductions in plasma ChE activity which averaged 51% were noted 
in the quail immediately after exposure, but no reduction was observed at 
24 hours nor at 7 days postexposure. Plasma ChE activity was reduced in 
quail by 84% immediately following and by 63% at 24 hours after exposure to 
malathion at 65 mg/cu m, but it was not affected 7 days postexposure. No 
toxic signs or changes in blood ChE activities were found at this 
concentration (65 mg/cu m) in rabbits, although at 123 mg/cu m, significant 
decreases in ChE activities were found in plasma at 24 hours, and in 
erythrocytes at 24 and 72 hours and at 7 days. Quail exposed to 123 
mg/cu m had significantly decreased plasma ChE activities Immediately 
following exposure and at 24 hours, but not at 7 days. Microscopic 
examination of the tissues and organs of the test animals killed 7 days 
after exposure showed no pathologic changes due to the compound. From 
these data, quail appeared to react to malathion exposure in qualitatively 
the same way as rabbits, but to be slightly more sensitive to the compound 
at these concentrations and this duration of exposure.
Six-hour exposures [83] of groups of the same species and numbers of 
animals to aerosols of 6% malathion in No. 2 fuel oil resulted in the same
59
mHtrtmal effects of ChE depression in quail at concentrations equivalent to 
24 and 34 mg/cu m of malathion as did exposures to aerosols of the 95% 
compound. Particle sizes were 12 jum mass median diameter (nmd) for the 95% 
formulation, and 25 jan ™nH for the 6% formulation. Thus, it would appear 
that particle size had no effect on the responses of quail and rabbits to 
these aerosols. Exposures to 6% malathion in No. 2 fuel oil at levels of 
66 and 128 mg/cu m resulted in mortalities due to respiratory distress, 
rather than to ChE inhibition, in both quail and rabbits. The respiratory 
difficulty appeared to have been caused by the heavy concentration of fuel 
oil in the formulation. One may conclude, then, that the possible toxic 
effects from the fuel oil may be a greater risk than those from malathion 
itself under these experimental conditions.
Oral administration of single doses of 0, 12, 120, 300, 600, or 1,200 
mg/kg of technical malathion in corn oil to groups of six rabbits of the 
same strain was undertaken by Weeks et al [83] for comparison with the 
aerosol exposure results. They found that an oral dose of 300 mg/kg caused 
approximately the same inhibition of AChE as did the estimated dose of 
about 15-20 mg/kg inhaled by rabbits exposed to an aerosol containing 123 
mg/cu m for 6 hours. These results indicated a greater hazard from 
inhalation than from ingestion of equivalent amounts of malathion.
Murphy et al [5] compared the abilities of malathion and its oxygen 
analog, malaoxon, injected ip, to inhibit the ChE activity in groups of 
four mice, of two or four chickens, and four of each of two fish species. 
They found that mice appeared to be 25 times more susceptible to malaoxon 
than to malathion, chickens 13 times, and bullheads about 80 times. The 
findings on sunfish were not appropriate for this kind of analysis, but the
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authors Indicated that this species vas much more susceptible to the 
effects of malaoxon than to those of malathion. These results were adduced 
from brain ChE Inhibition assays conducted in duplicate according to the 
manometric method of DuBols and Mangun. [64]
The occurrence and significance of in vivo interactions between 
malathion and other organophosphorus pesticides [53,80,85-91] and between 
malathion and certain drugs and chemicals [92,93] have been the subjects of 
numerous reports.
In 1957, Frawley et al [86] studied the effects of both single
and coadministration of malathion and 0-ethyl O-p-nitrophenyl 
phenylthiophosphonate (EPN) on 35 Osbome-Mendel strain adult male rats, 
and in male and female dogs. Rats in groups of five received ground diets 
containing 500 ppm malathion, 100 ppm malathion, 25 ppm EPN, 5 ppm EPN, 25 
ppm EPN with 500 ppm malathion, or 5 ppm EPN with 100 ppm malathion. 
During a 4-week pretreatment period, five whole blood ChE activity 
determinations were done on each rat. One group was kept as a control. 
ChE activity of whole blood was measured on each animal after 1, 2, 4, 6, 
and 8 weeks on the test diet. Marked ChE Inhibition (21% of pretreatment 
level) was observed in the group fed the combination of 25 ppm EPN and 
500 ppm malathion, and minimal but significant inhibition occurred in the
25-ppm EPN group.
One dog of each sex was placed for 12 weeks on a diet containing 250 
ppm of malathion, 100 ppm of malathion, 25 ppm of malathion, 50 ppm of 
malathion, 20 ppm of EPN with 100 ppm of malathion, or 3 ppm of EPN with 8 
ppm of malathion, followed by a control diet for 8 additional weeks. Two 
dogs of each sex were maintained as controls throughout the experiment.
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Both plasma and erythrocyte ChE determinations were made on five blood 
samples drawn during the course of 4 pretreatment weeks, and after 1, 2, 4, 
5, 6, 8, 10, and 12 weeks on the experimental diet and 3 and 8 weeks on the 
terminal control diet. Only slight, but significant, Inhibition of 
erythrocyte ChE was found at the 250-ppm dietary level, while 250 ppm of 
malathion and 50 ppm of EPN together caused up to 60% Inhibition of plasma 
ChE and 93% inhibition of erythrocyte ChE activities. A combination of 100 
ppm of malathion and 20 ppm of EPN caused questionable Inhibition of plasma 
ChE, but up to 68% inhibition of erythrocyte ChE. Up to 24% inhibition of 
erythrocyte ChE was noted after 8 weeks on the diet containing 8 ppm of 
malathion and 3 ppm of EPN, but the ChE activity of the erythrocytes
returned incompletely to pretreatment levels during the recovery period, 
thereby complicating the interpretation of the data. No animals exhibited 
gross manifestations of poisoning during the experiment.
Shortly thereafter, Cook et al [94] and Murphy and DuBois [78] 
demonstrated the capacity of the liver in vitro to alter malathion to a 
form not susceptible to conversion to malaoxon or any other active
inhibitor of ChE. This activity was inhibited by EPN and Diazinon more 
markedly than by any other organophosphate compounds tested. Murphy and 
DuBois [78] also demonstrated that single ip doses of 13 mg/kg of EPN (1/2 
LD50) clearly reduced the capacity of male and female Sprague-Dawley rats 
to detoxify malaoxon. This suggested that EPN increased the toxicity of
malathion by inhibiting the enzymes responsible for its detoxification. 
Principal among these enzymes are the carboxyesterases. Cook et al [94]
found that a number of organophosphorus compounds, after oxidation with 
bromine if they were thiophosphates, were Inhibitors not only of ChE but
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also of malathlonase; here, EPN and Diazinon were particularly effective. 
Cook and Yip [74] showed that the change in the constitution of malathion 
by malathlonase was caused by the formation of a monoacid homolog in the 
removal of one alcoholic residue from the dlethylsuccinate portion of the 
malathion molecule. DuBois [80] found that when 50 compounds being tested 
for use as pesticides were given simultaneously in pairs to rats, 
potentiation occurred with four pairs. Among these were malathion with 
EPN, Dlpterex, or Co-Ral. Certain other organophosphorus pesticides, such 
as Ronnel, [91] Delnav, [91] Dlpterex, and Baytex, [79,88,95-98] and drugs
of the phenothiazine family, [99] when administered for a period of days
before exposure to malathion, have been found to potentiate the toxicity of 
malathion.
In addition to their studies on human liver homogenates, which were 
discussed in the preceding section, Main and Braid [62] analyzed the in 
vivo inhibition of serum aliesterase by malathion in male Sprague-Dawley 
rats. Initial serum aliesterase activities were measured, and single oral 
doses of 1,250, 1,500, or 1,700 mg/kg of 96.8% malathion were administered. 
Aliesterase activity was measured colorimetrically (pH 6.3 and 25 C) at 
0.5, 1, 2, 3, 4, and 5 hours after dosing. The results are shown in Table
III-3. The data suggest that high doses of malathion inhibit aliesterase, 
an enzyme which detoxifies it in vivo. The data may have been influenced 
by an epizootic Infestation in the animal colony, but this was not
experimentally verified.
Male rats (weighing 200 ± 50 g) [62] were administered practical
grade tri-o-tolyl phosphate (TOTP) in single oral 0.5-mg/kg doses. Serum, 
erythrocyte, and brain ChE, and liver and serum aliesterase activities were
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{ i t moles/ml 
of serum/min)
X Initial Activity Remaining
0.5 hr 1 hr 2 hr 3 hr 4 hr 5 hr
1,700 12.67 73.2 48.2 31.2 25.8 21.3 —
1,700 3.06 25.5 0.0 0.0 Death aftez 2 hr
1,500 11.18 69 56.7 37.8 35.5 36.8 35.0
1,500 13.70 48 39.2 31.5 30.3 28.5 -
1,250 0.79 Death before 0.5 hr
1,250 5.80 76.5 35.3 12.0 — 6.5 9.8
Adapted from Main and Braid [62]
measured during 5-25 hours. Serum aliesterase activity was reduced to zero 
within 60 minutes, and that of liver to 12Z of its initial activity. After 
24 hours, liver aliesterase activity was only 1.5Z of the Initial value. 
The effect of an identical TOTP pretreatment on the oral LD50 of 96.8Z 
malathlon was then examined in rats fasted for 24 hours before 
administration of malathlon. Without TOTP, the oral LD50 of malathion was 
determined to be 1,600 mg/kg. This value fell to 35 mg/kg when malathion 
was given 1 hour after 0.5 mg/kg TOTP, and further still to 20 mg/kg when
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malathion was administered 24 hours after the same dose of TOTP. While the 
eightyfold decrease in the LD50 of malathion cannot be attributed 
unequivocally to inhibition of the aliesterase, these data support this 
hypothesis by agreeing with the findings by Cook et al, [95] Murphy and 
DuBois, [78] and Fr^wley et al [86] of potentiation of the toxicity of 
malathion by EPN, demonstrated by these authors [78,86,94] to follow 
Inhibition by EPN of carboxy-ester hydrolysis of malathion.
Welch and Coon [66] studied the effects of drug pretreatment on 
malathion toxicity. Young adult, unfasted, male Swiss-Webster mice 
(weighing 18-25 g) were pretreated for 4 days with SKF-525A, 
chlorcyclizine, phénobarbital, or cyclizlne before administration of 
technical malathion (95%). Malathion (1,500 mg/kg) was given orally in 
corn oil 24 hours after the last pretreatment dose, which had been given in 
amounts equivalent to about 1% of body weight: chlorcyclizine, cyclizine,
SKF-525A (each at 25 mg/kg, twice a day for 4 days), and phénobarbital (35 
mg/kg, twice a day for 4 days). They concluded that mice pretreated with 
chlorcyclizine and phénobarbital were less susceptible to the lethal 
activity of malathion than control mice.
Interactions in which organophosphorus compounds affect the 
metabolism of other drugs or chemicals have not been reported to any great 
extent. Rosenberg and Coon [100] reported that malathion, along with OMPA, 
EPN, chlorthion, and phostex, but not DFP and TEPP, Increased markedly the 
time during which a given dose of hexobarbital removes the ability of mice 
to right themselves from a position on one side. Malathion did not alter 
the toxicity of hexobarbital. Stevens et al [101] reported that several 
organophosphorus pesticides, Including malathion, impaired the metabolism
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of hexobarbital and aniline, as evaluated by hexobarbital sleeping time and 
para-hydroxylation of aniline. Male Swiss-Webster mice (25-35 g), Wistar 
rats (150-200 g), albino rabbits (900-1,200 g), and mongrel dogs (9-14 kg) 
were the experimental animals. Malathion (99.6%) dissolved in corn oil was 
administered orally at a dose of 5 ml/kg. First, the oral LD50 in mice was 
determined to be 5,896 ¿moles/kg. Mice were then dosed with 1/8, 1/4, or
1/2 the LD50 of malathion. The hexobarbital sleeping time (HST) was 
measured at 30-minute Intervals, beginning 1 hour after malathion 
administration. HST was designated as "the time interval elapsed from the 
loss to the recovery of the righting reflex after an ip injection of 100 
mg/kg of hexobarbital sodium." [100] The results indicated that the 
pretreatment with malathion significantly increased the HST.
Stevens et al [101] reasoned that this increase in HST caused by 
malathion might be related to an interference with the metabolism of 
hexobarbital in the liver and demonstrated this through in vitro 
experiments. Malathion at a concentration of 2 x 10*5 M (* means to the 
negative power of) significantly inhibited hexobarbital metabolism by liver 
in vitro. No inhibition by 2 x 10*6 M malathion, however, was observed. 
Further experiments showed that malathion (0.01-M range) consistently 
inhibited the metabolism of hexobarbital in all species (mice, rats, 
rabbits, dogs, and humans) studied. Stevens and Greene [102] were able to 
show that, despite the apparent interference with the metabolism of 
hexobarbital by malathion, such effects were not correlated highly with 
effects of this compound on the oxidation of nicotinamide adenine 
dinucleotide phosphate (reduced form), reduction of cytochrome C, or 
reduction of cytochrome P-450 in liver microsomal preparations in vitro.
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It is likely, therefore, that at least some of the metabolism of 
hexobarbital is performed by other than the mixed-function oxidase system.
Certain factors other than drug or chemical Interactions have been 
shown to influence malathion toxicity. Brodeur and DuBols [103] studied 
the differences between mature and immature rats In malathion toxicity. 
Twenty 23-day-old weanling (50-60 g) and 18 adult male (200-300 g) Holtzman 
rats were used. Undiluted malathion was administered to the adults and was 
dissolved in a mixture of 20% ethanol and 80% propylene glycol for 
administration to weanlings. The LD50 of malathion was determined to be 
340 mg/kg for weanling rats and 750 mg/kg for adults. Death or complete 
recovery occurred within the first 7 days after doses were administered. 
In a later study, Brodeur and DuBols [104] further investigated the 
previously documented [103] observation that weanlings were more 
susceptible than adult rats to malathion. The metabolism in the liver 
involves both the conversion of malathion to malaoxon, which is the active 
metabolite responsible for ChE inhibition, and splitting off by hydrolysis 
of one of the alcoholic residues In the diethylsucclnate portion of the 
molecule to produce a molecule that cannot be activated by the replacement 
of S with 0. [74] Brodeur and DuBols [104] concluded that the age
difference in susceptibility was due to relatively low levels of 
malathionase in the liver and other organs (especially, perhaps, brain) in 
young rats.
Weanling rats (23 days old, 50-60 g) and adult male and female rats 
(200-300 g and 175-250 g, respectively) were injected ip with malathion 
dissolved In a mixture of 20% ethanol and 80% propylene glycol. [104] 
Malathion was administered in amounts equivalent to 0.2% and 0.1% of
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weanling and adult body weights, respectively. ChE activity was determined 
by the method of DuBois and Mangun. [84] The livers of the males were 2.5 
times more active than those of the females in hydrolyzing malaoxon. Also, 
the detoxification process was more active in adults than in weanlings and 
young rats.
In addition, studies [104] indicated that ChE activity was decreased 
to 37 or 28% of normal in weanlings by 100 or 150 mg/kg of malathion. In 
adults, the same degree of inhibition resulted only after doses of 600 
mg/kg. The LD50 for young, 12-day-old rats was 125 mg/kg; for adults, it 
was 900 mg/kg. Eighteen-day-old rats tolerated 100 mg/kg of malathion; the 
LD50 was 200 mg/kg. Thirty-day-old rats tolerated 400 mg/kg with little 
ChE depression. The LD50 for the 30-day-old rats was 600 mg/kg, and 800 
mg/kg for the 42-day-old rats.
The effect of dietary protein on malathion toxicity has been studied 
by a number of investigators, among them Boyd et al. [105] At weaning, 
male albino rats were put on diets containing various amounts of casein for 
28 days. Oral LD50's of malathion were then determined for each group as 
follows: Group 1 - 5 1  rats, 0% casein, LD50 539 ± 42 mg/kg; Group II - 110
rats, 3.5% casein, LD50 599 ± 138 mg/kg; Group III - 52 rats, 9% casein, 
LD50 759 ± 91 mg/kg; Group IV - 108 rats, 26% casein, LD50 1,401 ± 99
mg/kg; Group V - 51 rats, 81% casein, LD50 649 i 51 mg/kg. Group IV (26% 
casein) represented normal dietary protein intake. The authors noted that 
prior to inclusion of malathion in the diet, the highest protein intake 
(Group V, 81% casein) had the following effects on the rats: diarrhea,
diuresis, polydipsia, and other unspecified effects. The highest casein 
concentration in the diet may have produced an unappetizing diet. The mean
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weight of the 28-day-old rats In Group V was only 70% of that of the rats 
In Group IV. This diet was noted also to cause definite pathognomonic 
changes, eg, renal capillary congestion and diarrhea, among others. The 
postulated lnappetence and the observed diarrhea both would operate to 
decrease the absorption of protein Into the body from the diet of Group V. 
Boyd et al [106] concluded that the toxicity of malathion was Inversely 
proportional to dietary protein Intake, except at extremely high protein 
levels.
Boyd and Tanlkella [106] administered technical malathion (95%) in 
cottonseed oil by lntragastric Intubation to young male albino rats to 
determine the oral LD50. The rats previously had been fed normal (Group 
II, 26% casein) or low-proteln (Group III, 3.5% casein) diets on days 28-56 
of age or until they weighed 5-10% more than Group I rats, which were on a 
lab chow diet. At the end of the modified-diet feeding period, malathion
was administered in single oral lethal doses (predetermined in a pilot
study) of 700-1,400 mg/kg to Group I; 1,000-2,000 mg/kg to Group II; and 
200-1,200 mg/kg to Group III. Each dose was given to 10 rats on the 
experimental diets, with 15-45 controls receiving cottonseed oil only. 
LD50’s were determined to be 1,090 ± 83 mg/kg for Group I; 1,041 ± 99 mg/kg
for Group II; and 599 ± 138 mg/kg for Group III. The authors concluded
that the twofold increase in malathion toxicity in Group III rats over that 
in Group II rats was due to their low-protein diet. The authors speculated 
that low-protein^ intake might result in hepatic enzyme activity reduction, 
thereby altering the animal's ability to detoxify malathion. This was not 
supported by either experimental data or theoretical considerations.
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Marton et al [107] studied the effect of chronic malathion treatment 
on tolerance to cold. Sixty-eight Wistar rats were randomly divided into 
four groups of 17 each according to treatment and sex. The control group 
received Fox Chow. The other groups were given the same chow mixed with 
95% technical grade malathion dissolved in corn oil. The concentration of 
malathion was 4,000 ppm, so that the daily intake of malathion approximated 
240 mg/kg of body weight. After 5 months, during which malathion had 
little effect, the experimental groups were exposed to an environmental 
temperature of 1.5 ± 1 C. They were given water but no food. Blood ChE
activity was determined 2-3 weeks prior to the experiment and again within 
15 minutes after death. The rats fed malathion survived the cold for a 
significantly shorter period than did the control animals (P less than 
0.01). ChE activity was also significantly lower in the malathion-fed 
animals but did not differ significantly between preexposure and cold 
exposure activities. Malathlon-fed rats did not appear to have increased 
heat loss over the controls. Hence, the authors [107] inferred that 
malathion decreased the ability of rats to produce a high rate of heat 
continuously over a prolonged period of time.
Durham et al [108] stated that the muscular weakness seen in the legs 
of chickens appeared to be the best available index of the possible 
paralytic effects of organophosphorus compounds in humans. They tested 
nine organophosphorus compounds, including malathion, for toxicity in 
atropinized chickens. Immediate muscle weakness appeared in 6 of 10 
chickens given one subcutaneous injection of 1,000 mg/kg of malathion. The 
lowest dose of malathion that produced Immediate muscle weakness was 100 
mg/kg. Although the weakness was reversible and disappeared completely
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within 4-21 days, the authors did not state whether this reversibility was 
a dose-related effect. Utilizing methods similar to those of Durham et al, 
[108] Gaines [109] Investigated the effects of 9 carbamates and 30 
organophosphates (In peanut orf.1 suspension or solution) In an unspecified 
number of chickens. Within a few hours after the subcutaneous Injection of 
malathion In doses of 100 mg/kg or more, leg weakness was observed and It 
persisted for 4-14 days. The results of microscopic examinations of 
tissues were not reported. Frawley et al [110] fed malathion to chickens 
at levels up to 10,000 ppm for 15 weeks. All of the birds died, but only 
one exhibited muscle weakness, and none showed microscopic evidence of 
nerve damage. O'Brien [64] pointed out that, while many known neurotoxic 
compounds are Inhibitors of plasma ChE, most inhibitors of this enzyme do 
not produce neurotoxic effects. Malathion appears to be a ChE inhibitor 
that is not neurotoxic and does not Induce demyellnatlon of long axons.
Krause et al [111] administered 40 mg/kg of malathion (purity
unstated) in corn oil to male rats on days 4 and 5 of age and 20 mg/kg to
another group on days 4-24. Controls and experimental animals received 0.1 
ml of corn oil/5 g body weight at each dose. Two rats from each group were 
killed for microscopic examination of the testes at 6, 12, 18, 26, 34, or 
50 days of age. From the results obtained with this rather limited
numerical base, the authors concluded that the weight of the testes and the
mean diameter of the seminiferous tubules, as well as the number of Leydlg 
cells, were reduced at some time during the experiment. All effects, 
however, disappeared by the rats' 50th day of life. The lesions in the 
testes caused by malathion were evaluated as "not very serious," and were 
limited essentially to the period of time during which the compound was
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administered, because of the rapid excretion of the compound. All cell 
counts were reported to be normal after the 24th day of life.
Mohn [112] applied 0.2 M malathion to Escherichia coli K-12/gal Rs,8, 
a phenotypic gal-, and incubated It for up to 300 minutes. The resulting 
cultures were examined for forward mutations to 5-methyl tryptophan (5-MT) 
resistant colonies. In these experiments, the author reported using a 
concentration of 20/ig 5-MT/ml and an inoculum containing 300,000-500,000 
cells/ml. Cultures with spontaneous mutation rates of less than 25/plate 
were used. The mean number of cell generations was 8-9 during residual 
growth. According to the author, the results with malathion did not differ 
significantly from spontaneous values, even when 70% of the cells were 
inactivated. Malaoxon was not examined.
A study by Huang [113] also failed to reveal a mutagenic potential in 
malathion. Eighty thousand cells/ml from three different human 
hematopoietic cell lines were treated with malathion dissolved in dimethyl 
sulfoxide at concentrations of 50 and 100 /ig/ml. Cells were harvested 6, 
12, 24, and 50 hours after exposure to malathion. Colcemid at a
concentration of 0.04 /ig/ml was added to the cultures 2 hours before 
harvesting for chromosome preparation. [113] Cells were treated with 1% 
sodium citrate and fixed in acid-methanol (1:3). Flame-dried slides were 
stained with Glemsa's stain, and 100 metaphase figures were studied with an 
oil-immersion objective. Clear chromosome lesions (gaps, breaks, 
exchanges, dicentrics, pulverization, etc) were recorded for each group. 
Cell growth was inhibited, but returned to normal in cells placed in 
malathion at a concentration of 50 /ig/ml after they were washed with fresh, 
pesticide-free medium. No resumption of growth was noted in cells placed
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in malathion at a concentration of 100 /xg/ml. Single gaps and breaks were 
found in 4% of the controls at 6 hours, 3% at 12 hours, 3% at 24 hours, and 
2 % at 50 hours. Similar counts had values of 2, 3, 5, and 0% at the same 
time periods for the 50-pg/ml concentration and of 5, 4, 5, and 5% for the 
100-jxg/ml concentration. These results, however, are contrary to the 
findings of Trinh Van Bao et al [54] reported in Effects on Humans.
The use of submammalian test systems and in vitro cell cultures 
should be regarded only as ancillary procedures to supplement mutagenic 
studies using Intact mammalian test systems, according to a recommendation 
by a WHO Scientific Group in its 1971 report entitled Evaluation and 
Testing of Drugs for Mutagenicity: Principles and Problems. [114] NIOSH
agrees with the general philosophy of this recommendation.
Kimbrough and Gaines [115] studied the possible teratogenic effects 
of several organophosphorus pesticides, including malathion, on rat fetuses 
after a single ip injection Into the mother. Six dams were Injected ip 
with 600 mg/kg of malathion and six others with 900 mg/kg on the 11th day 
of their pregnancy. The fetuses were removed on the 20th day of pregnancy. 
The higher dose of malathion produced a slight tendency for the weights of 
the placentas and the fetuses to be reduced and one instance of adactylia 
among 67 fetuses. The lower dose produced no evident effects. It should 
be noted that administration of the pesticide in a single dose on day 11 of 
gestation may have resulted in less teratogenic effect than either repeated 
or earlier doses.
Dobbins [116] conducted a screening study of the teratogenic 
potential of various malathion doses in 15 pregnant Wlstar rats. The drug 
was dissolved in corn oil and administered by stomach tube on day 9 or 10,
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or from days 8 to 12 or 12 to 15, of pregnancy. Seven control rats were 
untreated. On day 20 of gestation, the dams were killed and the fetuses 
examined. A suggestion of teratogenic effect on the urinary system was 
noted, but the data and the experimental detail were confused and 
Insufficient for any conclusion. None of 74 control fetuses was considered 
to be abnormal; the usual rate of spontaneous abnormalities would be about 
1Z.
Lillie [117] fed seven groups of 20 Leghorn pullets a breeder diet
containing either 0, 250, or 500 ppm of malathion, 250 or 500 ppm of
carbaryl, 250 ppm each of malathion and carbaryl, or 500 ppm each of both
pesticides. Observations during a 36-week period included changes in body 
weight, egg production, egg weight and specific gravity, feed consumption, 
mortality, fertility, hatchability, embryonic abnormalities, and 
performance of progeny. In the studies of performance by progeny, chicks 
from hens fed 0 or 500 ppm of malathion or malathion and carbaryl were fed 
a broiler diet supplemented with 0 or 500 ppm malathion or carbaryl for 4 
weeks. The only significant effect was a smaller weight gain in adult 
birds fed the mixture of carbaryl and malathion. Decreased growth was 
observed in the progeny fed carbaryl, irrespective of maternal diet, but it 
was not seen in those fed malathion. In a separate 4-week study, [117] the
incorporation of 500 ppm of malathion, of carbaryl, or of both, into the
diet of Leghorn cocks produced no significant changes in fertility pattern, 
production of sperm, or embryonic abnormalities.
Greenberg and LaHam [118] injected malathion at concentrations of
3.99 or 6.42 mg/egg into the yolk sacs of 50 hens' eggs incubated for 4 or
5 days. Twenty-five control eggs were used. The eggs injected with
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malathion produced chicks exhibiting sparse plumage, mlcromella, overall 
growth retardation, and beak defects. The authors speculated that the 
observed abnormalities could be attributed to an In vivo retardation of 
cell growth and protein synthesis, but they did not provide any 
experimental support for this contention.
Ho and Gibson [119] Injected hen's eggs with 0.1 ml of 2% malathion 
In corn oil on the 5th day of Incubation. The treated embryos showed a 
generalized reduction In body size, delayed patterns of mineralization In 
certain endochondral bones, and mlcromella. Tlblotarsl consistently 
exhibited retarded growth, cartilage necroses, and angulation. In another 
paper, [120] Greenburg and LaHam used the technique of Injecting Into the 
yolk sacs of 4- or 5-day Incubated hens' eggs 6.42 mg/egg of malathion 
either alone or with various amino acids, vitamins, and nicotinamide 
adenine dlnucleotlde precursors to attempt to find means for preventing the 
malformations and retardation of growth Induced by malathion. Nicotinamide 
(5 mg), nicotinic acid (5 mg), and quinolinic acid (4.3 mg) prevented the 
malformations, but growth was still stunted. Tryptophan (5.1 mg) was the 
only compound of 32 tested that prevented both malformation and growth 
retardation. Indole, Indoleacetlc acid, and serotonin had no antagonistic 
value. Indeed, In two of four experiments, Indole had a more marked effect 
than malathion Itself, and Indoleacetlc acid enhanced the effects of 
malathion. The authors suggested, therefore, that malathion may have had 
no direct metabolic effect on the egg but rather may have disturbed the 
electronic milieu within the egg, and that tryptophan nullified this effect 
by virtue of Its particular ionization potential. Compounds having an 
ionization potential near that of tryptophan (adenine, guanine, alpha-
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naphthol, beta-naphthol, indoleacetic acid, and quinoline) by themselves 
had no effect on the embryos, but did have a magnifying effect when given 
with malathion. Imidazole, with an ionization potential quite different 
from that of tryptophan, was neither therapeutic nor synergistic with 
malathion. The ionization potential appears, therefore, not to be the 
basis of either the ovotoxic effect of malathion or the protective action 
of tryptophan.
Wilson and Walker [121] reported that malathion in concentrations 
greater than 1 Mg/ml was toxic to primary cultures of chick embryo 
fibroblasts.
While many of the basic concepts of teratology were initially 
investigated using avian eggs, the absence of anatomic and physiologic 
maternal-fetal relationships during incubation makes it difficult to 
extrapolate from the effects on the avian egg to teratogenic hazards to 
humans. The use of mammalian species for evaluation of possible 
teratogenic hazard is now recommended by the WHO Scientific Group on the 
Principles for the Testing of Drugs for Teratogenicity. [122] Because of 
the difference between the conditions within an egg and within the amniotic 
sac of mammals, the production of terata within eggs Indicates a 
teratogenic potential but does not necessarily mean that manuals will be 
likely to develop terata on exposure of pregnant females to the same 
influence.
In a study using malathion administered in the diet at a rate of 
approximately 240 mg/kg/day, Kalow and Marton [123] found no effects 
attributable to malathion in the reproductive performance of 18 female and 
12 male experimental rats mated after 10 weeks of feeding on the malathion-
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containing diet compared with 18 female and 12 male control animals. 
However, the survival to weaning of the offspring of animals fed malathion 
was only 31.8% versus 64.7% in the control group. The mean gain In body 
weight of offspring from the malathlon-fed rats was only about 85% of that 
of control offspring from weaning to 9 weeks of age. The authors suggested 
that this effect may have been due to a lowered resistance of the treated 
animals to infection or "other noxious Influences" in the colony and not 
necessarily to ChE inhibition.
The effects of malathion on the reproductive capacity of rats in a 
three-generation reproduction study have been reported. [124,125] The test 
material (95% pure) was incorporated into the diets of all three 
generations of rats in concentrations of 100, 500, or 2,500 ppm
(approximately 5, 25, or 125 mg/kg/day). Sixteen pairs of rats in each
group were mated, beginning with the original weanling rats, as were an 
equal number of untreated paired controls. Signs of ChE inhibition were 
not present. The following effects ascribed to respiratory disease were 
observed in the 2,500-ppm group: death of 4 of 16 dams; lower ratios of 
litters to pregnancies and of pups weaned to pups aged 5 days plus lower 
pup weights in all 3 generations. Both matings of the second generation on 
the 2,500-ppm diet produced pups of lower body weight and reduced ratios of 
pups weaned to pups at 5 days, relative to the controls. The authors 
[124,125] suggested that this may have been due to a change of bedding 
material which, in turn, induced respiratory distress. The fertility of 
the rats used in the final mating at the 2,500-ppm level also was reduced, 
but no malformations in the pups were observed. Microscopic examinations 
of the pups from the third generation, first mating, of the control and
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high-level groups revealed similar minor lesions. The data revealed no 
adverse effects at the 100- and 500-ppm levels. However, the respiratory 
distress, reduced fertility, reduced pup weights, and poor pup survival at 
the 2,500-ppm level may have been due to malathlon.
Correlation of Exposure and Effect
A number of biologic effects associated with malathlon exposure have 
been documented In humans and experimental animals. The effects of 
exposure are the complex group of signs and symptoms which result to an 
unknown extent from the accumulation of ACh at various neural synapses and 
motor endplates. These signs and symptoms are discussed In detail In 
Effects on Humans and are tabulated In Table III-2. [48,49] Death due to 
malathlon Intoxication has been attributed to depression of the respiratory 
center of the brain, [126] presumably as a result of accumulation of ACh.
In humans, Ingestion of malathlon has been shown to produce all of 
the signs and symptoms of cholinergic stimulation up to and Including 
death. Nalln [50] reviewed 264 reports of attempted suicide collected over 
a period of 3 years In Guyana. All patients experienced signs and symptoms 
consistent with cholinergic stimulation, and 53 individuals (20% of the 
total) died.
Eight case study reports [19,20,25,39,44-46] found in the literature 
specified the amount of malathlon ingested and the characteristic
manifestations of cholinergic stimulation observed. In the first case,
[20] a 14-year-old boy weighing 165 lb ingested approximately 4 ounces 
(approximately 118 ml) of malathlon (purity not reported). The authors
calculated this to be a dose of approximately 0.4 g/kg of body weight. The
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victim exhibited a wide range of severe manifestations consistent with 
cholinergic stimulation. He was comatose and recovered only after 
Intensive therapy. In another case, a 45-year-old man ingested 50-90 ml of 
50% malathion in a petroleum hydrocarbon base. Although the patient's 
actual weight was not reported, assuming one of 70 kg, a maximum dose of 
approximately 0.8 g/kg can be calculated. The patient experienced the full 
range of cholinergic symptoms, including marked respiratory insufficiency 
requiring tracheostomy and mechanically assisted ventilation, cardiac 
arrhythmia, and unconsciousness. He survived only with intensive and 
prolonged therapy. In a third incident, [39] a 42-year-old woman Ingested 
120 ml of 50% malathion garden spray solution. Goldin et al [39] estimated 
the maximum intake at 1.0 g/kg. The victim displayed signs consistent with 
cholinergic stimulation, Including coma and profound shock. After 
intensive therapy, she survived without sequelae. In five similar cases, 
[25,44-46] the estimated doses consumed, which resulted in severe poisoning 
that would have been fatal but for intensive therapy, were in the order of 
0.5, 0.9, 0.7, 0.5, and 0.6 mg/kg. From the extremely grave clinical
picture exhibited by these patients, it is clear that all had absorbed 
doses of malathion which would have been lethal without intensive and 
prolonged therapy. Based on these cases, each of which was stipulated by 
the authors to have been nearly fatal, it appears that without treatment, 
the acute oral lethal dose of malathion in humans would be somewhat below
1.0 g/kg.
In a human experimental study, [21] five men ingested 16 mg of 
malathion/day for 47 days. The malathion was administered as a corn oil 
solution in gelatin capsules. The subjects exhibited no clinical effects
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and reported no subjective complaints during or after the study. There was
no drop in blood ChE activity. If an average weight of 70 kg is assumed,
the approximate daily dose for these men was 0.22 mg/kg.
In a similar study, [21] the same authors administered malathion at a 
dally oral dose of 24 mg to five men for 56 days. This dose would amount 
to 0.34 mg/kg, assuming an average weight of 70 kg. Although no clinical 
signs or symptoms of poisoning were observed, a statistically significant 
drop in plasma ChE activity was noted after 2 weeks. The maximum 
depression of 25% occurred after 3 weeks. However, the activity returned 
to normal throughout the remaining 5 weeks of the experiment. At 7 weeks, 
there was also a drop in erythrocyte ChE activity. This reached a maximum 
2 weeks after completion of administration of malathion.
There are very few human data available that give a quantitative 
relationship between respiratory exposure to malathion and biologic 
effects. In Golz's study, [56] four volunteers were exposed to malathion 
in a room in which an aerosol was dispersed at the beginning of a 1-hour 
exposure period. The maximum theoretical air concentration at the 
beginning of the exposure period was approximately 2.4 g/1,000 cu ft, or 
approximately 85 mg/cu m of malathion. The true concentration to which the 
men were exposed probably was smaller than this since the aerosolized 
formulation may have settled out within a short time following its 
generation. The subjects were examined weekly during the 42-day period of
twice-daily exposures, and no signs or symptoms consistent with excess ACh
accumulation were observed. Several studies [35-37] have been performed in 
which respiratory exposure to malathion during actual application was 
estimated. In cases in which workers were exposed to malathion during its
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application in field use, the respiratory rate of exposure ranged from 
approximately 0.01 to 1.23 mg/hour. The skin exposure rate was 10-100 
times the respiratory rate, that is, the amount of malathion which could 
have been deposited was 10-100 times the amount they inhaled. In none of 
these studies [35-37] did the investigators look for signs or symptoms of 
poisoning related to the exposure, but it is reasonable to assume that, had 
there been any significant effects, they would have been reported.
Signs and symptoms of cholinergic stimulation attributed to 
absorption of malathion through the skin have been reported. [24] An 8- 
year-old girl developed signs and symptoms consistent with ACh accumulation 
after having her hair washed with a 50% malathion-xylene solution. She 
died 5 days after the hairwashing. No quantitative estimate of the 
malathion exposure can be made in this case. In addition, Quinby and 
Lemmon [127] reported a case study of clinical poisoning in a group of 
field workers who were exposed to malathion residues on crop foliage. 
Again, no quantitative estimate of the exposure Is possible.
After iv injection of a dose of 14C-malathion into an unspecified 
number of normal male volunteers, [128] 90.2% of the label was recovered in 
the urine with a half-time of excretion of 3 hours. Using these figures to 
correct measured absorption from the skin, Feldmann and Maibach [128] found 
that 12 subjects absorbed an average of 6.8 ± 2.3% of malathion applied to 
the skin of the forearm during a period of 5 days after its application. 
In another study, [129] the skin of the axilla absorbed 4.2 times as much 
malathion as that of the forearm —  the highest absorption measured with 
malathion. (Scrotal skin was not used.) Therefore, the maximum absorption 
(outside of the scrotum) was 28.5% of that applied to the skin.
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The effects of malathion on laboratory animals are similar to those 
in man. Acute doses of malathion produce signs of anticholinesterase 
effects in dogs, rats, mice, and rabbits, [10,33,83] indicating a common 
analogous mechanism of action in these species.
Laboratory mammals can tolerate large quantities of malathion when it 
is absorbed at a moderate rate. [124,125] During the three-generation 
study, [124,125] rats survived average daily intakes of 125 mg/kg/day or 45 
g/kg each year.
Animal experiments indicate that the dermal application of malathion 
can cause cholinergic effects and death. The transdermal LD50 of malathion 
in rats has been reported as greater than 4,400 mg/kg. [109] This dose is 
approximately 3-6 times larger than the oral LD50’s in this species.
The study by Weeks et al [83] showed malathion aerosols to have no 
effect on blood ChE activity in concentrations of 6-8 mg/cu m in either 
rabbits or quail, and no effects at up to about 30 mg/cu m in rabbits or 
lasting effects (beyond 24 hours) in quail. The formulations tested were 
technical malathion (95% pure) and 6% malathion in No. 2 fuel oil. 
Particle size had no effect on toxicity, and the fuel oil component was 
found to be of greater toxic potential than malathion in the 6% 
formulation.
There are several experimental investigations whose results suggest a 
level of dermal exposure to malathion in humans below which no cholinergic 
effects can be detected. In three separate studies, [35-37] the dermal 
exposure of individuals during malathion application was estimated by using 
absorbent pads taped to various areas of the skin or clothing. Estimated 
dermal exposures ranged from 0.25 mg/hour to an extreme high of 194
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mg/hour. These individuals were also exposed via the respiratory route. 
In none of the subjects were ¿igns and symptoms of cholinergic stimulation 
looked for, but it may be assumed that any significant complaints would 
have been noted by the investigators. In another group of studies,
[32,129,130] volunteers were dusted daily with powdered formulations
containing various concentrations of malathion. Hay^s et al [32] reported 
no significant changes in ChE activities in 60 male volunteers exposed to 
dermal doses of malathion contained in talc dusting powder during an 8- to 
16-week period at levels sufficient to lead to urinary excretion of 
malathion-derived materials equivalent to a minimum of about 70 mg of 
malathion/day. Using Feldmann and Maibach's [128] figure for recovery of 
14C administered as malathion, the gross values from this study indicate 
that about 78 mg of malathion were absorbed from the application of 2.8 g 
of malathion powder to the skin. This absorbed quantity of malathion may 
be regarded, therefore, as a no-effect or safe dose.
In summary, malathion can cause signs and symptoms in humans 
resulting presumably from accumulation of ACh at various effector sites
after absorption. The approximate single oral lethal dose In humans is
probably somewhat below 1.0 g/kg. Although respiratory and dermal 
exposures to malathion have been reported to cause clinical effects 
consistent with pseudocholinergic (anticholinesterase) activity, no clear- 
cut cases of fatal poisoning by these routes of entry have been reported, 
and no quantitative relationship between exposure and cholinergic effect 
via these routes has been established. It Is evident that a brief exposure 
to atmospheric concentrations as high as 85 mg/cu m [56] and dermal 
exposure [55] sufficient to lead to urinary excretion of malathion-derived
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materials equivalent to a minimum of about 48 mg of malathion/day, as 
determined by ether extraction (78 mg/day total), caused no significant 
depression of ChE activity.
No findings of carcinogenesis by malathlon have been reported. There 
is some information on its possible teratogenic and mutagenic activities. 
[17,54,111-113,115—1i9,123-125] Because some of the papers on teratogenic 
activity are derived from studies on hens' eggs and some of those on 
mutagenesis relate to studies with unicellular organisms, little 
information applicable directly to mammals is available in this general 
field. The data are judged to be Insufficient to establish the existence 
of significant risk of the occurrence of these effects in human populations 
exposed to malathlon.
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IV. ENVIRONMENTAL DATA AND BIOLOGIC EVALUATION
Sampling and Analytical Methods
Various complications arise in the atmospheric sampling for malathion 
due to its formulation as an emulsifiable liquid, wettable powder, or dust. 
[131]
Packed column adsorption is efficient for trapping vapors, but sample 
recovery from the column is difficult. [58] Filters, whether glass fiber 
or cellulose pad, permit passage of large volumes of air in a short time, 
but they have low efficiency for vapors and lose unknown amounts of both 
particulate and aerosol samples during the collection period. [37,92] 
Scrubbers are good for aerosols and vapors, but the use of sintered glass 
precludes particle collection. [132,133]
Miles et al [134] determined the collection efficiency of Greenburg- 
Smith impingers using ethylene glycol as the collection medium. They 
compared the amount originally present in a U-tube or a vaporization 
chamber to that collected in Greenburg-Smith Impingers for parathion. 
Either the U-tube or the vaporization chamber was connected directly to two 
Greenburg-Smith impingers in series. The authors found that in a 240- 
minute sampling period, 94.8% of the parathion In the U-tube was collected 
by the first lmpinger connected to the U-tube, and 87.2% (19.8jug) of the
parathion was collected by the first lmpinger connected to the vaporization 
chamber. The flowrate was not given. Miles et al [134] also determined 
the collection efficiency of Greenburg-Smith impingers for parathion dusts. 
In this study, they dispersed parathion dust in a chamber and collected the 
dispersed dust with three Greenburg-Smith impingers connected in series.
85
The flowrate again was not given. The results indicated that 99.9% 
(3,000/ig) of the parathion dust was collected in the first impinger using 
ethylene glycol as the collection medium. NIOSH believes that these 
results are applicable to malathion as well. There is no reason to believe 
that the particle sizes are different, as the inert substrates for dry 
formulations of both malathion and parathion are the same. [135]
Culver et al [68] found that the collection efficiency of the midget 
impinger using ethyl alcohol as the collection medium was in excess of 90% 
for collecting malathion in the form of aerosolized liquid with a median 
diameter of 40-54 ju. No range of particle sizes within which this 
efficiency is applicable was given, and the method of determining the 
collection efficiency was not indicated. They also found that the midget 
impinger picked up particles of approximately the same size as did the 
upper respiratory tract. Since malathion may occur in air as vapor, as 
liquid droplets, or as an adsorbed film on solid particles, it is essential 
that the impinger be operated at a flowrate which will efficiently collect 
all forms of airborne malathion. Although no studies were found in which 
malathion or any other organophosphorus pesticide was used as the test 
compound, Roberts and McKee, [136] by comparing known concentrations of 
ammonia with those absorbed in midget lmpingers filled with distilled 
water, found that the most efficient air flowrate was 0.1 cu ft/min (2.8 
liters/min).
Miles et al [134] investigated a variety of solvents that may be used 
as collection media in impingers. By varying the solvents in otherwise 
identical trials, they found that iso-octane, toluene, and ethyl benzene 
trapped parathion with high efficiency (no percentage was given), but that
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losses of solvent from the lmplnger sampling train were high. Sampling
runs longer than 30 minutes could not be made because of saturation of the 
system. Aliphatic hydrocarbons of higher molecular weight, Including 
normal nonane and normal decane, formed aerosols when air was passed 
through the lmplngers, with the resultant loss of an unstated amount of 
solvent. The higher molecular weight hydrocarbons were difficult to 
evaporate. The authors found that samples of 10.7 and 205 /ug were trapped 
with 90% or better efficiency by ethylene glycol. In comparing the 
collection efficiency for a known amount of parathlon vapor, it was found 
that with ethylene glycol the collection efficiency was not dependent upon 
sampling time, whereas with water the collection efficiency decreased from 
100% for a 10-minute sample to 52.6% for a 60-minute sample.
Thomas and Seiber [137] evaluated the solid sorbent Chromosorb 102, 
an alternative to liquid solvents in lmplngers, for the collection of 
malathion. Collection efficiency for the vapor of 95% technical malathion 
(31.5 Mg malathion in a U-tube through which 9 cu m of air were drawn) in 
the first of two tubes, each containing 4 g of Chromosorb 102, was 
determined to be 102%. Upon separation of 4 g of adsorbent from a single 
tube into 1-g segments after sampling, no penetration of malathion vapors
beyond the second segment was found. Downwind trapping of aerosolized
technical (95%) malathion by Chromosorb 102-charged lmplngers was compared 
with that of similar lmplngers filled with ethylene glycol. Two separate 
runs were made, at 100 and 150 feet from the spray source, with the two
types of filled lmplngers side by side and each with a backup impinger. 
Chromosorb 102 at 100 feet collected 12.3 jug and less than 0.1 /ug of 
malathion vapor and aerosol in the first impinger and in the backup
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impingers, respectively; the ethylene glycol collected only 5.5 and 0.3 ¿tg, 
respectively. At 150 feet, the Chromosorb 102 impingers collected 8.6 and 
0.5 n g t respectively; no data were given for ethylene glycol at this 
distance. Although Chromosorb 102 appears to be a superior collecting 
medium, the breakthrough volumes, ideal sampling rate, and precision of the 
method still remain to be determined.
Pending further studies, the midget impinger [68] is recommended as 
the air sampling method of choice. Appendix I gives details of the 
sampling and airflow calibration procedures to be followed when using this 
method. Other air sampling methods which can be shown to be equivalent, or 
superior, in efficiency to the midget impinger [68] with ethylene glycol as 
the solvent [134] may be used.
In 1964, the thermionic emission or alkali flame ionization detector 
was introduced by Giuffrida. [138] In 1966, Brody and Chaney [139] in­
troduced the flame photometric detector. Both detectors are modifications 
of the universal flame ionization detector and are highly specific for 
phosphorus. Since the development of phosphorus-specific detectors, gas 
liquid chromatography has been the preferred method for malathion analysis. 
Formerly, organophosphorus pesticide analysis was done by colorimetric 
[140] and ultraviolet spectrophotometric [141] techniques. These, however, 
were highly subject to interference.
A major advantage of the gas liquid chromatography-phosphorus 
specific detector method of analysis is that changes in the composition, 
filling, and temperature of the column permit the separation of peaks due 
to interfering compounds from the peak of the compound of interest. These 
column changes result in a variation of retention times of all substances
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Involved. Giuffrida [138] Indicated that 0.024 jug (24 ng) of parathion 
could be detected using gas liquid chromatography with an alkali flame 
ionization detector. For normal analytical work, the convenient working 
range for the alkali flame ionization detector was between 50 and 1,000 pg 
(0.05-1.0 ng) in each injection volume. With acetone as the solvent, gas 
liquid chromatography combined with a flame photometric detector and a 
526-nm filter were reported [139] to be sensitive to 0.25 ng of malathion; 
the response was linear from 0.0063 to 63 ppm. Since the flame photometric 
detector is the more sensitive method, it is recommended over the alkali 
flame ionization detector. Details of this method can be found in Appendix
H -
Environmental Levels and Engineering Controls
Data on environmental levels of malathion in the workplace are 
scanty. The only information found was contained in articles describing 
workers exposed while applying malathion for purposes of agricultural pest 
and vector control.
Wolfe et al [35] studied the dermal and potential respiratory 
exposures to malathion of an unstated number of air-blast sprayers and 
aerosol machine operators who were applying malathion spray (0.04-0.08%, 
3.4 lb/acre), dust (4%, 1.4 lb/acre), or aerosol (2.5-5.0%, application 
rate not specified) to fruit trees or pole beans. From absorbent gauze 
pads attached to the workers' exposed skin areas (the face, back of neck, 
"V" of chest, forearms, and hands) and respirator filter pads, the authors 
calculated the mean dermal exposure to have been 30 mg/hour for employees 
spraying fruit orchards with air-blast machines, and 67 mg/hour for
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employees using high-pressure hand guns. Employees using a power duster on 
pole beans were calculated to have had a mean dermal exposure of 23 
mg/hour. Potential respiratory exposure was calculated to have been 0.11 
mg/hour for air-blast orchard sprayers, 0.09 mg/hour for the high-pressure 
hand-gun operators, and 0.73 mg/hour for those using a power duster to dust 
pole beans with malathion. These results indicate a potential for much 
higher dermal than repiratory exposure in the application of malathion. 
ChE determinations were not made in this study.
Culver et al [68] studied the dermal and potential respiratory 
exposure to 2.5% or 5% malathion (formulating solvent not stated) of two 
aerosol machine operators and three field observers from the drifting 
aerosol cloud during mosquito control application. Cellulose head and 
ankle bands and a cotton knit glove on one hand of each worker were used to 
estimate dermal exposure. Cellulose filter pads in front of the cartridge 
of toxic dust respirators were used to measure potential respiratory
exposure. Atmospheric sampling in the breathing zone was done with all­
glass midget impingers, with ethyl alcohol as the collecting medium. 
Exposures were intermittent and generally brief, lasting from 20 seconds to 
about 30 minutes, for a total of about 5 hours during a 2-week period. The
atmospheric concentration, as determined from 145 samples taken at the same
time as the dermal and respiratory samples, ranged from 0.52 to 7.70 
mg/cu m, depending on application distances (10-75 yards). The jeep driver 
received the highest dermal exposure, 32-86 mg, of which more than 90% was 
deposited on the hands. The total potential respiratory dose range for the 
2-week period was 11-21 mg, also from the jeep driver's samples. 
Erythrocyte and plasma ChE activities were measured by a microadaptation of
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the Michel method. [61] Either two or three preexposure examinations and 
dally examinations during the 2-week application period were performed. 
The authors concluded that slight decreases observed In ChE activities were 
Insignificant.
Caplan et al [37] measured the potential dermal and replratory 
exposures of Individuals who worked outside during a 2-week mosquito 
control project In which malathlon was applied Intermittently by aerosol 
machines. Dermal exposure was estimated from cellulose pads attached to 
various parts of the body, and respiratory exposure was calculated from 
atmospheric concentrations of malathlon collected at several points during 
and again 1 hour after spraying. The authors found atmospheric 
concentrations of malathlon as high as 0.67 mg/cu m. Skin exposure ranged 
from 0.45 to 2.62 jug/sq cm for a man working outdoors during the spraying 
operation. No ChE activities or other measurements of response were 
reported.
Jegler [36] measured the dermal and respiratory exposures of 52 
Individuals who operated tractor-driven, air-blast sprayers during 
application of Insecticides to fields of grain and vegetables. Spray 
formulations consisted of malathlon alone as well as mixtures of malathlon 
and DDT. Malathlon was applied In a concentration of 2 lb of 25% wettable 
powder/100 gal of water. Respiratory exposures were estimated from 
analysis of breathing-zone air samples and from respirator filter pads. 
Dermal exposure estimates were based on the amount of insecticide found on 
absorbent patches taped to the forehead and wrists of observers riding 
beside the tractor operator. In all, the exposure of four operators to 
malathlon was estimated. Breathing-zone samples had a range of 0.41 to
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0.76 mg/cu m, with a mean of 0.59 mg/cu m. The mean respiratory exposure 
dose was found to be 0.08 mg/hour of malathlon (range, 0.03-0.13 mg/hour) 
and the mean dermal dose was 2.5 mg/hour (1.5-4.9 mg/hour). The authors 
did not report any signs or symptoms of malathlon poisoning, nor did they 
report any ChE activity determinations.
Good industrial hygiene requires that adequate engineering controls 
and work practices be used, including personal protective equipment and, 
under certain conditions, respiratory protection. Exhaust systems are 
needed at loaders, blenders, mixers, mills, packaging equipment, and all 
other possible sources of vapor, spray, or dust containing malathlon. 
Liquid and dust exhaust systems must be so designed that the health of 
employees and that of people or animals in the surrounding community is not 
endangered. Dust exhaust systems should be vented Into a dust collector, 
not into the atmosphere. Guidance for design of a ventilation system can 
be found in Industrial Ventilation— A Manual of Recommended Practice, [142] 
or more recent revisions, and in ANSI Z9.2-1971. [143] Exhaust air should
not be recirculated and should be scrubbed to prevent pollution of the
outdoor air. Respiratory protective equipment is not an acceptable 
substitute for proper engineering controls, but should be available for
emergencies and for nonroutine maintenance and repair purposes.
Biologic Evaluation
Indicators of response to absorption of malathlon which have been 
reported include: determinations of erythrocyte and plasma ChE activities,
[25] electromyography, [144] electroencephalography, [145] and direct
measurement of serum malathlon levels. [40] With additional study,
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electromyography and electroencephalography eventually may prove to be 
useful diagnostic tools. Direct serum malathion measurement Is of 
extremely limited use, as the compound disappears rapidly from the blood. 
Only one case report [40] was Identified In which this phenomenon was 
examined. Although serum malathion levels were found to be zero 4.5 days 
after Ingestion of the compound, the patient remained critically ill and 
died 1 day later. Estimation of circulating erythrocyte and plasma ChE 
activities is the most effective method for monitoring occupational 
exposure to malathion, as reduction of ChE activity has been found 
consistently in clinical cases of malathion poisoning and has been far more 
extensively studied and documented than either of the other two 
examinations. Also, plasma and erythrocyte ChE activities are related 
generally to the severity of acute poisoning. NIOSH recommends only 
erythrocyte ChE monitoring as an effective measure of acute or chronic 
exposure. However, as plasma ChE activities are often electively monitored 
as well, both parameters will be discussed, and analytical methods for both 
are given in Appendix IV.
DuBois [146] examined the relationship between the lethal effects of 
six organophosphorus pesticides and their respective abilities to inhibit 
ChE in rat serum, liver, and brain. The numbers of animals were not 
specified. He found that the correlation between lethality, as reflected 
by the ip LD50 in rats, and inhibition of brain ChE were much better than 
the correlation between the ip LD50 and serum or liver ChE inhibition. 
Freedman et al, [147] in 1948, studied the relationship between the 
severity of symptoms and inhibitions of erythrocyte and plasma ChE's in 94 
adult male rats weighing 125-175 g and divided into groups of 20-25 each
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for 8ingle subcutaneous injections of either 1 or 2 mg/kg di-isopropyl 
fluorophosphate (DFP) in saline. Signs were graded as severe (marked 
spontaneous trembling of the body, great hyperreactivity on tapping of the 
spine, varying degrees of muscular weakness culminating in paralysis, and 
excessive salivation), moderate (intermittent periods of trembling, marked 
motor restlessness, moderate hyperreactivity on tapping of the spine, and 
spontaneous fasciculations of the muscles in the flanks), or slight 
(transient fasciculations while standing erect on their hindlegs and motor 
restlessness). Brain, plasma, and erythrocyte ChE activities were measured 
manometrically, and control values were obtained from 17 normal rats for 
these same parameters. Correlation between clinical signs and brain ChE 
activity was consistently significant at the 1% level. Erythrocyte ChE 
activity correlated less well with severity (2-5% significance), and plasma 
ChE activity only with severe signs (by classification). In the presence 
of toxic signs, erythrocyte and brain ChE activities remained closely 
parallel, and the correlation coefficient of erythrocyte with brain ChE was 
found to be 0.7 after a 1.0-mg/kg dose of DFP. Therefore, erythrocyte ChE 
activity seems to serve more accurately than that of plasma to approximate 
ChE activity in the brain in both the acute and recovery phases. The 
authors [147] pointed out the importance of the rapidity with which ChE 
activity in the circulating blood is lowered as an Indicator of the 
severity of poisoning by organophosphorus compounds.
In a discussion of clinical case reports of organophosphorus 
poisoning in humans, Namba et al [49] stated that, for diagnostic purposes, 
estimation of erythrocyte ChE (AChE) activity was preferable because it 
indicated the degree of inhibition of synaptic ChE, ie, the extent of
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inhibition directly determining the degree and visible manifestations of 
poisoning. Also, as observed in one of the cases described, following 
pralidoxime administration, erythrocyte ChE indicated the effectiveness of 
pralidoxime; plasma or serum ChE indicated the prior presence of ChE 
inhibition even after restoration of erythrocyte ChE activity by 
pralidoxime. They [49] reported that manifestations of acute poisoning in 
humans generally accompanied serum ChE inhibition of 50% or more. The 
ranges of serum ChE activity were 20-50% of normal in mild poisoning, 10- 
20% of normal in moderately severe poisoning, and less than 10% of normal 
in severe poisoning. Gage [148] pointed out that, while the inhibitory 
action of parathion and certain other organophosphorus compounds was more 
marked on the plasma enzyme than on the erythrocyte enzyme, various other 
organophosphates, notably the dimethyl esters, inhibited the erythrocyte 
enzyme first. Clinical case reports detailed in Chapter III 
[19,24,25,27,39,40] have all indicated that symptomatic malathion 
intoxication in man, irrespective of dose or route of entry, was 
characterized by profound Inhibition of circulating ChE's, as determined by 
laboratory measurement. Where both erythrocyte and plasma ChE activities 
were determined, both were clearly depressed [25,39,40]; and where either 
erythrocyte or plasma ChE activity was examined, depression was uniformly 
evident. [19,24,27] The consistent presence of this phenomenon in 
malathion poisoning, no matter which blood fraction was examined, 
reinforces the case for measurement of ChE activity as a clinical 
diagnostic test in cases of possible malathion poisoning.
Frawley et al [86] found that diets containing malathion at 
concentrations up to 250 mg/kg of body weight inhibited ChE activity in the
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erythrocytes of three dogs without significantly altering the activity of 
plasma ChE. Crowley and Johns [19] described a case of malathion ingestion 
in which erythrocyte ChE activity was reduced to less than 10% of normal 
during the first 7 days after ingestion and rose gradually (at the rate of 
about 1%/day) to 66% of normal 56 days after ingestion.
Initially, biologic assays were used to measure ChE activity. [149] 
Now outmoded, they have been replaced by methods classified as manometric, 
titrimetric, electrometric, colorimetric, radiometric, and chromatographic.
Witter [150] stated that the Warburg manometric technique, based on 
the measurement of carbon dioxide released when acetic acid reacts with 
bicarbonate, was one of the most accurate and versatile ChE measurement 
methods. Such techniques, however, are unsuitable for use with large 
populations because they require bulky apparatus and time-consuming 
procedures.
Methods of determination wherein ChE activity is indicated by 
discernible color changes have been described. The method of Limperos and 
Ranta [151] required only a very small blood sample; the authors found it 
reasonably accurate and reproducible away from the laboratory. Others who 
described modifications of such methods were Davies and Nicholls [152] who 
modified the Limperos and Ranta technique; Fleischer et al [153] who 
altered the Davies and Nicholls' modification; and Gerarde et al [154] who 
modified the procedures described by Wolfsie and Winter, [155] Limperos and 
Ranta, [151] and Hestrln. [156] All such methods are less accurate because 
the solutions used are not buffered, but they may be applicable for field 
screening use.
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Spectrophotometric methods have been described by Ellman et al [157] 
and Garry and Routh, [158] and by Dietz et al, [159] who modified the Garry 
and Routh method.
Baum [160] reported on a method utilizing a liquid membrane electrode 
highly selective for ACh that correlated well with Hestrln's method. [156] 
Descriptions of a variety of other methods of ChE activity determination 
have included titrlmetry by Jensen-Holm et al [161]; specially Impregnated 
test papers which yield an obvious visible result to be matched against 
standard colors by Oudart and Holmstedt [162]; radiometry by Wlnteringham 
and Disney [163-165]; and gas liquid chromatography by Cranmer and Peoples. 
[166]
The most widely used electrometric method has been that of Michel. 
[61] The Michel method, which utilizes readily available apparatus, 
depends on measurement of the activity of H+> ions released from acetic acid 
produced by the catalytic action of ChE in the hydrolysis of ACh. The 
change in the pH of a standard buffer resulting from the enzymatic activity 
during a definite period of incubation at 25 C is measured by a glass 
electrode and associated pH meter. The pH range of 6-8 was found to be 
appropriate for the change In ChE activity which one would expect to find 
in malathion poisoning. The method was applicable to both erythrocytes and 
plasma, with different buffers and certain variations in technique. Michel 
concluded that the electrometric pH method was preferable to the manometric 
method because of its simplicity, minimal equipment requirements, and 
capacity for processing a large number of determinations in a relatively 
short (less than 1 minute/reading) time. It should be noted that a 1974 
report by Ellin and Vlcarlo [167] showed that, when measured by the Michel
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method, [61] ChE levels varied with changes In temperature. A change of 1 
degree from the 25 C prescribed by Michel resulted In a 5.5% change In 
plasma ChE activity and In a 3.9% change In erythrocyte ChE activity, 
whether or not the enzyme was Inhibited. It is, therefore, necessary to 
carefully control temperatures when using this method. Wolfsle and Winter 
[155] developed a micromodification of the sampling technique used in the 
Michel method which was as accurate as the original.
Witter et al [168] presented a modification of the Michel method. 
[61] Theirs eliminated the initial pH reading, the enzyme reaction being 
started by adding a mixture of buffer and ACh to the diluted sample. The 
results are Identical to those obtained with the Michel method, but twice 
as many samples can be analyzed in the same period.
It has been accepted generally that electrometric methods (in which 
delta pH Is measured) and colorimetric methods are the preferred methods 
for measuring ChE activity because they utilize less expensive equipment 
and require less expertise for their operation. As colorimetric methods 
are subject to decreased accuracy by solution turbidity, such as would 
occur with erythrocytes, these methods can only be used to measure plasma 
ChE activity. An electrometric method is therefore recommended, 
specifically Wolfsle and Winter, [155] a microadaptation of the Michel 
method. [61] It is presented in Appendix IV.
The establishment of normal values for plasma and erythrocyte ChE in 
humans has become increasingly Important as the use of organophosphorus 
pesticides has become more widespread. Therefore, a range of normal values 
for comparison with ChE activities in potentially exposed people has become 
a necessity.
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Several studies in which normal ChE activities were determined have 
been reported. These ranges are given in Table XII-2. Further data may be 
found in Appendix IV. Pearson et al [169] calculated formulae to convert 
delta pH values to international enzyme units. These were given as: 
pM/ml/min - 23.15 delta pH/hr - 5.805 for erythrocyte ChE; and juM/ml/min - 
3.26 delta pH/hr -I* 0.15 for plasma ChE.
Vorhaus and Kark [170] determined the serum ChE in 120 healthy 
individuals for whom the range of activity was 0.58-1.37 delta pH/hour.
Fremont-Smith et al [171] reported mean serum ChE activities of 0.95 delta 
pH/hour for 20 "normal" men and of 0.78 delta pH/hour for women. Wolfsie
and Winter [155] tested 255 healthy men and reported ranges for plasma and
erythrocyte ChE values of 0.408-1.652 and 0.554-1.252 delta pH/hour,
respectively. Callaway et al [172] studied a group of 247 healthy adults, 
66 of whom were women, and concluded that "sex, age, occupation, and season 
are without effect upon the level of plasma enzyme."
Sldell and Kaminskis [173] studied the temporal variation of plasma 
and erythrocyte ChE activity, as opposed to laboratory-induced artifact. 
Eight female and fourteen male volunteers, aged 23-67, were tested biweekly 
throughout 1 year for ChE activity and simultaneously questioned on their 
medications, illnesses, alcohol intake, and exposure to ChE inhibitors. 
The average test period attendance was 23 times, and no subject was present 
every time. Nine healthy soldiers, aged 19-24, had blood drawn each 
working day for 3 weeks and completed questionalres similar to those of the
aforementioned subjects. No correlation was obtained between ChE activity
/
and age. A significant difference (P less than 0.01) was obtained in 
plasma ChE activity between men and women, but no seasonal variation in
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enzyme activity was noted for either sex. Six subjects handled 
organophosphates. One volunteer, who had hung Insecticide strips at home, 
experienced a 20% decrease in plasma ChE during the subsequent 6 weeks. 
The coefficient of variation for plasma ChE was reported to be about 6% for 
both sexes, with a mean of 25.7% for men and 24.3% for women.
Erythrocyte ChE activities in this study [173] were reported to be 
more constant, with an average coefficient of variation of 4.1%/slngle 
subject, 2.1% for men, and 3.1% for women. The average range of variation 
of erythrocyte ChE activity was ± 7.9% for men and ± 12.0% for women.
During the course of this study, measurements were made of packed 
cell volume, hemoglobin content, erythrocyte counts, mean corpuscular 
volume, erythrocyte ChE activity/unit volume, and ChE activity/erythrocyte. 
All of these were reported to vary more than the overall erythrocyte ChE 
activity above.
In a population studied twice at 1-year intervals, [173] the average 
change in plasma ChE was 9.3% for men and 16.5% for women. Changes In 
erythrocyte ChE activity of 6.3% for men and 6.7% for women were found at 
this same time. The results of this study [173] serve to vindicate the 
method employed as reliable within the demonstrated limits of temporal 
variation for this small sample. The nine control subjects, who were 
reported to have engaged in strenuous physical exercise, with occasional 
heavy drinking during the evenings, exhibited a maximum difference of 5.13% 
in erythrocyte and 12.8% in plasma ChE activity over the 3-week observation 
period.
Plasma ChE reportedly has been depressed by a variety of conditions 
unrelated to exposure to chemical anticholinesterase agents. Such
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conditions include, but probably are not limited to, liver diseases (such 
as hepatitis and cirrhosis), [174] cachexia, [174] pregnancy, [175] 
malignant neoplasia, [175,176] pulmonary tuberculosis, [175] anemia, acute 
infections and chronic debilitating disease, and malnutrition. [170] 
Familial Incidence of low plasma ChE activity was reported by Lehmann and 
Ryan [177] and by Kalow [178] and subsequently found to be related to the 
presence of an atypical gene. [179] About 1 in 5,000 healthy Canadians was 
found to be homozygous for this autosomal allele [178] and to have a 
genetically determined deficiency in plasma ChE. Heterozygotes were 
reported to have a mixture of normal and abnormal serum ChE. The frequency 
for the abnormal gene in a healthy population was reported to be 0.019 ± 
0.002. [180] The importance of these observations to susceptibility to 
organophosphorus pesticide poisoning does not appear to have been 
determined. However, in interpreting the results of ChE activity tests, it 
is necessary to consider the above-noted factors which could cause 
deceptively low activities.
The activity of erythrocyte ChE has been depressed by certain 
pulmonary and extrapulmonary cancers [175] and in paroxysmal nocturnal 
hemoglobinuria. [181] Familial asymptomatic reduction in erythrocyte ChE 
activity has also been reported. [182]
Drugs, such as caffeine and related xanthine compounds, [183] 
chloroquine and other antimalarlal drugs, [74] chloroform, [184] ether,
[184] narcotic analgesics such as morphine and codeine, [76] and thiamine
[185] have been shown to depress the activity of serum (ie, plasma) ChE 
activity. A few drugs have been reported to depress erythrocyte ChE 
activity, including quinine, [74] other antimalarlal drugs, [74] and 
echothlophate. [186]
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V. DEVELOPMENT OF STANDARD
Basis for Previous Standards
The American Conference of Governmental Industrial Hyglenists' 
(ACGIH) recommendation of a threshold limit value (TLV) for malathlon of 15 
mg/cu m was published In 1962. [187] A TLV of 10 mg/cu m was recommended 
In 1971 In a general reduction of the TLV's for "nuisance" dusts. [188] 
The TLV remained at that figure In 1975, without Indication of an Intended 
change in 1976. This TLV was based on studies both in experimental animals 
and in humans. The Documentation [188] cited the review of Johnson et al 
[189] in which the authors concluded that in animals, malathlon was not 
more than 1/100 as toxic as parathlon. The report of Tousey [190] was 
cited in support of this opinion, as was the work of Hazleton and Holland, 
[10] which showed little or no inhibition of blood or brain ChE activity 
and no other Injury to rats fed malathlon at a concentration of 200 ppm for 
2 years. The authors of the Documentation suggested that this animal
exposure was equivalent in humans to 350 mg/day. However, they did not 
present the assumptions underlying this estimate.
Studies in humans cited in support of the 10-mg/cu m TLV Include 
those by Culver et al, [68] Golz, [56] Rider et al, [191] and Hayes et al.
[32] The ACGIH TLV Documentation [188] reported that Culver et al [68]
found that "a group of entomologists with a maximal exposure of 5 hours at
a peak of 56 mg/cu m and an average of 3.3 mg/cu m had normal ChE levels."
The study group consisted of two entomologists, and the exposure period 
comprised multiple 20-second to 30-mlnute exposures which totaled 5 hours 
during a 2-week period. With reference to the aerosol studies of Golz,
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[56] the ACGIH committee wrote that "groups of 4 men each received 84 one- 
hour exposures in 42 consecutive days at dosages of 0, 0.15, 0.6, and 2.4 g 
of malathion/1,000 cu ft (5.3, 21.2, and 84.8 g/cu m)." In this study, the 
malathion was dispersed as an aerosol into the exposure room air in a
single application. The amount released was calculated to be sufficient to 
produce an initial peak concentration at the stated level. No additional 
malathion was released into the air during the 1-hour exposure period. 
Since the air concentration of aerosol had probably decreased by an unknown 
and undeterminable amount during the 1-hour exposure period, the actual 
dose received by the subjects cannot be calculated. The subjects did not 
manifest cholinergic signs or symptoms, nor did they exhibit dose-related 
changes in blood ChE activities.
The dermal exposure studies of Hayes et al [32] found that men
exhibited no significant decreases in blood ChE activity when exposed 5
days/week for 8-16 weeks to malathion-contalning dusting powder to an 
extent sufficient to lead to urinary excretion of malathion-derived 
materials extractable from acidified urine by ethyl ether equivalent to 
about 48 mg of malathion/day. Since the ether-extractable phosphates 
represent about 69% of the total urinary metabolites, the data suggest 
dermal absorption of malathlon of about 78 mg/day. The preliminary
investigations of Rider et al [191] found no effect on blood ChE activities 
when malathion was fed to human volunteers for a total of 88 days as 
follows: 47 days at a dose of 16 mg/day alone, followed by 41 days with
the same dose of malathion and 3 mg/day of EPN, a synergist of malathion.
The present federal standard for occupational exposure to malathion 
is 15 mg/cu m as a TWA limit (29 CFR 1910.93, published in the Federal
103
Register 39:23543, June 27, 1974). The American National Standards
Institute (ANSI) has made no recommendations for a malathlon standard to 
date. Foreign standards for malathlon listed in 1970 by the International 
Labour Office (ILO) [192] were given as 0.5 mg/cu m for Bulgaria and the 
USSR and 15 mg/cu m for Finland, Yugoslavia, and Rumania. The scientific 
bases for these standards are not known to NIOSH. The ILO publication
[192] gave the standard for malathlon in the federal Republic of Germany as 
15 mg/cu m and stated that it was based on the 1966 Documentation on 
Threshold Limit Values of the ACGIH.
Basis for the Recommended Standard
As shown by the case reports in Chapter III, [19,20,23-25,27,39] the 
main signs and symptoms of malathlon intoxication are increased bronchial 
secretion and excessive salivation, [19,20] nausea, [27] vomiting, [25] 
excessive sweating, [23] miosis, [24,39] and muscular weakness and 
fasciculations. [20] These signs and symptoms are induced by the 
inhibition of functional AChE in the nervous system. [1,2]
Malathlon has been responsible for a number of nonoccupationally 
related cases of human poisoning, many of which have been fatal. 
[22,39,50,188] All known reports of such fatalities in humans have 
involved ingestion of large quantities of malathlon, mainly in attempted 
suicide. [22,39,50] In the adult human, the approximate lethal oral dose 
can be estimated to be of the order of 0.4-1.0 g/kg based on case reports 
of ingestion. [19,20,25,44-46] Only extreme emergency measures, including 
massive therapy with atropine and 2-PAM and extensive artificial life- 
support systems over prolonged time periods, managed to save these
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patients. Serious poisoning by dermal exposure has been reported in a few 
Isolated instances. [27]
Only a few instances of occupationally related poisonings have been 
documented. [17,38,42,182] Following heavy dermal exposure to malathion 
for 3 or more days, applicators experienced mild-to-moderate intoxication 
with typical signs of inhibition of ChE. [182] In the carefully controlled 
experiments of Hayes et al, [32] repeated dally dustings of the entire body 
for 8 or more weeks with a 10Z talc formulation of malathion did not 
produce any signs or symptoms of ChE inhibition. Liquid preparations of 
malathion, either as technical grade or as formulations, probably represent 
more pronounced dermal hazards than a 10% talc formulation. Protection for 
the worker can be achieved by wearing protective clothing while handling or 
applying malathion. Following dermal exposure to large amounts of 
malathion from splashes and spills, the skin should be cleansed to prevent 
further absorption of the material.
The study by Culver et al [68] of workplace exposure under field 
conditions revealed a maximum mean atmospheric concentration of malathion 
of 7.70 mg/cu m at a 10-yard distance from the source of the spray. The 
jeep driver, who had the greatest total dermal exposure, formulated the 
insecticide from technical grade malathion and transferred all the material 
from mixing cans to the aerosol rigs. The exposure was intermittent over a 
2-week period. His minimum total dermal exposure was In the range of 32-86 
mg (calculated as 0.5-1.23 mg/kg by the authors) over a total of 5.23 hours 
comprising 23 separate runs. Of this exposure, 84-93Z was determined to be 
on his hands. Total respiratory exposures for the same jeep driver were 
measured at 11-21 mg over the same time span. Measurement of his
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erythrocyte and plasma ChE activities revealed maximum decreases of 19 and 
27%, respectively. No symptoms were reported other than "some signs of 
generalized fatigue," attributed by the authors to the work schedule. 
Since the exposure was intermittent during 2 weeks, spontaneous recovery of 
the ChE activity may have occurred. The authors [68] also calculated that, 
from the highest integrated total exposure during a month on a 40-hour 
workweek basis, without protective clothing, skin exposures of 17-45 mg/kg 
would have occurred.
A study by Jegler [36] of exposures to malathion during field- 
spraying operations reported a mean air concentration of 0.59 mg/cu m in 
the breathing zone of the tractor operator (a range of 0.41-0.76 mg/cu m). 
The mean rates of exposure of workers were 2.5 mg/hour by dermal contact 
and 0.8 mg/hour by the respiratory route. The maximum rate of exposure, 
both respiratory and dermal, was calculated as 5.03 mg/hour, according to 
the procedure described by Durham and Holfe. [133] Jegler's procedure was 
based on comparisons between the measured respiratory and dermal exposures 
and the animal toxicities given in Clinical Memoranda on Economic Poisons.
[193] No toxic effects were noted in the workers examined, although It was 
reported that 85% of the operators disregarded safety precautions and usual 
working procedures.
Studies by Weeks et al [83] demonstrated no effects on ChE activity 
levels in either rabbits or quail exposed for one 6-hour period to aerosols 
of technical malathion (95% pure) at 65 mg/cu m. ChE activity was 
significantly reduced when the rabbits were exposed to malathion at a 
concentration of 125 mg/cu m for 6 hours. The mass median diameter of the 
aerosolized particle was 12pm. The total amount of malathion absorbed
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under these experimental conditions cannot be estimated. While the data
indicated that extremely high concentrations of malathion aerosols can be
tolerated by rabbits for 6 hours, it is not possible to draw any
conclusions from this study about the effects on humans of repeated
■
exposures at low concentrations.
In view of the low vapor pressure of malathion (0.00004 mmHg at 30 C,
0.05 ppm), concentrations of malathion in the workplace can exceed the 
current environmental limit only when significant amounts of aerosols and 
dusts are present. The current environmental limit is consistent with the 
standard for protection against physical irritation initiated by the 
presence of physical matter. The present federal standard for malathion in 
the air of the workplace is 15 mg/cu m as a TWA limit (29 CFR 1910.93). 
The few reported cases of occupational poisoning have resulted from 
violation of sound work practices. [17,38,42,182] The toxicologic 
evidence [17,32,36,42,68,83] suggests that the current standard provides an 
adequate margin of safety for the worker. Therefore, NIOSH recommends that 
the current workplace TWA limit be maintained.
While it is unlikely that poisoning will occur because of 
occupational exposure, the possibility does exist for it to occur in 
extreme circumstances. Case studies by Namba et al [49] have Indicated 
that toxic effects caused by malathion appear when ChE activity is reduced 
to 50% of baseline. It is recommended that workers exhibiting erythrocyte 
ChE Inhibition to 60% of baseline be removed from their jobs until recovery 
to 75% of baseline is observed, and that, if any worker's erythrocyte ChE 
is found to be reduced to 70% of baseline, an immediate evaluation of work 
practices be undertaken to determine that they are properly observed.
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VI. WORK PRACTICES
Based on personal research, Wolfe [194] stated that over 97% of the 
pesticide to which the body is subjected during most exposure situations is 
deposited on the skin. Feldmaifti and Maibach [128] indicated that spraying 
or dusting with pesticides may result in the deposition on the exposed skin 
surface of an amount of pesticide 20-1,700 times greater than that which 
reaches the respiratory tract. Maibach, in the Report to the Federal 
Working Group on Pest Management, [195] stated that pesticide skin 
depositions of 718-1,755 mg/hr were observed during spraying operations. 
Studies by Maibach et al, [31] in which they applied malathion to various 
skin sites of human volunteers, indicated that dermal absorption ranged 
from 5.8% on the palm to 28.7% at the axilla. Because of this demonstrated 
deposition of pesticides on exposed skin surfaces and the experimentally 
reported dermal absorption of malathion, personal protective measures 
should be observed insofar as possible to limit malathion exposure.
For personal protection against pesticide exposure, Wolfe [194] 
recommended long-sleeved outer garments, such as coveralls, that can be 
washed dally, rather than rubberized or plastic waterproof clothing which 
may be too uncomfortable because of heat absorption and trapping of body 
heat. Wolfe [194] also recommended wide-brimmed waterproof hats, unlined 
waterproof boots or shoes, gauntlet gloves, goggles, and respirators for 
additional protection. When skin exposure does occur, the affected area 
should be washed promptly and medical surveillance instituted to determine 
whether overexposure has occurred. The rate of dermal absorption will vary 
with the composition of the formulation, but measurements of the degree of
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variation have not been found in the literature.
Malathion-contaminated equipment and surfaces should be
decontaminated to minimize exposure. Although only qualitative results 
were given, treatment of malathion by alkali has been shown by Kennedy et 
al [196] to degrade malathion to an inorganic phosphate. The use of alkali 
decontaminants, however, could be damaging to wooden surfaces. El-Refai 
and El-Essawi [197] found that laundering In detergent removed up to 98% of 
the malathion contamination from cotton fabric.
Another important route of entry is through the respiratory tract. 
If exposure to airborne concentrations of malathion cannot be reduced 
either by engineering controls or by administrative measures to the level 
specified in Chapter I, Section 1(a), then respiratory protection as 
specified in Chapter I, Section 4(b) must be utilized.
The other potential route of exposure is oral. Hence, effort should 
be made to avoid contamination of foodstuffs and their containers, tobacco 
products, and other materials placed in or near the mouth. Handwashing 
before eating, as recommended by NIOSH, is a common practice in malathion 
industries. [131]
Wolfe et al [198] and Mail et al [199] discussed the health problems 
of discarded pesticide containers and stressed the necessity of 
decontaminating and destroying them. Mail et al [199] recommended that 
fiber drums used as pesticide containers be crushed, and metal containers 
washed and punctured prior to their disposal. Lime slurry may be a highly 
effective agent for both destroying and Immobilizing malathion. Floor 
sweepings containing malathion should not be sent to a public sanitary 
landfill, but rather disposed of by trained plant personnel. Wolfe [194]
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recommended two thorough rinsings with water as a minimum decontamination 
procedure for 5-gallon metal drums after removal of their pesticide 
content. Both sets of recommendations by Hall et al [199] and by Wolfe
[194] were based on studies of parathlon decontamination. Containers may 
also be returned to the supplier or sold, burned, or buried 18 inches deep 
in isolated areas. However, when containers are sold, buyers must be 
informed of their previous use with pesticides, and decontamination must be 
accomplished by washing the outside with water and the inside with water 
and caustic soda (2 lb/55-gal drum). Glass containers should be broken, 
plastic containers punctured and mutilated, and metal containers punctured 
and crushed. [200]
The thermal decomposition of a commercial malathion formulation (5 
lb/gal) was measured [196] to be from 95.3 to 96.7% at temperatures of 600- 
1,000 C. At 900 C, decomposition products of burning analytical grade 
malathion were determined [201] to be carbon monoxide, carbon dioxide, 
sulfur dioxide, hydrogen sulfide, oxygen, and four unidentified products. 
Stojanovic et al [202] also tentatively identified diethyl succinate, 
diethyl maleate, and diethyl fumarate as thermal decomposition products.
I
Some of the undecomposed fraction of burning malathion will vaporize, and 
contaminated particles will become airborne. The National Agricultural 
Chemicals Association (NACA) [203] recommends that self-contained breathing 
apparatus, rubber gloves, hats, suits, and boots be worn by firefighters in 
the case of parathlon fires, and that these be cleaned before being 
removed. Firefighters are advised [203] to shower thoroughly and change to 
clean clothing after the operations have ended. Workers should avoid being 
downwind of the fire, and only those workers essential to the firefighting
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operation should remain In the vicinity of the fire.
NIOSH recommends that the procedures advised by NACA [203] for 
parathion fires be followed for malathlon fires as well. Attention should 
be given to the possibility of concomitant exposure to considerably more 
toxic organophosphates or to other pesticides and compounds which may also 
be burning in warehouse fires, and appropriate precautions should be 
observed.
The WHO Expert Committee on Insecticides, [41] in its 16th report, 
recommended that employees exposed to pesticides be properly informed of 
the associated hazards. Industrial experience indicates that written 
information on pesticides is sometimes not readily available at the 
worksite. [131] Recognizing the need for employees to have information on 
the materials with which they work, the WHO stressed the importance of 
employees being informed of the hazards of malathlon. [41]
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VII. RESEARCH NEEDS
Several aspects of the available information on malathion need 
extension, verification, or development. Information on the mutagenic and 
carcinogenic potentials of malathion Is very scanty. Studies designed to 
detect the induction of these deleterious effects in at least two species 
over their entire lifetimes should be Initiated as soon as possible.
The ingestion study of Moeller and Rider [21] needs confirmation. 
The results of 47 days of malathion administration indicated that the 
threshold of significant erythrocyte ChE inhibition was somewhat greater 
than 24 mg/day for 8 weeks.
The rate and mechanism of skin absorption of the various types of 
malathion formulations need to be determined. In particular, the enzymes 
or biochemicals which metabolize or activate the compound during dermal 
absorption need to be determined. This is the most likely area of exposure 
to malathion by way of liquid spills and splashes, atmospheric dust 
deposits, etc. It would be beneficial to better understand the degree of 
hazard posed via this route of exposure.
The physiologic significance of aliesterase inhibition should be 
examined further. The kinetics of inhibition and regeneration of 
allesterase should be studied as functions of the dose and route of 
malathion administration.
An accurate field test for ChE activity should be developed. Current 
methods are unsuitable as they require special laboratory equipment or 
lengthy procedures, or are insufficiently quantitative.
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The quantitative relationship between skin and respiratory exposure 
to malathlon and the excretion of metabolites In the urine should be 
determined and correlated with the rate of AChE Inhibition In vivo. Such 
knowledge would facilitate the development of a nonlnvaslve technique for 
measuring malathlon exposure.
Alternative methods, such as filters, for the collection of malathlon 
dusts, vapor, and aerosols In the workplace should be further Investigated. 
The efficacy of charcoal tubes in the collection of malathlon vapor should 
be investigated.
The equilibrium constant for the reaction of malaoxon with purified 
AChE and the rate of aging of the dlmethylphosphoryl AChE derivative should 
be measured. Such information is necessary to determine the rate of 
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The sampling and analytical methods presented In Appendices I and II 
are taken from those described by Culver et al, [68] by Brody and Chaney, 
[139] and In the NIOSH Manual of Analytical Methods. [204]
Atmospheric Sampling
Breathing zone samples representative of the Individual employee's 
exposure shall be collected. A description of sampling location and 
conditions, equipment used, time and rate of sampling, and any other 
pertinent information shall be recorded at the time of sample collection. 
Enough samples shall be collected to permit calculation of a TWA 
concentration for every operation or location in which there is exposure to 
malathion.
The midget impinger recommended in Chapter IV of this document must 
be operated In a uniform and consistent way if data obtained are to have 
meaning in the assessment of environmental conditions. The impinger should 
be made of glass lh all portions that may contact the collection medium or 
the air stream before collection is effected. It should be emphasized that 
the ethylene glycol used as a collection medium must be free of 
contaminants that produce interfering peaks when extracted with hexane and 
analyzed by gas liquid chromatography (GLC). Consequently, only ethylene 
glycol that has been preextracted and found to be free of interfering
METHOD FOR SAMPLING MALATHION IN AIR
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substances by GLC utilizing a flame photometric detector can be used.
(a) Equipment
The sampling train consists of an all-glass midget implnger filled 
with 10 ml of ethylene glycol. The sampling pump Is protected from splash- 
over or water condensation by an adsorption tube loosely packed with a plug 
of glass wool and Inserted between the exit arm of the Implnger and pump 
or, preferably, by a water trap Inserted In the same location.
(b) Calibration
Since the accuracy of an analysis can be no greater than the accuracy 
of the air volume measurement, the accurate calibration of a sampling pump 
Is essential to the correct Interpretation of the volume Indicated. The 
frequency of calibration Is dependent on the use, care, and handling to 
which the pump Is subjected. Pumps should also be recalibrated If they 
have been misused or If they have just been repaired or received from a 
manufacturer. If the pump receives hard usage, more frequent calibration 
may be necessary. Regardless of use, maintenance and calibration should be 
performed on a regular schedule and records of these kept.
Ordinarily, pumps should be calibrated In the laboratory. The 
accuracy of calibration Is dependent on the type of Instrument used as a 
reference. The choice of calibration Instrument will depend largely upon 
where the calibration Is to be performed. For laboratory testing, primary 
standards, such as a spirometer or a soapbubble meter, are recommended, 
although other standard calibration Instruments, such as a wet-test meter 
or dry gas meter, can be used. The actual setups will be similar for all 
Instruments.
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Instructions for calibration with the soapbubble meter follow. If
another calibration device is selected, equivalent procedures should be 
used. Since the flowrate given by a pump is dependent on the pressure drop 
of the sampling device, in this case an implnger, the pump must be 
calibrated while operating with a representative implnger in line. The 
calibration system should be assembled in series following this order: 
soapbubble meter, water manometer, midget implnger, and pump, as shown in 
Figure XV-2.
(1) The voltage of the pump battery is checked with a
voltmeter to ensure adequate voltage for calibration. The battery is
charged if necessary.
(2) The pump is turned on and the inside of the soapbubble
meter is moistened by immersing the buret in the soap solution and drawing
bubbles up the inside until they travel the entire buret length without
bursting.
(3) The pump rotameter is adjusted to provide the desired
flowrate.
(4) A soapbubble is started up the buret and the time
required for it to move between calibration marks is measured with a
stopwatch.
(5) The procedure in (4) above is repeated at least twice, 
the results averaged, and the flowrate calculated from the volume between 
the preselected marks divided by the time required for the soapbubble to 
traverse the distance.
%
(6) Data for the calibration include the volume measured, 
elapsed time, pressure drop, air temperature, atmospheric pressure, serial
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number of the pump, date, and name of the person performing the 
calibration.
(c) Sampling Procedure
Any air mover capable of drawing the desired flowrates through the
impingers may be used, so long as flowrates do not vary more than ± 5%
during the sampling period. The sampling pump must be capable of operating 
at a pressure drop of 1 inch of mercury while providing the designated flow 
of 2.8 liters/minute.
An air sample Is taken using a flowrate of 2.8 llters/mlnute. The 
flowrate of the pump must be calibrated and this calibration checked 
periodically to ensure that it has not changed.
When atmospheric samples are taken for determination of compliance 
with the recommended environmental limit, the implnger is placed within the 
breathing zone of the exposed employee to determine the employee’s actual 
exposure to airborne malathlon. This may be done by placing the midget
implnger In a holster and fastening it to a lapel of a coat or collar of a
shirt. The individual conducting the evaluation may also hold the implnger 
near the face of the employee during the sampling period.
The duration of sampling shall be such that the recommended
analytical method may detect concentrations as low as 1/10 the recommended
environmental limit, ie, 1.5 mg/cu m.
The contents of the implnger should be transferred to a sample bottle 
for shipping. The implnger and stem should be washed with 2-5 ml of 
ethylene glycol, the solution used for washing included in the sample 
bottle, and the exact amount of ethylene glycol used recorded. The bottle
should be sealed tightly and placed upright in a carrying case. Every
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attempt should be made to prevent any loss due to spillage or evaporation.
The trapped malathion Is extracted from the ethylene glycol with 
hexane and analyzed as described In Appendix II. Other collection methods 
shown to be equivalent may be used.
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X. APPENDIX II 
ANALYTICAL METHOD FOR MALATHION
The method presented in the NIOSH Manual of Analytical Methods [204] 
for analysis of parathion in air is recomnended for malathion.
Principle of the Method
Malathion from the air is trapped in ethylene glycol contained in a 
midget impinger. The ethylene glycol solution is diluted with water and 
extracted with hexane. The resulting hexane solution containing the 
malathion is concentrated and subjected to gas chromatographic analysis 
using a phosphorus flame photometric detector.
Range and Sensitivity
The linear range of the flame photometric detector is 0.5-25 ng for 
malathion and for a 50-liter air sample carried through the following 
procedure to solution in 1 ml of hexane, 2 p i  of which are injected into 
the gas chromatograph, ie, 5-250 pg/cu m. These limits can be lowered or 
raised by changing (1) the volume of air sampled, (2) the volume of the 
final hexane solution, or (3) the size of the aliquot injected into the gas 
chromatograph.
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Phosphorus compounds having retention times close to that of 
malathion will interfere with the analysis. Retention ratios, relative to 
ethyl parathion, have been tabulated for malathion on columns identical to 
column 4 as specified (see Apparatus Section), but operated at slightly 
different temperatures, by Thompson. [200] These indicate possible 
interference by malaoxon and methyl parathion. Resolution of such 
interference can be accomplished by varying the column compositions and 
temperatures used. The equipment used must be scrupulously cleaned to 
remove any traces of phosphate detergents.
Advantages and Disadvantages of the Method
(a) Advantages: The method is very sensitive, and the detector 
exhibits high specificity for phosphorus compounds. The analysis is 
performed directly on malathion. Separation and quantitation are 
accomplished in a reasonable amount of time.
(b) Disadvantages: The cost of the equipment and supplies may tax 
the budget of some laboratories. The sensitivity of the equipment depends 
on careful adjustment of the operating conditions. Contamination can occur 
easily through equipment or reagents. If interfering compounds are 
anticipated, a lengthy cleanup procedure is required.
Apparatus
(a) Forceps.
(b) Glass stirring rods.
Interferences
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(c) Separatory funnels, 250-ml.
(d) Beakers, 100-ml.
(e) Funnels, 65- or 75-mm (diameter at top).
(f) Glass wool.
(g) Hot-water bath.
(h) Kuderna-Danlsh evaporator-concentrator, consisting of a 125-ml 
Erlenmeyer-type flask, 3-ball Snyder column, and a 10-ml receiver graduated 
in milliliters.
(1) Glass beads, 3-mm.
(j) Volumetric flasks for standards.
(k) Graduated cylinders, 25- or 50-ml.
(1) Syringes, 5- or 10-jil and 100-pl.
(m) Gas chromatograph, with attendant equipment, Including a
phosphorus flame photometric detector.
(n) Gas-chromatography column constructed from 6-ft x A-mm Inside
diameter borosilicate glass packed with one of the following:
(1) 10% DC-200 (12,500 cst) on 80-100 mesh Gas Chrom Q.
(2) 7.5% QF-1 (10,000 cst)/5% DC-200 (12,500 cst) on 80-100 
mesh Gas Chrom Q.
(3) 2% diethylene glycol succinate (DEGS) (C6 stabilized) 
on 80-100 mesh Gas Chrom Q.
(4) 4% SE-30/6% OV-210 on 80-100 mesh Chromosorb W, HP. 
Columns 1 and 2 are heat-conditioned for 2-4 days at 240-250 C under
nitrogen flowing at 60 ml/minute, then primed by repeated injections of 
standard malathion solution under the conditions of analysis given below. 
Column 3 is conditioned by heating for 12 hours at 225-230 C under nitrogen
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flowing at 60 ml/minute. A column of 10Z Carbowax 20M on 80-100 mesh 
silanlzed support (2-in x 4-mm inside diameter glass tubing) is then 
inserted before Column 4, and the assembly is heated at 230-235 C for 17 
hours under nitrogen flowing at 20 ml/minute. The 10% Carbowax 20 M column 
is subsequently removed.
Reagents
(a) Ethylene glycol, chromatoquality.
(b) Hexane, pesticide quality.
(c) Distilled water, interference-free.
(d) Saturated aqueous sodium chloride, interference-free.
(e) Anhydrous sodium sulfate.
(f) Malathion of known purity.
Analysis of Samples
(a) Transfer the sample in 17-20 ml of ethylene glycol to a 125-ml
separatory funnel. Wash the sample container with a measured amount of
water and add the washings to the separatory funnel. Dilute the ethylene
glycol with a total of 70 ml of water.
(b) Extract the aqueous solution three times with 12 ml of hexane,
and discard the aqueous layer. Should an emulsion be formed, saturated
aqueous chloride can be used to disperse it.
(c) Dry the hexane solution by passing it through 2.6 g of 
anhydrous sodium sulfate contained in a funnel with a glass-wool retaining 
plug at the top of the stem. Collect the eluate in a 125-ml Kuderna-Danish
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flask which has been fitted with a 10-ml receiving tube containing one 3-mm 
glass bead. Rinse the separatory funnel with three consecutive 2-ml 
portions of hexane, washing down the walls of the funnel. Allow each rinse 
to elute before adding the next. Finally, rinse the funnel and the sodium 
sulfate with two more 2-ml portions of hexane.
(d) Place the Kuderna-Danish assembly in a boiling water bath and
concentrate the extract to a volume of approximately 5.0 ml. Remove the 
assembly from the bath, and after it has cooled, disconnect the receiving 
tube from the flask, rinsing the joint with a little hexane. Place the 
tube under a nitrogen stream at room temperature and further concentrate 
the extract to approximately 0.5 ml. Rinse down the wall of the tube with
hexane delivered from a 100-jtl syringe, diluting the extract to exactly 1.0
ml, and stir.
(e) Inject a suitable aliquot of the hexane solution into the gas 
chromatograph and obtain a chromatogram. The chromatographic conditions 
are:
Column temperature 220 C for columns 1 and 2
210 C for column 3
200 C for column 4
Injection port temperature 225 C
Detector temperature 200 C
Transfer line and
switching valve temperature 235 C
Carrier gas (nitrogen) flow 60 ml/minute
The solvent-flush sample injection technique is recommended. 
Duplicate injections should be made. The hexane, which precedes the 
malathion, should be vented so the detector flame will not be extinguished.
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The conditions of the run should be such that no malathion is lost during 
the venting process.
(f) The average of the areas under the malathion peaks is
converted to the amount (ng) of malathion seen by the detector by comparing 
it to a standard curve for malathion.
Calibration and Standards
(a) Prepare at least three standard solutions in the concentration 
range of 100-12,500 ng/ml from a stock solution of malathion in hexane.
(b) Make duplicate injections of aliquots of each standard 
solution into the gas chromatograph and determine the peak areas.
(c) Plot the amount (ng) of malathion seen by the detector against 
the peak area. A straight line passing through the origin should result. 
If this result is not obtained, either the linear range of the detector has 
been exceeded or a system malfunction has occurred.
(d) Injections of standards should be interspersed among sample 
Injections so that a watch can be maintained on detector sensitivity.
Calculations
(a) Determine the total amount in ng of malathion present in the
sample:




ng(o) “ nanograms of malathlon determined
from calibration curve based on 
peak area responses
Soln vol ■ volume In n l  of the final hexane
solution (usually 1,000 ¿tl)
Inj vol » volume in i l l  of the aliquot of
the final hexane solution Injected
Into the gas chromatograph
(b) Convert the volume of air sampled to standard conditions of 25 
C and 760 mmHg:
Vs - V x _P_ x 298
760 (T + 273)
where:
Vs ■ volume of air in liters at 25 C and 760 mmHg
V ■ volume of air in liters as measured
P - barometric pressure in mmHg where sample is collected
T ■ temperature (degrees C) of air sampled
(c) The concentration of malathlon can be expressed in ng/1 or 
pg/cu m:
¿cg/cu m * ng/liter




NOTES ON THE DIAGNOSIS AND MEDICAL MANAGEMENT 
OF ORGANOPHOSPHORUS INTOXICATION
The following paragraphs have been adapted from an article entitled 
"Prevention and Management of Organophosphate Poisoning" which appeared In 
the Journal of the American Medical Association and which was approved by 
the AMA Committee on Occupational Toxicology of the Council on Occupational 
Health. [205]
Diagnosis
A diagnosis of organophosphate intoxication is based primarily on a 
definite history of exposure to an organophosphate 6 hours or less before 
onset of illness and clinical evidence of diffuse parasympathetic 
stimulation. Laboratory verification is based on depression of plasma and 
red blood cell ChE activities to a level substantially (50% or more) below 
preexposure values if these are available. If preexposure values are not 
available, one can use laboratory normal ranges, observing, of course, the 
usual caution in interpreting such figures. There are many different 
methods for estimation of ChE content of blood, and associated with each 
method is a different set of normal values and a different set of reporting 
units. The laboratory report of a ChE determination should state the units 
involved along with the appropriate normal range. Based on the Michel 
method, [61] the normal range of red blood cell ChE activity (delta pH/hr) 
is 0.39 to 1.02 for men and 0.34 to 1.10 for women. The normal range of
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the enzyme activity (delta pH/hr) of plasma is 0.44 to 1.63 for men and 
0.24 to 1.54 for women.
In actual practice, the ChE test is often of more value as a 
confirmatory, rather than a diagnostic, procedure. For moderate-to-severe 
intoxication, the clinician should act on his clinical Impression and on 
the history of exposure rather than wait for laboratory confirmation.
Initial signs and symptoms of intoxication are headache, nausea, 
vomiting, sweating, blurred vision, weakness, diarrhea, abdominal pain, and 
pallor. In moderate-to-severe cases of intoxication, signs and symptoms 
may also include dyspnea, salivation, lacrimation, muscle fasciculation, 
convulsions, cyanosis, shock, and cardiac arrhythmias, coma, and death. In 
the case of mild poisoning where the differential diagnosis may be 
puzzling, the results of the ChE test may be necessary to establish a 
definite diagnosis.
ChE is an enzyme which hydrolyzes ACh. Two types are clinically 
significant: the first, true or acetylChE, is found principally in nervous
tissue and in the red blood cell; the other, plasma or BuChE, is found in 
nervous tissue and in the circulating plasma. Whereas the action of both 
is inhibited by organophosphate compounds, only depression of the amount of 
enzyme in the red blood cells is a specific response to these toxins. The 
level of the enzyme in the plasma may vary with a number of diseases or 
toxic states. A relatively wide variation exists in the normal levels of 
both enzymes from one individual to another as well as in the same 
individual at different times. Once enzyme activity is inhibited, the 
regeneration times differ between the two types. Red blood cell ChE 
regenerates at approximately 1%/day, whereas the enzyme in the plasma
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regenerates at a more rapid rate, approximating 25% in the first 7-10 days.
Circulating red blood cell and plasma ChE may be conveniently thought 
of as a buffer system which serves to protect the individual against the 
nervous system effects of organophosphate toxins by binding the pesticide 
in the circulating blood, thereby preventing it from reaching the nervous 
system. Although this is an oversimplified explanation, it is a clinically 
useful one. In practice, an Individual who has been chronically exposed to 
organophosphate pesticides should be withdrawn from further exposure when 
his ChE activity values drop to 25-50% of normal and should not be allowed 
to return until these values rise to at least 75% of normal. The 
individual who has been acutely poisoned and has shown marked ChE activity 
depression should not be allowed to return to work with organophosphate 
pesticides until his ChE levels have returned to approximately 75% of 
normal.
Treatment
Treatment of organic phosphate poisoning ranges from simple removal 
from exposure in very mild cases to the provision of very rigorous 
supportive and antidotal measures in severe cases. In the moderate-to- 
severe case, because of pulmonary Involvement, there may be a need for 
artificial respiration using a positive pressure method. Careful attention 
must be paid to removal of secretions and to maintenance of a patent 
airway. Anticonvulsants, such as thiopental sodium, may be necessary. The 
critical point is that respiration must be maintained since death usually 
results from weakness of the muscles of respiration and accumulation of 
excessive secretions In the respiratory tract. As soon as cyanosis has
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been overcome, 2-4 mg of atropine iv should be administered promptly. This 
dose is approximately 10 times the amount which is administered for other 
conditions in which atropine is considered therapeutic. This dose should 
be repeated at 5- to 10-minute intervals until signs of atropinization 
appear (dry, flushed skin, tachycardia as high as 140 beats/minute, and 
pupillary dilatation). A mild degree of atropinization should be 
maintained for at least 48 hours. Atropine is contraindicated in a 
cyanotic patient because of the possibility of inducing ventricular 
fibrillation.
Although atropine remains the drug of choice, particularly if the
treatment has to be continued for more than a day or two, pralidoxime
chloride (Protopam chloride) is a commercially available antidote which 
complements atropine and hastens the reactivation of ChE enzymes. For 
adults, in the moderate-to-severe cases, it should be used along with 
atropine, Injected iv as an Initial dose of 1 g at a rate not in excess of
500 mg/minute. After an hour, a second dose of 1 g is indicated if muscle
weakness has not been relieved. After an overwhelming inhalation or skin 
exposure to or after ingestion of the toxic agent, the doses may be
doubled. For children, the dose may be 25-50 mg/kg of body weight.
Treatment with pralidoxime chloride will be most effective if given within 
24 hours after poisoning. (Its usefulness after 36-48 hours is
questionable.) Together, the two antidotes, atropine and pralidoxime 
chloride, are more effective than either one alone. Morphine,
aminophylline, and the phenothiazlnes are specifically contraindicated.
It is of great importance to decontaminate the patient. The stomach 
should be lavaged and a saline cathartic administered if the toxin has been
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Ingested. Contaminated clothing should be removed at once and the skin 
should be washed with generous amounts of soap or detergent and a flood of 
water, which Is best accomplished under a shower or by submersion in a pond 
or other body of water if the exposure occurred in the field. Careful 
attention should be paid to cleansing of the skin and hair. The patient 
should be attended and monitored continuously for not less than 24 hours, 
since serious and sometimes fatal relapses have occurred because of 
continuing absorption of the toxin or dissipation of the effects of the 
antidote.
Atropine is antagonistic to the muscarinic effects, which include 
anorexia, nausea, vomiting, abdominal cramps, sweating, salivation, 
constricted pupils, pulmonary edema, and cyanosis. Atropine has no effect 
on the nicotinic manifestations, which include muscle fasciculation and 
weakness. Pralidoxlme chloride acts to regenerate ChE and to reverse 
muscle weakness. Muscle weakness, specifically weakness of the muscles of 
respiration, is responsible for respiratory impairment and death in the 




METHOD OF SAMPLING AND ANALYSIS FOR BIOCHEMICAL DETERMINATION 
OF CHOLINESTERASE ACTIVITY
The method of Wolfsie and Winter, [155] a micromodification of the 
Michel method, [61] is recommended for the measurement of ChE activity.
Sample Handling and Preparation
Blood is collected from a clean, dry fingertip in a heparinized glass 
capillary tube. The blood is allowed to flow into the capillary tube until 
the tube is approximately 3/4 full, leaving 1-1.25 inches free at one end 
to permit flame-sealing of the tip of the tube without overheating the 
blood sample. The finger should be pricked deeply and care taken to 
collect only free-flowing blood to prevent clotting before the blood 
contacts the heparin lining the wall of the capillary tube.
One end of the capillary tube Is plunged into solid (room 
temperature) paraffin and the other (free) end sealed in the flame of a 
Bunsen burner. The capillary tube Is labeled with an adhesive tape tag 
bearing a serial number or name and date. The sample should then be 
centrifuged at 3,000-3,500 rpm for 50-60 minutes or its equivalent. When 
so treated, the sample may be shipped to a laboratory for immediate 
analysis. The sample should be stored in the cold, Insofar as is feasible 
under field conditions.
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All reagents should be at least ACS reagent grade.
(a) Buffer solution I (for erythrocytes)
For 1 liter of buffer, dissolve 4.1236 g of sodium barbital (0.02 M), 
0.5446 g of potasium orthophosphate, di-H (0.004 M), and 44.730 g of 
potassium chloride (0.60 M) in 900 ml of distilled water. Add 28.0 ml of 
0.1 N hydrochloric acid while shaking the solution, and bring the flask to 
volume with distilled water. The pH of buffer I should be 8.10 at 25 C.
(b) Buffer Solution II (for plasma)
For 1 liter of buffer, dissolve 1.2371 g of sodium barbital (0.006 
M), 0.1361 g of potassium orthophosphate, di-H (0.001 M), and 17.535 g of 
sodium chloride (0.30 M) in about 900 ml of distilled water. Add 11.6 ml
of 0.1 N hydrochloric acid before bringing to volume. The pH of buffer II
should be 8.00 at 25 C.
The pH of a buffer solution may decrease over a period of several 
weeks. The pH should be checked before use. If it has dropped more than
0.03 pH units, the solution should be discarded and a fresh one made.
(c) ACh substrate (for erythrocytes)
This is 0.11 M ACh chloride. Dissolve 2.000 g in 100 ml of distilled
water.
(d) ACh substrate (for plasma)
This is 0.165 M ACh chloride. Dissolve 3.000 g in 100 ml of 
distilled water.
A few drops of toluene may be added to the ACh solutions as a 
preservative. The solutions must be refrigerated when not in use and 




This is 0.01Z saponin. Dissolve 100 mg in 1,000 ml of distilled
water.
Apparatus
(a) Centrifuge capable of maintaining 3,500 rpm and holding 
capillary sample tubes.
(b) A pH meter, calibrated to 0.01 pH units.
(c) 0.02-ml Sahli-type hemoglobin pipet.
(d) Constant-temperature bath, 25 C ± 0.1.
(e) 100- and 1,000-ml volumetric flasks.
Analysis
For analysis, the capillary tube is cut cleanly with a sharp ampule 
file. From the packed-cell section of the capillary, draw 0.02 ml directly 
into a Sahli-type hemoglobin pipet. The ends of the capillary must be cut 
evenly to provide satisfactory juxtaposition with the tip of the pipet. 
Discharge the contents of the pipet directly into 1.0 ml of 0.01Z saponin 
in a microbeaker, and rinse the pipet well (three times) in the solution. 
Glass vials, 1 inch (2.5 cm) deep by 3/4 inch (19 mm) in diameter, are 
convenient for electrometric testing. They will fit in the carrier of a 
standard pH meter and, when used with a clean rubber stopper, will 
eliminate transferring the sample from a test tube for each pH measurement. 
Plasma is taken from the appropriate section of the capillary in the same 
manner as the packed erythrocytes and discharged into 1.0 ml of distilled
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water, the Sahli-type pipet being rinsed in the solution (three times) as 
with the erythrocytes.
Erythrocyte Assay
(a) One milliliter of hemolyzed erythrocyte solution is added to 1
ml of buffer solution I and placed in a 25 C water bath.
(b) After a 10-minute equilibration period, the initial pH (pH(i))
is determined to the nearest 0.01 pH unit with the pH meter.
(c) A volume of 0.2 ml of 0.11 M ACh solution is added with rapid
mixing and the time is recorded.
(d) The reaction proceeds for 1-1.5 hours and then the final pH
(pH(f)) is noted.
The beaker containing the solution should be shaken when the glass 
electrode Is introduced to expedite the establishment of equilibrium.
Note: Buffer solution I is designed to yield a pH of 8.00 after the
addition of hemolyzed human erythrocytes.
Plasma Assay
(a) One milliliter of diluted plasma is mixed with 1 ml of buffer
solution II.
(b) The solution is allowed to equilibrate in a 25 C water bath
for 10 minutes.
(c) At the end of 10 minutes, the pH (pH(i)) is noted to the
nearest 0.01 pH unit.
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(d) A volume of 0.2 ml of 0.165 H ACh solution Is added with rapid 
mixing.
(e) The reaction mixture is incubated for 1-1.5 hours and the
final pH (pH(f)) is noted.
Calculations
The final units derived from this assay are delta pH/hour:




time elapsed in hours between pH(i) and 
pH(f) readings
nonenzymatic hydrolysis corresponding to pH 2 
correction for variations in delta pH/hour 
with pH corresponding to pH 2
The b and c correction factors are given in Table XII-1. Average 
baseline values of erythrocyte and plasma ChE activities in men and women 










CORRECTION FACTORS FOR USE IN EQUATION 1
Erythrocyte ChE Plasma ChE
Corrections Corrections
pH 2 b c b c
7.9 0.03 0.94 0.09 0.98
7.8 0* 02 0.95 0.07 1.00
7.7 0.01 0.96 0.06 1.01
7.6 0.00 0.97 0.05 1.02
7.5 0.00 0.98 0.04 1.02
7.4 0.00 0.99 0.03 1.01
7.3 0.00 1.00 0.02 1.01
7.2 0.00 1.00 0.02 1.00
7.1 0.00 1.00 0.02 1.00
7.0 0.00 1.00 0.01 1.00
6.8 0.00 0.99 0.01 1.00
6.6 0.00 0.97 0.01 1.01
6.4 0.00 0.97 0.01 1.02
6.2 0.00 0.97 0.01 1.04
6.0 0.00 0.99 0.01 1.09
Adapted from Michel [61]
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TABLE XI1-2
NORMAL VALUES FOR CIRCULATING CHOLINESTERASES 
IN HEALTHY NONEXPOSED PERSONS*
Subjects Erythrocyte ChE Plasma ChE Ref­
Activity (delta pH/hr) Activity (delta pH/hr) erence
Range Mean SD Range Mean SD
400 men 0.58 -0.95 0.766 0.081 0.52 -1.39 0.953 0.187 112**
400 women 0.56 -0.94 0.750 0.082 0.38 -1.25 0.817 0.187 112**
255 men 0.554-1.252 0.861 0.091 0.408-1.652 0.912 0.112 89***
120 men 
and women
- - 0.58 -1.37 0.94 0.16 113
20 men - - - 0.95 0.24 114
20 women - - - 0.78 0.12 114
*A11 analyses by method of Michel [61]
**Ranges, means, and standard deviations estimated from data extrapolated 
to age 40; highest 1Z and lowest 1% values eliminated from ranges 
***Analytical method modified for smaller blood samples
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XIII. APPENDIX V 
MATERIAL SAFETY DATA SHEET
The following items of information which are applicable to a specific 
product or material shall be provided in the appropriate block of the 
Material Safety Data Sheet (MSDS).
The product designation is inserted in the block in the upper left 
corner of the first page to facilitate filing and retrieval. Print in 
upper case letters as large as possible. It should be printed to read
upright with the sheet turned sideways. The product designation is that 
name or code designation which appears on the label, or by which the 
product is sold or known by employees. The relative numerical hazard 
ratings and key statements are those determined by the rules In Chapter V, 
Part B, of the NIOSH publication An Identification System for 
Occupationally Hazardous Materials. The company identification may be 
printed in the upper right corner if desired.
(a) Section I. Product Identification
The manufacturer's name, address, and regular and emergency telephone 
numbers (including area code) are inserted in the appropriate blocks of
Section I. The company listed should be a source of detailed backup
Information on the hazards of the material(s) covered by the MSDS. The 
listing of suppliers or wholesale distributors is discouraged. The trade 
name should be the product designation or common name associated with the 
material. The synonyms are those commonly used for the product, especially 
formal chemical nomenclature. Every known chemical designation or
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competitor's trade name need not be listed.
(b) Section II. Hazardous Ingredients
The "materials" listed in Section II shall be those substances which 
are part of the hazardous product covered by the MSDS and individually meet 
any of the criteria defining a hazardous material. Thus, one component of 
a multicomponent product might be listed because of its toxicity, another 
component because of its flammabillty, while a third component could be 
Included both for its toxicity and its reactivity. Note that an MSDS for a 
single component product must have the name of the material repeated in 
this section to avoid giving the impression that there are no hazardous 
Ingredients.
Chemical substances should be listed according to their complete name 
derived from a recognized system of nomenclature. Where possible, avoid 
using common names and general class names such as "aromatic amine," 
"safety solvent," or "aliphatic hydrocarbon" when the specific name is 
known.
The may be the approximate percentage by weight or volume
(indicate basis) which each hazardous ingredient of the mixture bears to 
the whole mixture. This may be indicated as a range or maximum amount, ie, 
"10-40% vol" or "10% max wt" to avoid disclosure of trade secrets.
Toxic hazard data shall be stated in terms of concentration, mode of 
exposure or test, and animal used, ie, "100 ppm LC50-oral-rat," "25 mg/cu m 
LD50-skin-rabblt," "75 ppm LC man," or "permissible exposure from 29 CFR 
1910.93," or, if not available, from other sources of publications, such as 
the American Conference of Governmental Industrial Hyglenlsts or the 
American National Standards Institute Inc. Flananable or reactive data
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could be flash point, shock sensitivity, or other brief data Indicating 
nature of the hazard.
(c) Section III. Physical Data
The data in Section III should be for the total mixture and should 
Include the boiling point and melting point in degrees Fahrenheit (Celsius 
in parentheses); vapor pressure, In conventional millimeters of mercury 
(mmHg); vapor density of gas or vapor (air * 1); solubility in water, in 
parts/hundred parts of water by weight; specific gravity (water ■ 1); 
percent volatiles (indicated if by weight or volume) at 70 degrees
Fahrenheit (21.1 degrees Celsius); evaporation rate for liquids or 
sublimable solids, relative to butyl acetate; and appearance and odor. 
These data are useful for the control of toxic substances. Boiling point, 
vapor density, percent volatiles, vapor pressure, and evaporation are 
useful for designing proper ventilation equipment. This Information is 
also useful for design and deployment of adequate fire and spill
containment equipment. The appearance and odor may facilitate
identification of substances stored in improperly marked containers, or
when spilled.
(d) Section IV. Fire and Explosion Data
Section IV should contain complete fire and explosion data for the
product, including flash point and autoignition temperature in degrees
Fahrenheit (Celsius in parentheses); flammable limits, in percent by volume 
in air; suitable extinguishing media or materials; special firefighting 
procedures; and unusual fire and explosion hazard information. If the 
product presents no fire hazard, insert "NO FIRE HAZARD" on the line 
labeled "Extinguishing Media."
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The "Health Hazard Data" should be a combined estimate of the hazard 
of the total product. This can be expressed as a TWA concentration, as a 
permissible exposure, or by some other indication of an acceptable 
standard. Other data are acceptable, such as lowest LD50, if multiple 
components are involved.
Under "Routes of Exposure," comments in each category should reflect 
the potential hazard from absorption by the route in question. Comments 
should indicate the severity of the effect and the basis for the statement, 
if possible. The basis might be animal studies, analogy with similar 
products, or human experiences. Comments such as "Yes" or "Possible" are 
not helpful. Typical comments might be:
Skin Contact— single short contact, no adverse effects likely; 
prolonged or repeated contact, mild irritation and possibly some 
blistering.
Eye Contact— some pain and mild transient irritation; no corneal 
scarring.
"Emergency and First Aid Procedures" should be written in lay 
language and should primarily represent first-aid treatment that could be 
provided by paramedical personnel or individuals trained in first aid.
Information in the "Notes to Physician" section should include any 
special medical information which would be of assistance to an attending 
physician including required or recommended preplacement and periodic 
medical examinations, diagnostic procedures, and medical management of 
overexposed workers.
(e) Section V. Health Hazard Information
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(f) Section VI. Reactivity Data
The comments In Section VI relate to safe storage and handling of 
hazardous, unstable substances. It Is particularly Important to highlight 
Instability or Incompatibility to common substances or circumstances such 
as water, direct sunlight, steel or copper piping, acids, alkalies, etc. 
"Hazardous Decomposition Products" shall include those products released 
under fire conditions. It must also include dangerous products produced by 
aging, such as peroxides In the case of some ethers. Where applicable, 
shelf life should also be Indicated.
(g) Section VII. Spill or Leak Procedures
Detailed procedures for cleanup and disposal should be listed with 
emphasis on precautions to be taken to protect workers assigned to cleanup 
detail. Specific neutralizing chemicals or procedures should be described 
in detail. Disposal methods should be explicit including proper labeling 
of containers holding residues and ultimate disposal methods such as 
"sanitary landfill" or "Incineration." Warnings such as "comply with 
local, state, and federal antipollution ordinances" are proper but not 
sufficient. Specific procedures shall be identified.
(h) Section VIII. Special Protection Information
m
Section VIII requires specific information. Statements such as 
"Yes," "No," or "If necessary" are not informative. Ventilation 
requirements should be specific as to type and preferred methods. 
Respirators shall be specified as to type and NIOSH or US Bureau of Mines 
approval class, ie, "Supplied air," "Organic vapor canister," "Suitable for 
dusts not more toxic than lead," etc. Protective equipment must be 
specified as to type and materials of construction.
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"Precautionary Statements" shall consist of the label statements 
selected for use on the container or placard. Additional information on
any aspect of safety or health not covered in other sections should be
inserted in Section IX. The lower block can contain references to 
published guides or in-house procedures for handling and storage. 
Department of Transportation markings and classifications and other 
freight, handling, or storage requirements and environmental controls can 
be noted.
(j) Signature and Filing
Finally, the name and address of the responsible person who completed 
the MSDS and the date of completion are entered. This will facilitate 
correction of errors and identify a source of additional information.
The MSDS shall be filed in a location readily accessible to workers 
potentially exposed to the hazardous material. The MSDS can be used as a 
training aid and basis for discussion during safety meetings and training 
of new employees. It should assist management by directing attention to 
the need for specific control engineering, work practices, and protective 
measures to ensure safe handling and use of the material. It will aid the 
safety and health staff in planning a safe and healthful work environment 
and suggesting appropriate emergency procedures and sources of help in the 
event of harmful exposure of employees.
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XIV. APPENDIX VI 
CLINICAL CLASSES OF MALATHION POISONING
Class Criteria
I No significant signs or symptoms,
Clinically vital signs normal, physical examination
Insignificant negative; history of minimal exposure-
exposure inhalatlons, skin contact, mouth-rinse or 
ingestion - some malingerers - sometimes 
no malathlon odor




III Sialorrhea, with foaming if taken po,
Mild to moderately few rales of rhonchi, pupils small
severe specific (sometimes not pinpoint); conscious,
clinical symptoms sometimes stuporous; glycosuria not 
infrequent
IV As above, but more marked, including
Severe specific hypotension; Cheyne-Stokes respirations,
clinical symptoms involuntary defecation, coma, cyanosis, 

















at 25 C and 760 mmHg
Adapted from 11 and
TABLE XV-1 










0.00004 mmHg at 30 C
156-157 C at 0.7 mmHg
2.85 C
1.232 at 25 C
Slightly soluble in water (145 ppm) 
at 25 C, miscible with many organic 
solvents
Above 325 F TOC
1 mg/cu m - 0.075 ppm 
1 ppm ■ 13.333 mg/cu m
XV. TABLES AND FIGURES
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TABLE XV-2 






Dicarboethoxyethyl 0,0-dimethyl phosphorodithioate 
S-(l,2-di(ethoxycarbonyl)ethyl dimethyl phosphorothiolothionate 
l,2-di(ethoxcarbonyl)ethyl 0,0-dimethyl phosphorodithioate 
Diethyl mercaptosucclnate, 0,0-dimethyl dithiophosphate, S-ester 
Diethyl mercaptosucclnate, 0,0-dimethyl phosphorodithioate 




0,0-dimethyl S-(l,2-dicarboethoxyethyl) dithiophosphate 




TRADE NAMES AND SYNONYMS FOR MALATHION
Dithiophosphate de 0,0-dimethyle et de S-(l,2-dicarboethoxyethyle) (Fr)















































From O'Brien and Dannelley [71] and O'Brien [206]
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TABLE XV-4
SOME METABOLITES OF MALATHION
Product Species Location Reference
Dimethyl phosphate Cow Feces 186
Human Urine 207
Dimethyl phosphorothloate Human Urine 200
Dimethyl phosphorodlthloate ti »1 200
Dimethyl thlophosphate ti II 200
Dimethyl dlthlophosphate h Urine and 
serum
207




Malathion dlacld Cow II 64
Rat It 64
Dog II 64
Phosphatase products Mouse II 76
Malaoxon Mammal Tissue 64
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TABLE XV-5
LD50'8 (MG/KG) FOR RATS, MICE, AND GUINEA PIGS
Species Exposure Route Reference
Oral Dermal Ip
Rats 1,400 - 1,500 M 208
If 1,401 M 105






VI 480 M 209







If 200 F 136 F 210
Mice 885 M 209
It 775 M 208




Dogs 1,400 M 211
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TABLE XV-6
EFFECTS ON HUMANS FROM MALATHION EXPOSURE
Exposure
Routes of Concentration Ref-
Exposure Subjects and Duration Effects erence
Dermal, oral, 
respiratory
3 men (Unknown conc) 
35 - 40 d
4.5 mo
No signs or symptoms, 
no ChE activity changes
17
1 man









5.3 mg/cu m 
21.2 mg/cu m
84.8 mg/cu m 
84 hourly 
over 42 d







50 - 90 mi
(Spray 50%)
Symptoms of ChE poisoning 182





No changes in ChE activ- 56
ity; no cholinergic signs 
or symptoms
No changes (1 and 5%), non- 32 
significant decrease (10%), 
in erythrocyte ChE activ­
ity; no illness
Coma, bronchial hypersecre- 39 
tion, miosis, diarrhea, a- 
reflexia, fasciculations, 
reduced erythrocyte ChE ac­
tivity, ECG changes
Nausea, vomiting, diarrhea, 91 
incontinence, bronchial hy­
persecretion, areflexia, 





EFFECTS ON HUMANS FROM MALATHION EXPOSURE
Exposure
Routes of Concentration Ref-
Exposure Subjects and Duration Effects erence




coma, fasciculations, are- 
flexia, miosis, excessive 
sweating, blepharoptosls
16 mg/d No signs or symptoms; re- 
x 47 d duced ChE activity only







1 child 8 ml 
(50% In xylene)





Excessive mucus secretion, 47
hypersalivation, vomiting, 
incontinence, miosis, ab­
sence of deep tendon re­
flexes, stupor
1 woman Miosis, coma, areflexia, 
pulmonary edema, respira­
tory and cardiac arrest, 
death
40



















Oral 1 woman 0.6 g/kg




tress, miosis, diarrhea, 
fasciculations
44
II 1 man 0.5 g/kg 
(liquid 57%)
Cyanosis, Incontinence, re­
spiratory distress, miosis, 
hypotension
46
If ii 0.5 g/kg 





Coma, respiratory distress, 
hypertension, bronchial hy­
persecretion and constric­
tion, areflexia, miosis, 
vomiting, incontinence, re­
duced ChE activity, ECG ab­
normal, death
25





*For an estimated whole body maximum of 28 g
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TABLE XV-7
EFFECTS ON ANIMALS FROM MALATHION EXPOSURE
Exposure
Routes of Concentration Ref-






128 mg/cu m 
6% aerosol in 
No. 2 fuel oil 
6 hrs
123 mg/cu m 
95% aerosol 
6 hrs
66 mg/cu m 
6% aerosol in 
No. 2 fuel oil 
6 hrs
65 mg/cu m 






after exposure, 4 
dead by 24 hrs, 1 
dead by 72 hrs, 
all dead by 7 d
Plasma ChE inhibi- 83
tion of 32% by 24 
hrs, 35% by 72 hrs, 
normal by 7 d; 
erythrocyte ChE in­
hibition of 34% by 
24 hrs, 51% by 72 
hrs, 45% by 7 d
Respiratory dis- 83
tress during and 
for 7 d after ex­
posure, 1 dead 
after exposure, 1 
dead by 72 hrs
No significant in- 83
hibition of blood 
ChE; no toxic signs
It
II 30 mg/cu m 24 mg/cu m 
6% aerosol in 
No. 2 fuel oil 
6 hrs
83






EFFECTS ON ANIMALS FROM MALATHION EXPOSURE
Exposure
Routes of Concentration Ref-
Exposure Species No. and Duration Effects erence
Respi­
ratory
Quail 20 128 mg/cu m 
6% aerosol 
No. 2 fuel oil 
6 hrs
All dead at end of 
In exposure
83
20 123 mg/cu m
95% aerosol 
6 hrs
20 66 mg/cu m
6% aerosol 
No. 2 fuel oil 
6 hrs
20 65 mg/cu m
95% aerosol 
6 hrs
20 34 mg/cu m
95% aerosol 
6 hrs
20 30 mg/cu m
6% aerosol In 
No. 2 fuel oil 
6 hrs
Significant plasma 83 
ChE Inhibition, 95% 
Immediately after 
exposure, 75% at 24 
hrs, normal by d 7
Death of 14 during 83 
In exposure, 4 by 24 
hrs; 2 survivors
Significant plasma 83 
ChE inhibition, 84% 
immediately after 
exposure, 63% at 24 
hrs, normal by d 7
Significant plasma 83 
ChE inhibition, 51% 
immediately after 
exposure, normal by 
24 hrs
Significant plasma 
ChE inhibition, 54% 
Immediately follow­
ing exposure, 28% 





EFFECTS ON ANIMALS FROM MALATHION EXPOSURE
Exposure
Routes of Concentration Ref-
Exposure Species No. and Duration Effects erence
Respi­
ratory
Quail 20 24 mg/cu m 
6% aerosol in 
No. 2 fuel oil 
6 hrs
Significant plasma 
ChE inhibition, 45% 
immediately after 
exposure, normal by 
24 hrs
83

















ma, and erythrocyte 
ChE activity in 
guinea pigs and 
rats; pulmonary hy­
























No inhibition of 
brain, plasma, or 
erythrocyte ChE
10











EFFECTS ON ANIMALS FROM MALATHION EXPOSURE
Exposure
Routes of Concentration Ref-
Exposure Species No. and Duration Effects erence
Respi­
ratory






tion in 1; no inhi­
bition of plasma or 
erythrocyte ChE in 1
10
Oral Rats 388 200 - 2,000 mg/kg 
x 28 d
Decreased toxicity 106 
with increased die­
tary protein
tl II 21 F 900 mg/kg 
in corn oil 
d 9 or d 10, 
d 8 - d 12, or 











II 11 5 M 500 ppm with 
25 ppm EPN* 
8 wks
Whole blood ChE in­
hibition of 79%
86
11 II 5 M 100 ppm with 





If II 192 M 1,600 mg/kg LD50 reduced to 62
20-35 mg/kg by pre­
vious administra­




EFFECTS ON ANIMALS FROM MALATHION EXPOSURE
Exposure
Routes of Concentration Ref-
Exposure Species No. and Duration Effects erence
Oral Rats 6 275 mg/kg/d
68 - 70 wks
17 M 240 mg/kg
17 F 5 mos
8 M 100 mg/kg/d
8 F x 5 d
77.9 mg/kg/d 
x 63 wks
10 M 62 mg/kg/d
4 - 6  wks
10 F 68 mg/kg/d
4 - 6  wks
Body weight of 2 33
survivors 36% below 
controls
Significant de- 107
crease in cold 
temperature surviv­
al time
Average total uri- 55
nary excretion of 
24% (M) and 48% (F)
Body weight 12% be- 33
low controls




cyte ChE inhibition 
in 5
2 M 40 mg/kg on
d 4 and d 5 of age 
or 20 mg/kg on




number of Leydig 
cells; all cell 
counts normal by d 
24 of age; reversal 








99.6% in corn oil
Significant in­





EFFECTS ON ANIMALS FROM MALATHION EXPOSURE
Exposure
Routes of Concentration Ref-
Exposure Species No. and Duration Effects erence
Oral Mice 42 M 1,400 - 1,500 mg/kg
95% in corn oil
Decrease in toxi­










in co m  oil followed 
30 min later by 
200 or 250 mg/kg 
of hexobarbital ip
1,200 mg/kg
95% in corn oil
Toxicity of hexo- 100 
barbital not al­
tered at either 
dose; all dead in 
30 min
Death 83
Dogs 1 M 
1 F
600 mg/kg 
95% in corn oil
300 mg/kg 
95% in corn oil
120 mg/kg 






Same degree of 83
erythrocyte ChE in­
hibition as respi­
ratory exposure to 
123 mg/cu m x 6 hrs
Inhibition of plas- 83 
ma (41%) and eryth­
rocyte (32%) ChE 
after 6 hrs
No effects on plas- 86 
ma ChE; slight but 
significant eryth­
rocyte ChE inhibi­
tion at 250 ppm
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TABLE XV-7 (CONTINUED)








Oral Dogs 1 M 
1 F
250 ppm with 
50 ppm EPN 
12 wks
Up to 60% inhibi­
tion of plasma ChE 
and 93% inhibition 
of erythrocyte ChE
86
II II 1 M 
1 F
100 ppm with 
20 ppm EPN 
12 wks
Questionable inhi­
bition of plasma 




II If 1 M 
1 F
8 ppm with 
3 ppm EPN 
12 wks
Significant inhibi­
tion up to 24% of 
erythrocyte ChE at 




II Chickens *“ up to 10,000 ppm 
15 wks
No nerve damage, 
muscle weakness in 
1; death of all
110
ip Rats 16 F 900 mg/kg or 
600 mg/kg on 
d 11 of gestation




II 18 M 750 mg/kg LD50 (adults) 103
II « 20 M 340 mg/kg LD50 (weanlings) 103
























Subcu- Chickens 24 
taneous
1,500 mg/kg
99.5% in corn oil
1,000 mg/kg
99.5% in corn oil
500 mg/kg 
99.5% in co m  oil
500 mg/kg 
99.5% in c o m  oil
250 mg/kg 
99.5% in c o m  oil
400 mg/kg 
99.5% in co m  oil
400 mg/kg 




50 - 1,600 mg/kg
100 mg/kg
Death of 2 in 2 hr
No deaths
Death of 1 in 2 hr
No deaths









signs in 21; imme­
diate muscle weak­
ness in 8; 4 deaths
Leg weakness for 109
d 4-14
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Injection Chick 25 6.42 mg/egg at Sparse plumage, mi- 120
into embryo d 5 cromelia, overall
yolk sac 25 3.99 mg/egg at 
d 4
95% in corn oil
growth retardation, 
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Malaoxon may undergo the tame metaboliim at malathion, ihown above, and it indicated by (0) In tha pathway scheme.
P « phosphatase« j  haye not b8#n jpjdfjggiiy Identified 
C ■ carboxyeiteraiei * j r
» at tne 1AlieiteraseU) may act ha lama titai at both P and C.
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FIGURE XV-2
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